Academic Press is an imprint of Elsevier 32 Jamestown Road, London NW1 7BY, UK 30 Corporate Drive, Suite 400, Burlington, MA 01803, USA 525 B Street, Suite 1900, San Diego, CA 92101-4495, USA First edition 2009 Copyright © 2009, Elsevier Ltd. All rights reserved No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher Permissions may be sought directly from Elsevier’s Science & Technology Rights Department in Oxford, UK: phone (44) (0) 1865 843830; fax (44) (0) 1865 853333; email:
[email protected]. Alternatively visit the Science and Technology Books website at www.elsevierdirect.com/rights for further information Notice No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made British Library Cataloguing in Publication Data A catalogue record for this book is available from the British Library Library of Congress Cataloging-in-Publication Data A catalog record for this book is available from the Library of Congress ISBN: 978-0-12-374248-3 (Set) ISBN: 978-0-12-374967-3 (Volume 1) ISBN: 978-0-12-374968-0 (Volume 2) For information on all Academic Press publications visit our website at elsevierdirect.com Typeset by Macmillan Publishing Solutions www.macmillansolutions.com Printed and bound in China 09 10 11 12 13 11 10 9 8 7 6 5 4 3 2 1
List of Contributors
Mary Pat Aardrup Senior Vice President, National Pain Foundation, Englewood, Colorado, USA
Guy Amit, MD, MSc Heart and Vascular Research Center, MetroHealth Campus, Case Western Reserve University, Cleveland, Ohio, USA
David Abejón, MD, FIPP Pain Unit, Puerta de Hierro University Hospital, Madrid, Spain
Michael L.J. Apuzzo, MD Edwin M. Todd/Trent H. Wells, Jr Professor of Neurological Surgery and Professor of Radiation Oncology, Biology, and Physics, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
Farag Aboelsaad, MD Assistant Professor, Physical Medical & Rehabilitation, Albany Medical Center, New York, USA Daniel J. Abrams, MD Departments of Psychiatry and Neurosurgery, University of Colorado at Denver and Health Sciences Center, Denver, Colorado, USA
Jeffrey L. Ardell, PhD Department of Pharmacology, East Tennessee State University, Johnson City, Tennessee, USA
D. Michael Ackermann, Jr Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA
Tipu Z. Aziz, FRCS, MD, DMedSci Oxford Functional Neurosurgery, Department of Neurological Surgery, The John Radcliffe Hospital, Oxford, UK
Linda Ackermans, MD Department of Neurosurgery, University Hospital Maastricht, Maastricht, The Netherlands
Roy A.E. Bakay, MD Department of Neurosurgery, Rush University, Chicago, Illinois, USA
Adnan A. Al-Kaisy, MB ChB, FRCA Consultant in Pain Medicine, Pain Management and Neuromodulation Centre, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
Gordon H. Baltuch, MD, PhD, FRCSC Department of Neurosurgery, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
Kenneth M. Alo’, MD President, Kenneth Alo’ MDPA, Houston Texas Pain Management PA, TOPS Surgical Specialty Hospital, Palladium for Surgery–Houston, Houston, Texas, USA
Giancarlo Barolat, MD Director, The Barolat Institute, Lone Tree, Colorado, USA Allan I. Basbaum, PhD, FRS Department of Anatomy and W.M. Keck Foundation Center for Integrative Neuroscience, University of California San Francisco, California, USA
Ron L. Alterman, MD Department of Neurosurgery, Mount Sinai School of Medicine, New York, USA Arun Paul Amar, MD Department of Neurosurgery, Permanente Medical Group, and Stanford University School of Medicine, Stanford, California, USA
Marshall D. Bedder, MD, FRCP(C) Coastal Pain Management and Rehabilitation, Florida, USA
xiii
xiv
List of contributors
Narendra Bhadra, MD, PhD Neural Engineering Center, Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA Sharon Bishop, BNurs, MHSci Department of Neurosurgery, Regina General Hospital, Regina, Canada Charles D. Blaha, PhD Department of Psychology, University of Memphis, Tennessee, USA Jonathan M. Bledsoe, MD Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA Nicholas Boulis, MD Department of Neurosurgery, Emory University School of Medicine, Atlanta, Georgia, USA Joao Braz, PhD Department of Anatomy and W.M. Keck Foundation Center for Integrative Neuroscience, University of California San Francisco, California, USA Giovanni Broggi, MD Division of Neurosurgery, Istituto Nazionale Neurologico “Carlo Besta”, Milan, Italy Adam P. Burdick, MD Department of Neurosurgery, University of Florida, Gainesville, Florida, USA Gennaro Bussone, MD Division of Neurology, Istituto Nazionale Neurologico “Carlo Besta”, Milan, Italy Linda L. Carpenter, MD Mood Disorders Research Clinic, Department of Psychiatry and Human Behavior, Butler Hospital, Brown University Medical School, Providence, Rhode Island, USA Daniel B. Carr, MD, DABPM Javelin Pharmaceuticals CEO; Saltonstall Professor of Pain Research, Departments of Anesthesiology and Internal Medicine, Tufts-New England Medical Center, Boston, Massachusetts, USA
John Chae, MD Cleveland Functional Electrical Stimulation Center, and Departments of Physical Medicine and Rehabili tation, and Biomedical Engineering, Case Western Reserve University, Cleveland; MetroHealth Rehabili tation Institute of Ohio, MetroHealth Medical Center, Cleveland, Ohio, USA Jin Woo Chang, MD, PhD Department of Neurosurgery, Brain Research Institute, Yonsei University College of Medicine, Seoul, Korea Jiande D.Z. Chen, PhD Division of Gastroenterology, Department of Internal Medicine, University of Texas Medical Branch at Galveston, Texas, USA David B. Cohen, MD Drexel University College of Medicine, Division of Neuromodulation, Department of Neurosurgery, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA Jeffrey W. Cozzens, MD, FACS Associate Professor of Neurosurgery, Northwestern University Feinberg School of Medicine, NorthShore University HealthSystem, Evanston, Illinois, USA Firouz Daneshgari, MD Department of Urology & Female Pelvic Surgery, Upstate Medical University, Syracuse, New York, USA Ross Davis, MD Neurosurgeon, Neural Engineering Clinic, Melbourne, Florida, USA Timothy R. Deer, MD President and CEO, Center for Pain Relief, Department of Anesthesiology, University of West Virginia, Charleston, West Virginia, USA Mike J.L. DeJongste, MD, PhD, FESC Department of Cardiology, Thoraxcenter, Groningen University Hospital and University of Groningen, Groningen, The Netherlands Daniel M. Doleys, PhD Director, Pain and Rehabilitation Institute, Birmingham, Alabama, USA
James Cavuoto Editor and Publisher, Neurotech Reports, San Francisco, California, USA
John P. Donoghue, PhD Director, Brown Institute for Brain Science, and Department of Neuroscience, Brown University, Providence, Rhode Island, USA
Amanda Celii, BS Department of Neurosurgery, Jefferson Medical College, Philadelphia, Pennsylvania, USA
Michael F. Dorman, PhD Department of Speech and Hearing Science, Arizona State University, Tempe, Arizona, USA
List of contributors
Thomas Dresing, MD Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA Dominique M. Durand, PhD Neural Engineering Center, Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA Allen R. Dyer, MD, PhD Professor of Psychiatry and Behavioral Sciences, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, Tennessee, USA Anthony Eidelman, MD Instructor Anesthesiology, Division of Pain Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA Rosana Esteller, PhD NeuroPace, Inc., Mountain View, California, USA Steven Falowski, MD Department of Neurosurgery, Jefferson Medical College, Philadelphia, Pennsylvania, USA Thais Federici, PhD Department of Neurosciences and Center for Neurological Restoration, Cleveland Clinic, Cleveland, Ohio, USA Joseph J. Fins, MD, FACP Chief, Division of Medical Ethics, Professor of Medicine, Professor Public Health, Professor of Medicine in Psychiatry, Weill Medical College of Cornell University, New York; Member, Adjunct Faculty, The Rockefeller University, New York, USA Kelly D. Foote, MD Department of Neurosurgery, University of Florida, Gainesville, Florida, USA Robert D. Foreman, PhD Department of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA Kostas Fountas, MD, PhD Department of Neurosurgery, University of Larissa School of Medicine, Larissa, Greece Angelo Franzini, MD Division of Neurosurgery, Istituto Nazionale Neurologico “Carlo Besta”, Milan, Italy David Friedland, MD, PhD Department of Otolaryngology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
xv
Gerhard M. Friehs, MD Department of Clinical Neurosciences (Neurosurgery Division), Brown University Medical School, Providence, Rhode Island, USA Loes Gabriëls, MD Department of Psychiatry, Katholieke Universiteit Leuven, Belgium Rollin M. Gallagher, MD, MPH Clinical Professor of Psychiatry and of Anesthesiology and Critical Care, University of Pennsylvania School of Medicine; Director of Pain Medicine, Philadelphia Veterans Medical Center; Pain Medicine Service, Philadelphia VA Medical Center, University and Woodland, Philadelphia, Pennsylvania, USA Philip L. Gildenberg, MD, PhD, FACS Adjunct Professor of Neurosurgery, Baylor Medical College; Houston Stereotactic Concepts, Inc., Houston, Texas, USA Teodor Goroszeniuk, FCA, RCSI, DA Pain Management and Neuromodulation Centre, Guy’s and St Thomas’ NHS Foundation Trust, London, UK Alexander L. Green, MB BS, MRCS Oxford Functional Neurosurgery, Department of Neurological Surgery, The John Radcliffe Hospital, Oxford, UK Benjamin D. Greenberg, MD Department of Psychiatry and Human Behavior, Warren Alpert Medical School at Brown University, Butler Hospital, Providence, Rhode Island, USA Roy K. Greenberg, MD, FACS Departments of Vascular & Cardiac Surgery and Biomedical Engineering, Cleveland Clinic, Cleveland, Ohio, USA David A. Greene, BS NeuroPace, Inc., Mountain View, California, USA Beverley Greenwood-Van Meerveld, PhD, FACG VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma Warren M. Grill, PhD Department of Biomedical Engineering, Duke University, Durham, North Carolina, USA William C. de Groat, PhD Department of Pharmacology and Chemical Biology, University of Pittsburgh Medical School, Pittsburgh, Pennsylvania, USA
xvi
List of contributors
Katherine E. Groothuis Departments of Neurological Surgery and Physiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
Michael W. Keith, MD MetroHealth Medical Center, Case Western Reserve University, Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, USA
Shivani Gupta, MD Department of Neurosurgery, Regina General Hospital, Regina, Canada
Yves Keravel, MD Service de neurochirurgie, Hôpital Henri Mondor, Créteil, France
Casey H. Halpern, MD Department of Neurosurgery, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
K. Riaz Khan, MB BS, DO, MD, FRCA Clinical Fellow in Pain Medicine, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
Mouchir Harb, MD Neurologist and Pain Practice Physician, Las Vegas, Nevada, USA
Kevin L. Kilgore, PhD MetroHealth Medical Center, Louis Stokes Cleveland VA Medical Center, Case Western Reserve University, Cleveland, Ohio, USA
Bradley C. Hiner, MD Department of Neurology, Medical College of Wisconsin, and Clement J. Zablocki VA Medical Center, Milwaukee, Wisconsin, USA Leigh R. Hochberg, MD, PhD Rehabilitation Research and Development Service, Providence VA Medical Center; Department of Neuroscience, Brown University, Providence, Rhode Island, USA Svante Horsch, MD, PhD Department of Vascular Surgery, Hospital Porz am Rhein, Academic Teaching Hospital of the University of Cologne, Cologne, Germany Joseph C. Hsieh, MD, MBA, MPH, MS Section of Neurosurgery, University of Chicago, Chicago, Illinois, USA Jurg L. Jaggi, PhD Department of Neurosurgery, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA Patrick D. Jenkins, PhD Department of Neurosurgery, Medical College of Georgia, Augusta, Georgia, USA Hyun Ho Jung, MD Department of Neurosurgery, Brain Research Institute, Yonsei University College of Medicine, Seoul, Korea Leonardo Kapural, MD, PhD Clinical Research Director, Department of Pain Management, Cleveland Clinic; Associate Professor of Anesthesiology, Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Cleveland, Ohio, USA
David King-Stephens, MD Department of Neurosciences, California Pacific Medical Center, San Francisco, California, USA Jayme Knutson, PhD Cleveland Functional Electrical Stimulation Center, and Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA Brian Harris Kopell, MD Departments of Neurosurgery and Psychiatry, Medical College of Wisconsin, Milwaukee, Wisconsin, USA Sandesha Kothari, FRCA, DA, DNB, MNAMS Pain Management and Neuromodulation Centre, Guy’s and St Thomas’ NHS Foundation Trust, London, UK Elliot S. Krames, MD, DABPM Medical Director, Pacific Pain Treatment Centers, San Francisco, California, USA; President, International Neuromodulation Society; Editor-in-Chief, Neuromodulation: Technology at the Neural Interface (The Journal of the International Neuromodulation Society) Krishna Kumar, MB, MS, FRCSC, FACS Department of Neurosurgery, Regina General Hospital, Regina, Canada Kris van Kuyck, PhD Department of Neurosciences, Laboratory for Experimental Functional Neurosurgery, Katholieke Universiteit Leuven, Belgium Kendall H. Lee, MD, PhD Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA
List of contributors
xvii
Kwangdeok Lee, PhD Department of Stem Cell Biology and Regenerative Medicine, Cleveland Clinic, Cleveland, Ohio, USA
Tara M. Mastracci, MD, MSc, FRCSC Department of Vascular Surgery, Cleveland Clinic, Cleveland, Ohio, USA
Jean Pascal Lefaucheur, MD, PhD Département des explorations fonctionnelles, Hôpital Henri Mondor, Créteil, France
Paolo Mazzone, MD Operative Unit of Stereotactic and Functional Neuro surgery, Ospedale CTO “A. Alesini”, Rome, Italy
Massimo Leone, MD Division of Neurology, Istituto Nazionale Neurologico “Carlo Besta”, Milan, Italy
Sarah McAchran, MD Formerly Glickman Urological Institute, Cleveland Clinic, Cleveland, Ohio; Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
Michael L. Levy, MD Division of Neurosurgery, Children’s Hospital of San Diego and University of California San Diego School of Medicine, San Diego, California, USA Robert M. Levy, MD, PhD Departments of Neurological Surgery and Physiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA Dianyou Li, MD Center for Functional Neurosurgery, Shanghai Jiaotong University Rui Jin Hospital, Shanghai, China Goran Lind, MD Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden Bengt Linderoth, MD, PhD Department of Neurosurgery, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Department of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA Brian Litt, MD Department of Neurology, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA Charles Y. Liu, MD, PhD Department of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California, USA Andre G. Machado, MD, PhD Center for Neurological Restoration, Departments of Neurosurgery and of Biomedical Engineering, Cleveland Clinic, Cleveland, Ohio, USA Sandra Machado, MD Bakken Heart–Brain Institute; Anesthesiology Institute, Cleveland Clinic, Cleveland, Ohio, USA Carlo Marras, MD Division of Neurosurgery, Istituto Nazionale Neurologico “Carlo Besta”, Milan, Italy
Cameron C. McIntyre, MS Department of Biomedical Engineering, Cleveland Clinic, Cleveland, Ohio, USA Paul Meadows, MS Vice President of R&D, ImThera Medical, Inc., Glendale, California, USA Muhammad Memon, MD Former Research Fellow, Department of NeuroOphthalmology, Massachusetts Eye and Ear Infirmary, Harvard University, Boston, Massachusetts, USA; PhD student, Department of Neurosciences, Imperial College, London, UK Giuseppe Messina, MD Division of Neurosurgery, Istituto Nazionale Neurologico “Carlo Besta”, Milan, Italy Björn A. Meyerson, MD, PhD Department of Neurosurgery, Karolinska Institutet and Karolinska University Hospital Stockholm, Sweden Alon Y. Mogilner, MD, PhD Chief, Section of Functional and Restorative Surgery, North Shore-LIJ Health System, Manhasset, New York, USA Liz Moir, RGN Oxford Functional Neurosurgery, Department of Neurological Surgery, The John Radcliffe Hospital, Oxford, UK Gregory F. Molnar, PhD Senior Research Manager, Medtronic Neuromodulation, Minneapolis, Minnesota, USA J. Thomas Mortimer, PhD Neural Engineering Center, Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA
xviii
List of contributors
Anthony M. Murro, MD Department of Neurology, Medical College of Georgia, Augusta, Georgia, USA
Marc S. Penn, MD, PhD, FACC Director, Bakken Heart–Brain Institute, Cleveland Clinic, Cleveland, Ohio, USA
Jean Paul Nguyen, MD Service de neurochirurgie, Hôpital Henri Mondor, Créteil; Service de neurochirurgie, Hôpital Laennec, Nantes, France
Richard D. Penn, MD Section of Neurosurgery, University of Chicago, Chicago, Illinois, USA
Richard B. North, MD Director, Neuromodulation, Surgical Pain Management & Surgical Spine Pain Program; LifeBridge Health Brain & Spine Institute, Baltimore; Professor of Neurosurgery, Anesthesiology and Critical Care Medicine (ret.), Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Bart Nuttin, MD, PhD Department of Neurosciences, Laboratory for Experimental Functional Neurosurgery, Katholieke Universiteit Leuven, Belgium Michael Y. Oh, MD Drexel University College of Medicine, Division of Neuromodulation, Department of Neurosurgery, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA Michael S. Okun, MD Department of Neurology, University of Florida, Gainesville, Florida, USA John P. O’Reardon, MD Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA Michael H. Ossipov, PhD Department of Pharmacology, University of Arizona, Tucson, Arizona, USA Joseph J. Pancrazio, PhD Neural Engineering Program Director, The National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, USA Yong D. Park, MD Department of Neurology, Medical College of Georgia, Augusta, Georgia, USA P. Hunter Peckham, PhD Donnell Institute Professor, Department of Biomedical Engineering, Case Western Reserve University, Cleveland; Director, Functional Electrical Stimulation Center, Louis Stokes Cleveland VA Medical Center, and MetroHealth Medical Center, Cleveland, Ohio, USA; Editor of Neuromodulation: Technology at the Neural Interface (The Journal of the International Neuromodulation Society)
Erlick A.C. Pereira, MA, MRCS(Eng) Oxford Functional Neurosurgery, Department of Neurological Surgery, The John Radcliffe Hospital, Oxford, UK Yann Péréon, MD, PhD Département des explorations fonctionnelles, Hôpital Laennec, Nantes, France Julie G. Pilitsis, MD, PhD Department of Neurosurgery, Rush University, Chicago, Illinois, USA Katharine H. Polasek, PhD Investigator, Functional Electrical Stimulation Center of Excellence, Cleveland VA Medical Center, Cleveland, Ohio, USA Dejan Popovic, Dipl. Eng., PhD, Dr Techn. Professor, Aalborg University, Center for Sensory Motor Interaction, Aalborg, Denmark; and Faculty of Electrical Engineering, University of Belgrade, Serbia Frank Porreca, PhD Department of Pharmacology, University of Arizona, Tucson, Arizona, USA Joshua P. Prager, MD, MS Director, Center for the Rehabilitation of Pain Syndromes (CRPS), Departments of Internal Medicine and Anesthesiology, David Geffer School of Medicine at UCLA, Los Angeles, California, USA; Immediate Past President, North American Neuromodulation Society (NANS) Kara J. Quan, MD Heart and Vascular Research Center, MetroHealth Campus, Case Western Reserve University, Cleveland, Ohio, USA Raymond Rackley, MD Glickman Urological Institute, Cleveland Clinic, Cleveland, Ohio, USA Matthew T. Ranson, MD Center for Pain Relief, Department of Anesthesiology, University of West Virginia, Charleston, West Virginia, USA Sylvie Raoul, MD, PhD Service de neurochirurgie, Hôpital Laennec, Nantes, France
List of contributors
xix
Richard L. Rauck, MD Pain Fellowship Director, Wake Forest University Health Sciences, Winston Salem, North Carolina, USA
Ashwini D. Sharan, MD Department of Neurosurgery, Jefferson Medical College, Philadelphia, Pennsylvania, USA
Enrique Reig, MD, PhD, FIPP Clínica del Dolor de Madrid, Madrid, Spain
Lynne R. Sheffler, MD Cleveland Functional Electrical Stimulation Center, and Departments of Physical Medicine and Rehabilitation, and Biomedical Engineering, Case Western Reserve University, Cleveland; MetroHealth Rehabilitation Institute of Ohio, MetroHealth Medical Center, Cleveland, Ohio, USA
Ali R. Rezai, MD Director, Center for Neurological Restoration, Neurological Institute, and Jane and Lee Seidman Chair in Functional Neurosurgery, Department of Neurosurgery, Cleveland Clinic, Cleveland, Ohio, USA; Editor of Neuromodulation: Technology at the Neural Interface (The Journal of the International Neuromodulation Society) Jonathan Riley, BSE Department of Neurosciences and Center for Neurological Restoration, Cleveland Clinic, Cleveland, Ohio, USA Joseph F. Rizzo III, MD Director of Neuro-Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard University, Boston, Massachusetts, USA Joshua M. Rosenow, MD, FACS Director, Functional Neurosurgery Northwestern Memorial Hospital; Assistant Professor of Neurosurgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA Vincent Roualdes, MD Service de neurochirurgie, Hôpital Laennec, Nantes, France Uzma Samadani, MD, PhD Department of Neurosurgery, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA Eugenio Scarnati, PhD Department of Biomedical Sciences and Technologies, University of L’Aquila, Italy Nicholas D. Schiff, MD Director, Laboratory of Cognitive Neuromodulation; Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, USA
Frank G. Shellock, PhD, FACC, FACSM Founder, Institute for Magnetic Resonance Safety, Education, and Research; Departments of Radiology and Medicine, Keck School of Medicine, Los Angeles, California, USA Jane Shipley, BA Executive Director, The Neuromodulation Foundation, Inc., Baltimore, Maryland, USA Karl A. Sillay, MD Department of Neurological Surgery, University of Wisconsin, Madison, Wisconsin, USA Janna L. Silverstein, BA Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA Kathleen A. Sluka, PT, PhD Professor, Graduate Program in Physical Therapy and Rehabilitation Science, Pain Research Program, Neuroscience Graduate Program, University of Iowa, Iowa City, Iowa, USA Howard S. Smith, MD Associate Professor and Director of Pain Management, Department of Anesthesiology, Albany Medical College, Albany, New York, USA Joseph R. Smith, MD Department of Neurosurgery, Medical College of Georgia, Augusta, Georgia, USA Michael Stanton-Hicks, MD Department of Pain Management, Anesthesiology Institute, Cleveland Clinic, Cleveland, Ohio, USA
Stefan Schulte, MD, PhD Center for Vascular Medicine and Vascular Surgery, MediaPark Clinic, Cologne, Germany
Philip A. Starr, MD, PhD Department of Neurosurgey, University of California San Francisco, California, USA
Cristian Sevcencu, PhD Center for Sensory-Motor Interaction (SMI), Department of Health Science and Technology, Aalborg University, Denmark
Douglas Stewart, PA-C, MBA Center for Pain Relief, Department of Anesthesiology, University of West Virginia, Charleston, West Virginia, USA
xx
List of contributors
Bomin Sun, MD Center for Functional Neurosurgery, Shanghai Jiaotong University Rui Jin Hospital, Shanghai, China Michele Tagliati, MD Department of Neurology, Mount Sinai School of Medicine, New York, USA Rod S. Taylor, PhD Peninsula Medical School, Universities of Exeter & Plymouth, Exeter, UK Yasin Temel, MD, PhD Department of Neurosurgery, University Hospital Maastricht, Maastricht, The Netherlands Giovenni Tringali, MD Division of Neurosurgery, Istituto Nazionale Neurologico “Carlo Besta”, Milan, Italy Dustin J. Tyler, PhD Nord Distinguished Assistant Professor, Case Western Reserve University, Department of Biomedical Engineering; Associate Director, Advanced Platform Technology Center of Excellence, and Principal Investigator, Functional Electrical Stimulation Center of Excellence, Cleveland VA Medical Center, Cleveland, Ohio, USA Sandip Vasavada, MD Glickman Urological Institute, Cleveland Clinic, Cleveland, Ohio, USA Veerle Visser-Vandewalle, MD, PhD Department of Neurosurgery, University Hospital Maastricht, Maastricht, The Netherlands Deirdre M. Walsh, PT, PhD Professor of Rehabilitation Research, Health and Rehabilitation Sciences Research Institute, University of Ulster, Newtownabbey, Co. Antrim, Northern Ireland, UK
Richard L. Weiner, MD Chair, Department of Neurosurgery, Presbyterian Hospital of Dallas; Clinical Associate Professor of Neurosurgery, University of Texas Southwestern Medical School, Dallas, Texas, USA Donald Weisz, PhD Department of Neurosurgery, Mount Sinai School of Medicine, New York, USA Donald M. Whiting, MD Drexel University College of Medicine, Division of Neuromodulation, Department of Neurosurgery, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA Blake S. Wilson, BSEE Department of Surgery, Division of Otolaryngology, Head & Neck Surgery, Duke University Medical Center, Durham, North Carolina, USA; MED-EL GmbH, Innsbruck, Austria Jaleh Winter, RN Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden Margaret C. Wyche, BS Mood Disorders Research Clinic, Department of Psychiatry and Human Behavior, Butler Hospital, Warren Alpert Medical School at Brown University, Providence, Rhode Island, USA Hemmings Wu, MD Center for Functional Neurosurgery, Shanghai Jiaotong University Rui Jin Hospital, Shanghai, China Jieyun Yin, MD Division of Gastroenterology, Department of Internal Medicine, University of Texas Medical Branch at Galveston, Texas, USA Shikun Zhan, MD Center for Functional Neurosurgery, Shanghai Jiaotong University Rui Jin Hospital, Shanghai, China
Foreword Joseph J. Pancrazio, PhD
The National Institute of Neurological Disorders and Stroke
It is indeed an honor to provide a foreword for Neuromodulation. Without a doubt, this book bears the burden of being the first of its kind, and may well set the standard for efforts that follow. In the broadest sense, neuromodulation involves the use of technology to alter, adjust or modify neural activity. By its multidisciplinary nature, the research and development underlying neuromodulation draws upon the talents and experience of scientists, engineers, and clinicians, often working most productively as teams. In addition, the emergence of neuromodulation in several cases from the proof-of-concept stage to a clinical standard of care has also brought individuals with business experience to the field. This reference work is not an exception to this team science endeavor; it too is the product of a diverse group of multidisciplinary individuals who share the vision of relieving the burden of neurological diseases and injuries through the judicious use of devices. The charge for the contributors is consequently and necessarily ambitious: to convey the basic, translational, and clinical science underlying neuromodulation while providing insight into the ethical, corporate, and historical bases for such devices. Therefore, the scope of the book is wide, encompassing theoretical, applied, and logistical issues. For readers with interests in basic science, there is information concerning the fundamentals of the nervous system with emphasis on neurobiology, neuroanatomy, and the basis for electrical stimulation/recording. For readers with clinical interests, there are chapters that address the physiology and pathophysiology of regions of the nervous system relevant to movement disorders, pain, epilepsy, and psychiatric illnesses such as depression and obsessive–compulsive disorder. For clinical practitioners, the book surveys neuromodulation
approaches, primarily through electrical stimulation and drug delivery, to treat a range of neurological disorders. Of no less importance is the chapter concerned with ethical issues – a significant challenge since neuromodulation can affect the capacity of patient to provide consent. In addition, the chapter entitled “ Whom Do We Serve?” reminds the reader that this book is about treating patients. While the notion of implanted devices that interact with the nervous system may inspire the fantasies of enhancement among science fiction enthusiasts, the goal of neuromodulation is to relieve the burden of neurological disease. Insights into the future of neuromodulation require reflection on what has driven its success. While studies in basic neuroscience have been essential, neuromodulation is also indebted to advances in engineering and physics. Implanted devices of ever increasing sophistication have been enabled by the age of the integrated circuit, microfabrication methodologies, and higher density power storage systems. Physics has provided non-invasive real-time imaging technologies that allow an unprecedented view of the anatomy and functionality of the nervous system in health and disease. Indeed, hypothesis-driven applications of implanted systems are emerging where seemingly simple block diagram representations of neural network pathways important to neurological disease drive the choice of implantation targets. It is expected that this trend towards modeling will continue and become more sophisticated and the device capabilities will grow such that the activity of dysfunctional networks or even neurons will be selectively and precisely modulated in patients. Undoubtedly, to fully embrace this potential, neuromodulation will continue to be a multidisciplinary pursuit capitalizing on the strength of diverse teams.
xxi
Preface
Neuromodulation is the first comprehensive reference work encompassing all aspects of the field of neuromodulation – a field that involves individuals with many different backgrounds and interests. We, the Editors, have chosen our contributors for this project because they are the leading experts in their field with significant contributions to neuromodulation. We believe that this book will be a reference for neuromodulation practitioners and clinicians, scientists, biomedical engineers, and members of industry for years to come. This reference work is divided into 11 major sections that represent the entire scope of neuromodulation. These sections include an introduction, the fundamentals of neuromodulation, biomedical engineering considerations, neuromodulation for chronic pain, neuromodulation for movement disorders, neuromodulation for epilepsy, neuromodulation for psychiatric disorders, neuromodulation for functional restoration, neuromodulation for specific body organs, emerging new applications for neuromodulation, implantation techniques, and finally the appendices. Each section has an introductory overview by a prominent section editor. The information presented includes the latest updates for each specific topic, including a review of the current literature. When applicable, a historical perspective of the use of neuromodulation for the specific topic is
included as well as an anatomical review, and technical considerations are provided along with a look into the future of neuromodulation for the specific condition. The purpose of this book is to provide our readers with an improved awareness and understanding and provide a comprehensive reference pertaining to the ever-growing field of neuromodulation. Fundamental principles as well as current and emerging applications are included in this book. In light of the fact that neuromodulation of the nervous system is capable of modulating all nervous system elements (brain, cranial nerves, peripheral nerves, spinal cord, and the autonomic nervous system), body organs and the corresponding functions of the human body, the potential of this field is enormous. In this regard, education, research, device development, and maturing clinical applications are crucial to further advance this field and realize its enormous impact for helping patients. We dedicate this book to our patients, neuromodulation practitioners, scientists, biomedical engineers, entrepreneurs, the medical device industry, and others working in the exciting world of neuromodulation. E.S.K. P.H.P. A.R.R.
xxiii
C H A P T E R
1
What Is Neuromodulation? Elliot S. Krames, P. Hunter Peckham, Ali R. Rezai, and Farag Aboelsaad
o u t line Defining Neuromodulation Other Definitions and Terms
3 5
The Field of Neuromodulation
5
Neuromodulation for Chronic Pain Brain Neuromodulation
5 6
Neuromodulation for Spasticity Functional Electrical Stimulation (FES) Neuromodulation and GI Disorders Neuromodulation for Urological Disorders Neuromodulation for Cardiac Disorders References
Defining neuromodulation
7
the science of how electrical, chemical, and mechanical interventions can modulate the nervous system function. Neuromodulation is inherently non-destructive, reversible, and adjustable. The INS (the International Neuromodulation Society) (Sakas et al., 2007) defines neuromodulation as a field of science, medicine, and bioengineering that encompasses implantable and non-implantable technologies, electrical or chemical, for the purpose of improving quality of life and functioning of humans. At the present time, neuromodulation implantable devices are either neural stimulators or microinfusion pumps. These devices are being utilized for the management of chronic pain, movement disorders, psychiatric disorders, epilepsy, dismotility disorders, disorders of pacing, spasticity, and others (Figure 1.2). Neuroprostheses such as cochlear implants and sacral root stimulators are also commonly included within the definition of neuromodulation.
Neuromodulation is among the fastest-growing areas of medicine, involving many diverse specialties and impacting hundreds of thousands of patients with numerous disorders worldwide. In the past decade, neuromodulation has witnessed significant advances with regard to the science, mechanisms, clinical applications, and technology development. These advances have been coupled with the rapid growth of the neuromodulation device industry and improvements in current devices and development of next generation neuromodulation systems (Figure 1.1). Neuromodulation is “technology impacting on the neural interface.” It is the process of inhibition, stimulation, modification, regulation or therapeutic alteration of activity, electrically or chemically, in the central, peripheral or autonomic nervous systems. It is
Neuromodulation
6 6 7 7 7
© 2008, 2009 Elsevier Ltd.
1. what is neuromodulation?
$3000.0
Market value (US$m)
$2500.0 $2000.0 $1500.0 $1000.0 $500.0 $0.0
2004
2005
2006
2007
2009
2008
2010
Year Spinal cord stimulators
Implantable drug pumps
Deep brain stimulators
Sacral nerve stimulators
Vagus nerve stimulators
Gastric electric stimulators
Figure 1.1 The growing neuromodulation market between 2004 and 2010. By the year 2010, the market is expected to reach $3bn (Source: Millennium Research Group, 2006)
Neurostimulation addressable population (000′s patients) 16000 14000 12000 10000 8000 6000 4000 2000 0
401
3069
768 13850
850
123
200
645
1635 2625
l
in
ta To
n
pa
ai
ic
Pe
lv
lp
he
rip
iv
ra
de
r
ty
ad bl
e Pe
ct ve O
M
ov
em
ra
is td en
bo e
si
in
be O
k ec N
rs de
or
pa
D
)
e
(P
in
e
ra ig
M
sy
nd
ro
m
io ct un
sf
el
dy
w
e til ec
ita bl
Irr
Er
n
y ps
io
ile
Ep
ss
D
ep
re
re
at
iti
s
na gi
nc
An
pa ic
n
118
460
on hr C
657
2300
Figure 1.2 Some of the disorders and the numbers of persons affected by these disorders available to being treated by neurostimulation, a form of neuromodulation (Source: US qualitative research with referrers and potential implanters, literature search, internal discussions, and data analysis)
Jan Holsheimer (2003) suggests that for a therapy to be considered neuromodulation, the therapy must consist of the following:
3. The clinical effect is continuously controllable by varying one or more stimulation parameters to satisfy a patient’s need.
1. The therapy must be dynamic, ongoing (continuous or intermittent) intervention, and not a short and non-recurring procedure. 2. The activity of specific neural networks is affected by the ongoing electrical stimulation or by ongoing neuropharmacological stimulation.
Neuromodulation therefore is either electrical or chemical. Electrical neuromodulation is electrical stimulation of the brain, spinal cord, peripheral nerves, plexuses of nerves, the autonomic system, and functional electrical stimulation of the muscles, while chemical neuromodulation uses direct placement of
I. an introduction to neuromodulation
neuromodulation for chronic pain
chemical agents to neural tissues through utilization of technology of implantation such as epidural or intrathecal delivery systems.
Other Definitions and Terms The term neuromodulation can be defined as a technology that impacts upon neural interfaces and is the science of how electrical, chemical, and mechanical interventions can modulate or change central and peripheral nervous system functioning. It is a form of therapy in which neurophysiological signals are initiated or influenced with the intention of achieving therapeutic effects by altering the function and performance of the nervous system. The term neuromodulation, in the opinion of these authors, should replace other terms that are relevant to the field and are being used, including neuroaugmentation, neuro stimulation, neuroprosthetics, functional electrical stimulation, assistive technologies, and neural engineering (Sakas et al., 2007). These terms have much overlap and tend to confuse the uninitiated. Neuroaugmentation is defined by the OnLine Medical Dictionary as the use of electrical stimulation to supplement the activity of the nervous system. Neurostimulation is the process or technology that applies electrical currents, in varying parameters, by means of implanted electrodes to achieve functional activation or inhibition of specific neuronal groups, pathways, or networks. Functional electrical stimulation, also known as FES, is defined as a technique that uses electrical currents to activate nerves innervating extremities affected by paralysis resulting from spinal cord injury (SCI), head injury, stroke, or other neurological disorders, restoring function in people with disabilities (Wikipedia: Functional Electrical Stimulation). FES is electrical stimulation of a muscle to provide normal control in order to produce a functional useful contraction, therefore, electrical stimulation that produces only sensory response generally would not be termed as FES and electrical stimulation that reduces pain is also not FES. Neuroprosthetics “is a discipline related to neuroscience and biomedical engineering concerned with developing neural prostheses, artificial devices to replace or improve the function of an impaired nervous system. The neuroprosthetic that has the most widespread use today is the cochlear implant with approximately 100 000 in worldwide use as of 2006” (Wikipedia: Neuroprosthetics). Neural engineering is an emerging interdisciplinary field of research that uses engineering techniques to investigate the function and manipulate the behavior of the central or peripheral nervous systems. The field draws heavily on the fields of computational neuroscience, experimental
neuroscience, clinical neurobiology, electrical engineering and signal processing of living neural tissue, and encompasses elements from robotics, computer engineering, neural tissue engineering, materials science and nanotechnology (Answers.Com.).
The field of neuromodulation Neuromodulation, paraphrasing Jan Holsheimer (2003), should be concerned with long-term treatment of chronic conditions. It is a rapidly evolving multidisciplinary biomedical and technical field and is among the fastest-growing fields of medicine today. Multiple specialties are now utilizing neuromodulatory techniques to benefit their patients. The field of neuromodulation covers a wide and heterogeneous range of conditions that include disorders of cardiac pacing, eyesight, gastric motility, epilepsy, headaches, hearing , limb and organ ischemia, movement disorders, occipital neuralgia, chronic pain, peripheral neuralgias, psychiatric and neurobehavioral disorders, spasticity, stroke, traumatic brain injury, urinary frequency, urinary urgency, urinary and fecal incontinence, and more (see Figure 1.3). Because the nervous system controls body functions and because disorders of body functions are ubiquitous, many clinical specialists, including anesthesiologists, cardiologists, gastroenterologists, neurologists, neurosurgeons, ophthalmologists, otolaryngologists, pain physicians, psychiatrists, physical medicine and rehabilitation specialists, and urologists use the therapies of neuromodulation. The goal of this book was to provide a comprehensive review and discussion pertaining to all aspects of the field of neuromodulation. Specific chapters will address the fundamentals of neuromodulation, including mechanisms of neuromodulation, neural networks, neuroscience, basics of device design, impact of technology at the neural interface, computational science, modeling, and others. This essential information benefits all those involved with neuromodulation. In addition to the fundamentals and general background topics, specific clinical applications of neuromodulation for various conditions will be provided with chapters pertaining to the following topics.
Neuromodulation for chronic pain An extensive and detailed discussion of neuromodulation for pain management will be provided in
I. an introduction to neuromodulation
1. what is neuromodulation?
Figure 1.3 Uses of neuromodulatory devices, both electrical and chemical, to treat a myriad of disorders of the human body (Reproduced with permission of Advanced Neuromodulation Systems, Plano, TX)
multiple chapters. Chronic pain is estimated to be the third largest healthcare problem in the world, afflicting around 30% of the worldwide population (Latham and Davis, 1994). Chapters on micro-infusion therapy, spinal cord, peripheral nerve and brain stimulation will review the various methods and approaches used to treat chronic pain conditions. This includes chronic regional pain syndrome (CRPS), headaches, occipital neuralgia, failed back pain, neck pain, extremity pain, degenerative spinal disease pain, central pain, cancer pain, visceral pain, and other pain conditions.
neuromodulation implants. In this context, the emerging use of brain stimulation for the treatment of neurobehavioral disorders such as obsessive–compulsive disorder and depression as well as epilepsy will be discussed. Additional applications of brain stimulation for eating disorders, addiction, obesity, tinnitus, blood pressure control, and traumatic brain injury will be discussed in the emerging application section. Additional brain neuromodulation chapters pertain to novel uses of brain infusion and neuromodulation approaches for Alzheimer’s and other neurodegenerative disorders.
Brain Neuromodulation Brain neuromodulation involving cortical and sub-cortical neurostimulation has been growing significantly, with a number of emerging applications involving multiple disorders. The most visible among these has been the use of deep brain stimulation (DBS) for treatment of movement disorders (Parkinson’s disease, dystonia, essential tremor). The success of DBS for movement disorders in over 55 000 patients worldwide has provided a platform for acceptance of the concept of a brain stimulator or a brain pacemaker. The use of DBS in Parkinson’s disease and other movement disorders has ushered in a new ear of brain
Neuromodulation for Spasticity The use of intrathecal baclofen infusion pumps has provided significant relief for patients suffering from spasticity secondary to multiple sclerosis, stroke, and other conditions. This is one of the most common and successful uses of neuromodulation infusion devices.
Functional Electrical Stimulation (FES) FES encompasses the control of movements that are compromised because of impairment. It enhances
I. an introduction to neuromodulation
neuromodulation for chronic pain
exercise of paralyzed extremities, and augments activity of afferent neural pathways (Popovic et al., 2002). Applications to improve functional ability of patients include enhancing upper and lower extremity functions as well as increasing range of motion of affected joints. FES devices serve as neuro-orthoses or external controls for motor function. Other benefits of FES include increasing muscle mass, reducing venous pooling, increasing stroke volume and cardiac output, and improvement of cardiovascular fitness, especially for paralyzed patients, as in patients with spinal cord injury. Neuroprosthetics that employ FES are effective in providing functional enhancement in patients with severe neurological impairment as in patients with spinal cord injury or stroke. The goals of these devices are to provide independence of functions of daily living such as standing, walking, breathing, micturition, and defecation (Grill and Kirsch, 2000; Troyk and Donaldson, 2001; Chae et al., 2002).
Neuromodulation and GI Disorders The use of electrical gastric stimulation for the management of gastroparesis (Forster et al., 2001) has proven to be an effective therapy for the problem. Gastric stimulation normalizes gastric dysrhythmias, entrains gastric slow waves, accelerates gastric emptying, and significantly reduces symptoms of nausea and vomiting in gastroparetic patients (Zhiyue et al., 2003). A number of approaches using neurostimulation are being explored for the management of obesity (Cigaina, 2002, 2004). Additional stimulation of the enteric plexii and the endothelium, itself, has been used for motility disorders of the small and large intestines (Kenefick and Christiansen, 2004; Baeten, 2007; Dinning et al., 2007; Sevcencu, 2007). We have provided chapters on gastric stimulation for obesity, dysmotility disorders and intestinal electrical stimulation are presented.
bladder (and bowel) is a complication of many common neurological disorders as in multiple sclerosis and spinal cord injury (Brookoff, 2000). Treatment of refractory overactive bladder was first successfully performed using an implanted percutan eous tibial nerve stimulator (van der Pal et al., 2006). Neurally augmented sexual function can be achieved by the application of electrical stimulation to spinal cord or peripheral nerves, including the sacral nerves (Meloy and Southern, 2006). Sacral nerve stimulation for IC, for overactive bladder, and urinary incontinence is mainstream therapy, today. These various neuromodulation approaches for treating urological disorders are covered in this specific section.
Neuromodulation for Cardiac Disorders Cardiovascular diseases impose a heavy socioeconomic burden on any healthcare system. Today, pacemakers and defibrillators are common therapeutic tools for cardiac disorders which have improved and saved the lives of millions of patients worldwide. Cardiac pacing devices and neurostimulators have many similarities in evolution and development and significant knowledge can be learned from the story of cardiac pacemakers and defibrillators as applied to the future of neurostimulation. In addition, a number of neurostimulation approaches are being explored for treating cardiovascular disorders and these will be discussed in specific chapters. In light of the fact that neuromodulation of the nervous system is capable of modulating all nervous system elements (brain, cranial nerves, peripheral nerves, spinal cord, and the autonomic nervous system), as well as body organs and the corresponding functions of the human body, the potential of this field is indeed enormous.
References Neuromodulation for Urological Disorders Sacral neuromodulation (Ganio and Masin, 2000; Hohenfellner et al., 2001) has become a valid therapeutic option for patients with urological painful and dysmotility conditions such as interstitial cystitis, neurogenic bladder, and overactive bladder. There is an estimated 6% prevalence of classic interstitial cystitis (IC) in American women while an overactive bladder syndrome affects approximately 17% of the adult population of the USA with an estimated worldwide prevalence of 50 million. Additionally, neurogenic
Answers.Com. http://www.answers.com/topic/neural-engineering (accessed October 2008). Baeten, C.G.M.I. (2007) Sacral nerve stimulation for fecal incontinence: current worldwide results. Neuromodulation 10 (1): 185–6. Brookoff, D. (2000) Chronic pelvic pain. In: S.E. Abram and J.D. Haddox (eds), The Pain Clinic Manual. Philadelphia, PA: Lippincott, Williams & Wilkins, pp. 239–47. Chae, J., Triolo, R., Kilgore, K.L., Creasey, G. and DeMarco, A. (2002) Neuromuscular electrical stimulation in spinal cord injury. In: S. Kirshblum, D. Campagnola and J. DeLisa (eds), Spinal Cord Injury Medicine. Philadelphia, PA: Lippincott, Williams & Wilkins, pp. 360–88. Cigaina, V. (2002) Gastric pacing as therapy for morbid obesity: preliminary results. Obesity Surgery 12 (S1): S12–S16.
I. an introduction to neuromodulation
1. what is neuromodulation?
Cigaina, V. (2004) Long-term follow-up of gastric stimulation for obesity: the Mestre 8-year experience. Obes. Surg. 14 (S1): S14–S22. Dinning, P.G., Fuentealba, S.E., Kennedy, M.L., Lubowski, D.Z. and Cook, I.J. (2007) Sacral nerve stimulation induces pan-colonic propagating pressure waves and increases defecation frequency in patients with slow-transit constipation. Colorectal Dis. 9 (2): 123–32. Forster, J., Sarosiek, I., Delcore, R., Lin, Z. et al. (2001) Gastric pacing is a new surgical treatment for gastroparesis. Am. J. Surg. 182: 676–81. Ganio, E. and Masin, A. (2000) Short-term sacral nerve stimulation for functional anorectal and urinary disturbances: results in 49 patients. Dis. Colon Rectum, 43: A17. Grill, W.M. and Kirsch, R.F. (2000) Neuroprosthetic applications of electrical stimulation. Assist. Technol. 12: 6–20. Hohenfellner, M., Humke, J., Hampel, C. et al. (2001) Chronic sacral neuromodulation for treatment of neurogenic bladder dysfunction: long-term results with unilateral implants. Urology 58: 887–92. Holsheimer, J. (2003) Letters to the editor. Neuromodulation 6 (4): 270–3. Kenefick, N.J. and Christiansen, J. (2004) A review of sacral nerve stimulation for the treatment of faecal incontinence. Colorectal Dis. 6 (2): 75–80. Latham, J. and Davis, B.D. (1994) The socioeconomic impact of chronic pain. Disability Rehab. 16: 39–44. Meloy, T.S. and Southern, J.P. (2006) Neurally augmented sexual function in human females: a preliminary investigation. Neuromodulation 9 (1): 34–40.
OnLine Medical Dictionary. http://cancerweb.ncl.ac.uk/cgibin/ omd?neuroaugmentation (accessed October 2008). Popovic, D.B., Popovic, M.B. and Sinkjær, T. (2002) Neuro rehabilitation of upper extremities in humans with sensorymotor impairment. Neuromodulation 5 (1): 54–66. Sakas, D.E., Panourias, I.G., Simpson, B.A. and Krames, E.S. (2007) An introduction to operative neuromodulation and functional neuroprosthetics, the new frontiers of clinical neuroscience and biotechnology. In: D.E. Sakas, B.A. Simpson and E.S. Krames (eds), Operative Neuromodulation, Vol. 1. Vienna: Springer Verlag, pp. 3–10. Sevcencu, C. (2007) A review of electrical stimulation to treat motility dysfunctions in the digestive tract: effects and stimulation patterns. Neuromodulation 10 (1): 85–99. Troyk, P.R. and Donaldson, N.D. (2001) Implantable FES stimulation systems: what is needed? Neuromodulation 4: 196–204. van der Pal, F., van Balken, M.R., Heesakkers, J.P.F.A., Debruyne, F.M.J. and Bemelmans, B.L.H. (2006) Implant-driven tibial nerve stimulation in the treatment of refractory overactive bladder syndrome: 12-month follow-up. Neuromodulation 9 (2): 163–71. Wikipedia. http://en.wikipedia.org/wiki/Functional_electrical_stim‑ ulation (accessed October 2008). Wikipedia. http://en.wikipedia.org/wiki/Neuroprosthetics (accessed October 2008). Zhiyue, L., Forster, J., Sarosiek, I. and McCallum, R.W. (2003) Review: treatment of gastroparesis with electrical stimulation. Digest. Dis. Sci. 48 (5): 837–48.
I. an introduction to neuromodulation
C H A P T E R
2
Neuromodulation: A Historical Perspective Philip L. Gildenberg
scientific side, he amused his friends and admirers at his home by literally shocking them as they touched a contact charged by a static electricity generator. The remarkable breadth of his contributions is all the more impressive if one recognizes that this report antedated the demonstration of electrical contraction of frog muscle by Galvani in 1780 (De viribus electricitatis in motu musculari. Commentarius. Pars prima. Bolonien Scientiarium Art Inst Adad 1791; 7: 363–418, cited in Pruel, 1997). The popular curiosity about electricity was intensified in 1818 by Mary Shelley (1818). In the introduction to her novel Frankenstein, she cited the observation of Dr Erasmus Darwin (Charles Darwin’s grandfather) that electricity might have caused reanimation of a rehydrated worm “vorticellae” (which she incorrectly quoted as vermicelli). She speculated that “perhaps a corpse would be reanimated; galvanism had given token of such things; perhaps the component parts of a creature might be manufactured, brought together, and imbued with vital warmth.” Galvanic current is direct current, which stimulates as the current is suddenly applied or suddenly discontinued. As early as 1804, Aldini (1804) stimulated the facial nerve in fresh cadavers with galvanic current and noted contraction of the facial muscles. Faradic or alternating current applies a continuous stimulation to nerve or muscle. When faradic current generators were developed early in the nineteenth century, they were soon used in the experimental animal laboratory. As early as 1824, Flourens reported on stimulation of the exposed cortex. He erroneously concluded that the cortex was homogenously non-responsive to stimulation. He was able to elicit muscle contraction on stimulating the brain stem, and concluded that was the site of motor control (P. Flourens: Recherches expérimentales sur
We are presently in a time of growth of neuromodulation. All of the information that makes for a successful technology has come together, and progress is rapid. But what is that information and where did it come from? From the standpoint of this review, we will consider neuromodulation to be chronic therapeutic electrical stimulation of the central nervous system or special nerves with an implanted stimulating device. This term does not apply to naturally occurring electrical stimulation, primitive electrical devices, cutaneous stimulation, acute or intraoperative stimulation, or sensory stimulation of peripheral nerves. Motor stimulation via peripheral nerves, as in functional electrical stimulation (FES), is a subject beyond this chapter. We take electricity for granted today, but it was unknown until the middle of the eighteenth century. It was recognized that contact with an eel or torpedo fish was acutely painful, and it was observed that lightning made noise and even caused fires, but those two things seemed unrelated. Even so, the first use of therapeutic electrical stimulation occurred in about 15 AD. As the story is reported (Stillings, 1971), a freed slave of Emperor Tiberius was suffering from painful gout. He accidentally stepped on an electric torpedo fish and suffered a sudden severe shock. Afterward, he had much less gout pain. The Emperor’s physician, Scribonius, wrote that thereafter he recommended the torpedo fish treatment for chronically persistent pain. This apocryphal story represents the beginning of neuromodulation, although nothing further happened for more than 1700 years. By the end of the eighteenth century, electricity was identified as a form of energy. Its ability to cause sudden shock and muscle contraction was recognized. One of the first to report that phenomenon in 1774 was Benjamin Franklin (Isaacson, 2003). In addition to his
Neuromodulation
© 2008, 2009 Elsevier Ltd.
10
2. neuromodulation: a historical perspective
Figure 2.2 Sir Victor Horsley (Source: http://cache.viewimages.com)
Figure 2.1 Roberts Bartholow (Source: http://www.nlm.nih.gov)
les propriétés et les fonctions du système nerveux, dans les animaux vertébrés, Paris, 1824, cited in Morgan, 1982). It was not until 45 years later, in 1870, that Fritsch and Hitzig (1870) demonstrated limb movement on stimulating the motor cortex of the dog, proving that the cerebral cortex was excitable by electricity. The first documented electrical stimulation of the living human brain occurred in 1874. A patient with a purulent ulcer of the scalp with skull osteomyelitis was admitted to Good Samaritan Hospital in Cincinnati by Dr Roberts Bartholow (see Figure 2.1). The parietal area of the brain became exposed when debridement was done. Bartholow made a faradic stimulation device to stimulate the exposed brain, since there was no such device to be purchased. When mechanical stimulation was done, there was no response, but when electrical stimulation was applied, contralateral muscle spasm was seen, documenting that the cortex was responsive to electricity (Experimental investigations into the function of the human brain. Am. J. Med. Sci. 1874; 67: 305–13, cited in Morgan, 1982). Ten years later, in 1884, the first intraoperative cortical electrical stimulation was performed by Sir Victor Horsley, the father of functional neurosurgery (see Figure 2.2). He applied faradic electrical stimulation to the tissue within an occipital encephalocele, and he demonstrated conjugate eye movements that he concluded were due to stimulation of the corpora quadrigemina. Two years after that, in 1886, after a
tumor resection, he identified the thumb area of the motor cortex that had been involved in localized seizures and resected it, the first time intraoperative stimulation was used to guide a resection (Horsley, 1909; Vilensky and Gilman, 2002). In 1909, Cushing stimulated the post-central gyrus in an awake patient and demonstrated contralateral motor movement. The twentieth century began with a widespread fascination of everything electrical. Electric lights had become a reality. Electric power was just being supplied to residences and businesses. Electric motors were used in industry. Electric batteries made electricity available everywhere. Electrical stimulation was touted as the cure to all ills, and improbable treatments were offered in stores, street corners, and carnivals. One such battery-powered device was the Electreat – Relieves Pain, sold for $1.00 by the Electreat Manufacturing Company of Peoria, Illinois, “to improve vitality and health in every organ” (see Figure 2.3). It was arguably the first TENS unit. To digress, in 1968 when Shealy began to use dorsal column spinal cord stimulation for pain management, he used the Electreat to screen patients. When it was modified to a more modern, safer, and convenient device, it was used for treatment as well as screening, and transcutaneous stimulation was born (Shealy et al., 1967). Let us return to the early twentieth century. Animal stereotaxic surgery began when Horsley and Clarke (1908) introduced the first animal stereotaxic apparatus in 1908. Their classic paper should be read by anyone with a deep appreciation of science history. The paper reported a study of cerebellar physiology in the
I. an introduction to neuromodulation
Neuromodulation: A Historical Perspective
11
Figure 2.3 The Electreat – Relieves Pain (Source: http://www.thebakken.org/artifacts/database/imagebase/ 082-135.jpg)
laboratory. It is divided into five sections. After a brief introduction, the “Material and Methods” section describes their apparatus, which used a Cartesian coordinate system. The first stereotaxic atlas was consulted to identify the location of the desired structure in relation to the landmarks on the skull. Registration of the position of the animal head to both the atlas and the stereotaxic apparatus involved bony landmarks of the skull, that is, the external auditory canals, the inferior orbital ridges, and the midline. They applied electrical stimulation to the cerebellar cortex and subcortex and observed the effects. They produced electrolytic lesions in the cerebellar nuclei with a direct current, which they describe in a detail that has never been matched. During the first half of the twentieth century, intraoperative stimulation was performed in patients to localize functional areas by Cushing (1909), as well as others. Detailed mapping of primarily cortical functional areas was performed in conjunction with epilepsy surgery by Penfield and Jasper (1954). In 1947, Spiegel and Wycis introduced human stereotactic surgery1 (Spiegel et al., 1947) (see Figure 2.4). From the very first case, electrical stimulation of subcortical structures was used to identify electrode placement, as well as to take the opportunity to study human neurophysiology. The first patient had Huntington’s chorea. A lesion was made in the globus
1
The original spelling was “stereotaxic,” and that is still the spelling for the technique used in the animal laboratory. When the technique was applied to human patients in 1947, Spiegel and Wycis used the term “stereoencephalotomy,” which never caught on, since it involved the use of brain or encephalic landmarks to register the atlas and the apparatus to the same Cartesian space as the head. Other clinicians, particularly in Europe, began to use the spelling “stereotactic.” When the World Society for Stereotactic and Functional Neurosurgery was founded in 1973, it was necessary to agree on a spelling. A vote was taken and “stereotactic” was adopted as the proper spelling for such surgery performed in the human (Gildenberg, 1993).
Figure 2.4 Spiegel and Wycis in the operating room in 1948. Spiegel is second from left and Wycis is sitting. Note the Model I device as it appeared in Science and faraday cage so recording can be done in the operating room
pallidus, in order to interrupt the extrapyramidal pathway, and a second lesion was made in the dorsomedian nucleus of the thalamus, a psychosurgical target, since the patient had magnification of symptoms when he became stressed or upset. Originally, they made the lesion by injection of alcohol, in hopes of sparing fibres en passage, but that was soon replaced by the use of electrolytic lesions, similar to what Horsley and Clarke had described (Spiegel et al., 1952). As the technology developed, they as well as other stereotacticians adopted the use of radiofrequency lesions (Cosman et al., 1983). This author had the great fortune of having difficulty finding a neurophysiologist to sponsor a newly designed summer research program when I was a freshman student at Temple Medical School in 1953. The Professor of Physiology referred me to his old teacher, Ernest Spiegel, Professor of Experimental Neurology, whose laboratory was down the hall. That was six years after the introduction of stereotactic surgery, and I continued to work with him throughout my residency and graduate school over the next 13 years, a front row seat as the field was in its most rapid stage of development.
I. an introduction to neuromodulation
12
2. neuromodulation: a historical perspective
Electrical stimulation was used in almost every stereotactic case. It was used to verify the placement of the electrode, since imaging technology at that time did not allow direct visualization of the target structure. Many targets had no response to stimulation, in which case stimulation was used to assure that the electrode was not in an exquisite structure, especially the pyramidal tract. Reports from that era rarely reported effects of stimulation that were only casually observed. Effects of stimulation on symptoms were recorded only subjectively, since there were few means to quantitate the severity of the symptoms in the operating room. The patients were often under considerable stress so symptoms were not consistent or typical, procedures were frequently of long duration, and the use of the stimulation was primarily for localization. Electrical recordings during the early years of stereotactic surgery required shielding in a faraday or grounded cage around the head. Localization was done by selecting the landmarks from which measurements would be made, which by the end of the 1950s were most often the anterior and posterior commissure and the intervening intercommissural line, consulting an atlas to determine the relationship of the intended target to that line and noting the three coordinates that indicate that localization, identifying the commissural landmarks during surgery, calculating the settings of the stereotactic frame to achieve the intended three coordinate settings, introducing the electrode to those coordinates, and then making physiologic observations to fine tune the electrode placement prior to making the lesion. Such physiologic observations might include change in movement disorder on insertion of the electrode into the target (mechanical effect), noting any change in physiologic signs on low and high frequency stimulation, making a mini-lesion (presumably reversible) at a modest temperature to note the effect, and making the lesion, which was irreversible. Since intraoperative stimulation was an almost universal adjunct to electrode localization, it was reported only casually without sufficient detail to reconstruct just what had been done. In 1950, Spiegel, Wycis and Umlauf used stimulation to localize thalamotomy, and then noted electroencephalographic changes after the lesion was made. In 1964, Spiegel, Wycis et al. (1964) used intraoperative stimulation prior to making lesions in Forel’s field for Parkinson’s disease. Not only was an improvement in symptoms noted on stimulation after satisfactory electrode placement, but the dramatic abrupt monocular eye movements indicated when the electrode had been lowered just below the target to involve the oculomotor fibers just below that structure. In 1966,
Alberts et al. reported improvement in dystonia on stimulation in awake patients. It was soon recognized that stimulation might either enhance the symptom, especially with tremor or other involuntary movement disorder, or it might subdue it – either effect was evidence of proper electrode placement. The effects were sometimes correlated to stimulation frequency, but often stimulation was not done with a variety of frequencies to make that distinction. In general, it was felt that higher frequency stimulation tended to subdue the symptoms and lower frequency stimulation might enhance them. There was no general agreement, however, on what constituted high verses low frequency. Low frequency might be between 6 and 60 Hz, and high frequency between 50 and 100 Hz. The picture was complicated when Riechert (1980) reported a patient who suffered a seizure following 50 Hz stimulation, which he attributed to kindling, so he discouraged colleagues from stimulating at higher than that frequency. Hassler et al. (1960) reported that stimulation within VL thalamus (later refined to Vim) might cause cessation of parkinsonian or essential tremor, and that has remained the target of choice for tremor. He had had extensive experience with chronic stimulation as a graduate researcher with Rudolph Hess in Switzerland during the 1940s, where chronic stimulation was routinely administered to cats. Although Hess had spoken encouragingly about using similar techniques in patients, the technology of his day did not permit the application of stimulation over a long period. Intraoperative stimulation was also used for physiological and anatomical studies on the human brain. Ronald Tasker produced a detained physiologic atlas of the human thalamus based on mapping of responses to stimulation in several hundred patients in and around the thalamus (Tasker et al., 1982). He had worked with Clinton Woolsey as a graduate student from 1961 to 1963, who had used similar point-by-point mapping in experimental animals (Woolsey, 1964). Tasker kept detailed records of intraoperative stimulation responses over 40 years to produce a data base reflecting the orientation of targets of interest to the stereotactic surgeon. Although the benefits of stimulation were known, there was no practical way through the 1960s to apply chronic stimulation as a permanent therapy. Nevertheless, reports appeared that touted the potential benefits of stimulation, but required intermittent connection to electrodes through the scalp. One of the earliest was Pool (1954), who, as early as 1948, stimulated the frontal projection tracts as a form of nondestructive psychosurgery. Starting in the early 1950s, Heath (1955) implanted electrodes and stimulated intermittently over long periods to study the physiology
I. an introduction to neuromodulation
Neuromodulation: A Historical Perspective
of mentation and to manage psychiatric disorders. (One of his junior associates was Donald Richardson, who extended these techniques when implantable stimulators became available more than a decade later.) In Russia, Bechtereva (1969) used chronic stimulation to study the physiology of human higher mental activity and to treat movement disorders. Even after implantable stimulators became available in the West, it was necessary for her to stimulate intermittently in 1972 for the first therapy of motor disorders by chronic stimulation via electrodes emerging through the scalp (Bechtereva et al., 1972). Meanwhile, chronic stimulation in laboratory animals directly connected to stimulators was permitting interesting observations. In 1954, Olds and Milner reported intense stimulation-seeking behavior in rats with septal electrodes implanted. That observation was used by Heath (1958, 1996) to manage cancer pain. He hypothesized that pleasure is the opposite of pain, so that stimulating the septal pleasure center might alleviate cancer pain. Stimulation at intervals of one day to one week provided pain relief throughout the final seven months of a cancer patient’s life. This procedure was repeated by Gol in 1967, when implantable stimulator technology was on the brink of full implementation. The concept that led directly to the commercial introduction of implantable stimulators for pain relief by neuromodulation was provided in Melzack and Wall’s “gate theory” presented in 1965 (see Figure 2.5). Their concept involved a gate at each spinal segment which opened to allow pain transmission and closed to inhibit pain perception. Whether the gate was open or closed depended on the balance of firing of large touch peripheral nerves versus small pain nerves. That is why pain feels better when you rub it, stimulating the large pain-inhibiting nerves to close the gate, and why weak stimulation of skin or peripheral nerve may inhibit pain. By anatomical coincidence, the large nonpain fibers also ascend in the dorsal columns of the spinal cord, which consists almost entirely of large C Fibers
�
� �
Inhibitory interneuron �
2° neuron To forebrain
A�/A� Fibers
Figure 2.5 The gate control theory of Melzack and Wall
13
nerve fibers. This offers the possibility of stimulating the dorsal columns to promote firing of the large nerve fibers with retrograde transmission down to each segment to close the gate and inhibit pain. The first TENS (transcutaneous electrical nerve stimulation, an inaccurate description) unit had been introduced a half century previously as the Electreat, but for the first time its efficacy to help pain was explained. In the late 1960s a wide variety of TENS units for pain management were introduced, each consisting of a battery-operated stimulator connected to tape-on or paste-on skin electrodes. (See Chapter 24 for a full description of TENS units.) Localized anesthesia produced by stimulation of peripheral nerve was demonstrated in 1967 by Wall and Sweet, who inserted needle electrodes into their own infraorbital nerves to produce analgesia throughout the distribution of those nerves. By definition, if the stimulation has low enough voltage so it is not painful, the large fibers are being stimulated. If pain occurs on increasing the voltage, the small pain fibers are also being stimulated. Thus, the subject can adjust the voltage according to the sensation produced, and anticipate decreased pain sensation if the electrical stimulation does not stimulate pain fibers. Bill Sweet recruited Roger Avery, an engineer, to make an implantable peripheral nerve stimulator, consisting of an entirely implantable electrode connected to an induction coil and an external battery operated control unit (which, in turn led to the formation of the Avery Company that made a variety of implantable stimulators; when Roger Avery retired 20 years later he sold the company to Bill Dobelle, who developed the phrenic nerve stimulator that is still in use to treat prolonged respiratory paralysis). At just about the same time, Norm Shealy at Western Reserve Medical School (now Case Western Reserve) had the idea of stimulating the dorsal columns of the spinal cord to take advantage of the Melzack–Wall gate to inhibit pain anywhere in the body below the level of stimulation. In 1964 he recruited Tom Mortimer, a graduate student at Case Institute of Technology, to design an implantable device to apply such stimulation. The first model was not fully implantable. The electrode behind the spinal cord was attached to subcutaneous contacts that could be addressed through hypodermic needles that were attached to an external stimulator. Coincidentally, Mortimer had met Norm Hagfors, Chief Technical Officer of Medtronic, Inc., when he interviewed for a job at the company, which was making cardiac and cardiac nerve stimulators. Hagfors provided Mortimer with a circuit diagram for a radio frequency coupled stimulator, and Mortimer made the first fully implantable spinal cord stimulator with
I. an introduction to neuromodulation
14
2. neuromodulation: a historical perspective
an external radiofrequency control and power supply. In October, 1967, Shealy, who had in the meantime moved to LaCrosse, Wisconsin, implanted that first dorsal column stimulator for cancer pain. The patient had good pain relief for the last few months of his life. The second patient reported by Shealy in 1967 had pain relief for four years, although Shealy commented that she required an occasional “tune up,” especially at holiday time (Shealy et al., 1967). Since Mortimer had since left to study in Sweden, Shealy contacted Medtronic directly to provide more stimulators. Medronic had a line of implantable stimulators that were used for cardiovascular disease. The model supplied to Shealy was a modified version of a carotid sinus nerve stimulator. Their Barostat, released in 1963, was designed to stimulate the carotid sinus nerve for hypertension. In 1965, they released the Angiostat to stimulate the carotid sinus nerve for the treatment of angina. Soon thereafter, in 1968, Medtronic made such radiofrequency coupled spinal cord stimulators commercially available as the Myelostat. The availability of that device, more than any other single event, signaled the birth of neuromodulation. That was coincidentally the year that functional neurosurgeons were most receptive to new techniques since levodopa had just come on the market and there was little call for stereotactic surgical treatment of Parkinson’s disease. The earliest stimulators consisted of two parts. The implantable part contained the electrodes placed behind the spinal cord, connected to an antenna located subcutaneously. There was no implanted power source. The external part contained the battery, and transmitted both power and control to the implanted part.2 In 1968, this author was at the Cleveland Clinic, just down the road from where Shealy and Mortimer had worked, so I was aware of their work very early. I soon began to use the spinal cord stimulator for pain management. In the meantime, I had a large series of spasmodic torticollis patients I had treated surgically, a series which had begun when I was still working with Wycis (Wycis and Gildenberg, 1969). It seemed that these patients might benefit from spinal cord stimulation, especially if one were able to disrupt the cervical proprioceptive reflex arc, which I thought might require very high frequency stimulation. In order to test that hypothesis, I inserted electrodes into the epidural space at the C2 level and stimulated with an external stimulator. Many patients had significant improvement, but only at frequencies between 800 2
In 1981, Medtronic released a totally implantable stimulator, containing the electrodes, battery, and a control unit that was programmed by radiofrequency coupling to an outside programmer.
and 1200 Hz (Gildenberg, 1977a). Medtronic and later Avery supplied spinal cord stimulators modified to provide those frequencies over the following 10 years, and 50% of patients implanted during that time had significant, but not always permanent relief, which may have constituted the first use of implanted stimulators specifically for a motor disorder. When the modified stimulators were no longer available, I could no longer provide this procedure.3 The use of dorsal column stimulation for pain became widespread over the next decade. It was felt that the effect was not only from stimulation of the dorsal columns, so the preferred nomenclature was changed to spinal cord stimulation (SCS) (Bantli et al., 1975; Hoppenstein, 1975; Larson et al., 1975). In 1976, both Cook and Dooley (Dooley and Sharkey, 1977) noted an improvement in spasticity in several patients with multiple sclerosis who were being treated with SCS for muscle pain. That same year, Ross Davis, in concert with Dooley, convinced Bill Murphy at Cordis Cardiac Pacemaker Company to make the first implantable SCS device specifically intended for motor disorders (Davis and Gray, 1981). A modification of that stimulator from Medtronic was used also by Cooper (Davis et al., 1976) to stimulate the anterior lobe of the cerebellum for cerebral palsy and spasticity, as well as epilepsy, since that area had been recognized to have an inhibitory influence on the motor system (Cooper et al., 1974). There were concerns about the safety of cerebellar stimulation which were eventually allayed (Davis et al., 1985). Efficacy in epilepsy was uncertain, but in 1985 Davis et al. (1983) reported satisfactory results on long-term follow-up. In 1976, Dooley and Kasprak documented by measurement an improvement in blood flow to the extremities when patients turned on their spinal cord stimulators. However, it was not until 1986 that SCS was advocated in Europe for peripheral vascular insufficiency (Augustinsson et al., 1985), and only more recently in the USA. With the rapid growth of neuromodulation, a symposium on Safety and Efficacy of Neuroaugmentive Devices was held in March, 1977 (Gildenberg, 1977b). Reports on stimulation for pain, epilepsy, spasticity, cerebral palsy, and bladder control were presented. The symposium was sponsored by the Food and Drug Administration in conjunction with the Association for the Advancement of Medical Instrumentation, 3
As an interesting aside, in 1970, I asked Medtronic to provide percutaneous electrodes to test patients without the need for surgery, but they saw no market for percutaneous electrodes for spinal cord stimulation at that time. However, we made percutaneous electrodes by hand, which worked well for temporary screening.
I. an introduction to neuromodulation
Neuromodulation: A Historical Perspective
the American Association of Neurological Surgeons, the Congress of Neurological Surgeons, and the Joint Committee on Materials and Devices. The unanimous opinion was that neuroaugmentation, now called neuromodulation, for the relief of pain by SCS had been demonstrated to be both safe and effective and should be regarded as standard for neurosurgical practice (Gildenberg, 1977c),4 but there was insufficient evidence for similar designation of neuroaugmentation for the other considered indications. In order to review deep brain stimulation (DBS), we must back up a few years. In 1973, several years after SCS for pain management had been introduced, Yoshio Hosobuchi et al. initiated DBS for pain management when he stimulated the somatosensory thal amus for the management of intractable denervation pain, based on the observation that this artificial input of non-painful sensation inhibited anesthesia dolorosa. About the same time, Mazars (1975) applied intermittent stimulation to the same areas for pain following amputation or stroke. Meanwhile, new concepts of pain physiology were emerging. In 1969, Reynolds observed, on stimulation of the periventricular area in rats, profound anal gesia intense enough to perform surgery with no sign of pain. Meyer and Price (1976) related that effect to endorphin release. Those observations led Richardson and Akil (1977a, 1977b) to implant DBS electrodes in the periventricular area of patients for the management of pain, and they verified that pain relief was correlated with endorphin release. As the use of brain stimulation became more widespread, regulatory forces began to intervene. In the late 1970s the FDA decided that all implantable devices were to be regulated and require pre-approval. At that time, there were three companies that made implantable deep brain stimulators – Medtronic, Avery, and Neuromed. They were given time to provide documentation of safety and efficacy, but two of the companies felt that such a complex study in patients who were particularly difficult to evaluate would be too expensive for the number of units to be sold, so they did not submit such a report. The only company that successfully complied was Avery, but shortly after approval in 1983, Roger Avery retired and sold the company to Bill Dobelle as stated above. At that time, Dobelle was concentrating on cortex stimulation for blindness and phrenic nerve stimulation for respiratory paralysis, so his company did not make stimulators for pain. Consequently, DBS for pain management was deapproved and has not since been reestablished.5 4
And much later for pain medicine practice. The use of DBS for movement disorders was approved in 2002.
5
15
Stimulation was a routine part of stereotactic surgery for movement disorders, so there had been a great deal of relatively informal information acquired about its effects. Generally, high frequency stimulation mimics the effect of making a lesion (Toth and Tomka, 1968), which provided a great deal of information about potential targets for DBS to treat movement disorders. In addition, as early as 1980, improvement in movement disorders was sometimes seen in patients who had DBS for pain management by Mazars et al. (1980). Even so, the mechanism for that observation has not been well defined (Anderson et al., 2004; Lee et al., 2004). The first report of patients without pain who had DBS implanted to treat a motor disorder was presented in 1980 by Brice and McLellan. They had several multiple sclerosis patients with intention tremor who were significantly improved by stimulation of the ventrolateral (VL) area of the thalamus. In 1986, Siegfried (1986) observed improvement in dyskinesia in a patient who had a stimulator inserted to treat the pain of Dejerine–Roussy syndrome,6 and advocated the use of stimulation for motor disorders. It was not until 1987, however, that Benebid et al. reported on the use of ventrointermedius nuclei (Vim) stimulation for parkinsonian tremor (see Figure 2.6). Since the response was incomplete with maximum frequency of 130 Hz, he also made a lesion to obtain a satisfactory result. Both Benabid and Siegfried had made observations over the prior few years concerning patients who had improvement in motor symptoms on implantation of a DBS for pain, but I have been unable to determine in talking with them who had made the observation first. In the 1980s, the stage had been set for the development of DBS for movement disorders. Targets were available from experiences with lesion production. Stimulators had been produced that made chronic stimulation feasible. However, the main population of patients for surgery for movement disorder was still the large group of Parkinson’s disease patients, but there remained a feeling that they could be managed indefinitely with levodopa, even though the evidence 6
Thalamic syndrome (Dejerine–Roussy) is a rare neurological disorder in which the body becomes hypersensitive to pain as a result of damage to the thalamus, a part of the brain that affects sensation. The thalamus has been described as the brain’s sensory relay station. Primary symptoms are pain and loss of sensation, usually in the face, arms, and/or legs. Pain or discomfort may be felt after being mildly touched or even in the absence of a stimulus. The pain associated with thalamic syndrome may be made worse by exposure to heat or cold and by emotional distress. Sometimes, this may include even such emotions as those brought on by listening to music (http://www.peacehealth.org/kbase/nord/nord796.htm).
I. an introduction to neuromodulation
16
2. neuromodulation: a historical perspective
Figure 2.6 Professor Alim Benebid of Grenoble, France
was accumulating that this was not so. There were few neurosurgeons who still remained expert in stereotactic surgery, since there had been so little activity in the field. That changed in 1992, when Laitinen resurrected Leksell’s old observations about successful treatment of bradykinesia and dyskinesia of Parkinson’s disease by ventral posterior pallidotomy (Laitinen et al., 1992a, 1992b). Neurosurgeons returned to pallidotomy with enthusiasm, especially since there were so many Parkinson patients who had significant medicationinduced dyskinesia that might respond to surgery. During the next decade, stereotactic surgery for Parkinson’s disease grew significantly. Vim thala motomy was indicated for tremor (Gildenberg and Tasker, 1998) and pallidotomy was generally used for bradykinesia or dyskinesia (Lozano and Lang, 1998). Stereotactic lesions were made for a variety of other movement disorders (Parrent, 1998) and pain (Gybels and Sweet, 1989). Neurologists, the gatekeepers for referring patients for surgery, had become interested in intraoperative microelectrode recording, which was used to improve final placement of the lesion (Kelly, 1980). Imaging had improved significantly, so it was now possible to identify the target structure anatomically (Giller et al., 1998). Interest grew in techniques to replace the deficient neurotransmitters in Parkinson’s disease by implantation of adrenal medulla (Lindvall et al., 1987; Bakay, 1993; Watts et al., 1997) and embryonic tissue (Hitchcock, 1994). Additionally, during this time, surgery for epilepsy had increased dramatically, to a large extent because of
the availability of long-term monitoring with both scalp and implanted electrodes, as well as the identification of anatomic lesions by the vastly improved imaging modalities (Ojemann, 1983). Stimulators, however, offered a distinct advantage over lesions, in that the risk of implanting electrodes was low, and any adverse effect from stimulation was not permanent, so there remained great interest in DBS for epilepsy. Although the technology was available for implanted stimulators, their use had been de-approved by the FDA, so their re-incorporation into stereotactic surgery came only gradually. Nevertheless, a number of centers were set up in the USA, Canada, and overseas to study the effects of deep brain stimulators on movement disorders, so that by the time DBS obtained FDA approval in 2002, the procedure was well documented and well established (Lozano et al., 1996; Rezai et al., 1999; Benabid et al., 2000). After pallidotomy was reintroduced, that same target was used for DBS by Siegfried for the treatment of Parkinson’s disease (Siegfried and Lippitz, 1994a), as had later Lozano (2001) and Ashby et al. (1998), as well as many others. Siegfried (Siegfried and Lippitz, 1994b) and Benabid et al. (1991) stimulated Vim targets that had been the site of lesion production for tremor in Parkinson’s disease. The subthalamic nucleus, as a target for DBS, warrants special note. In 1964, Forel’s field in the subthal amic area was used as a lesion target by Spiegel, Wycis et al. in a procedure they called campotomy (campus Forelli) (Wycis and Gildenberg, 1965). As early as 1965, the potential beneficial effects of acute stimulation during surgery in the subthalamic area were documented (Johansson and Laitinen, 1965). Although most neuro surgeons were concerned about potential hemiballism7 if lesions were made in the subthalamic nucleus, Story (Story et al., 1965) and Houdart et al. (1965) found beneficial effects by making lesions in the subthalamic nuclei in Parkinson’s patients. When DBS became available, its risk was felt to be less than the risks presented by lesioning, so bilateral subthalamic nuclei stimulation
7
Hemiballism is a neurological sign, a movement disorder, characterized by unilateral wild, large amplitude flinging movements of the arm and leg, normally causing falls and preventing postural maintenance. It is caused by a lesion or infarction in the contralateral subthalamic nucleus or its connections, usually in patients with a history of hypertension or diabetes, or following TB meningitis. The subthalamic nucleus normally regulates the globus pallidus by exciting the GPi, which in turn normally inhibits the ventral anterior nucleus, ventral lateral nucleus and lateral dorsal nucleus of the thalamus. The reduced discharge in both causes disinhibition of the thalamus and consequent involuntary stimulation of the motor cortex. Altered dopaminergic feedback mechanisms may also be involved.
I. an introduction to neuromodulation
Neuromodulation: A Historical Perspective
was an attractive target, particularly for patients with significant bradykinesia and dyskinesia (Benabid et al., 1994). Benabid has been a particular advocate of that target since 1991, and has been a moving force in the elucidation of the mechanism of DBS (Benabid et al., 2002). Although Forel’s field itself has not been claimed as a target, reports of pre-lemniscal, pre-rubral or zona inserta stimulation suggest that the same pathways are being stimulated (Velasco et al., 2001). In addition, DBS has been used for a variety of other movement disorders such as dystonia (Kumar et al., 1999; Loher et al., 2000; Tronnier and Fogel, 2000). It is noteworthy that stereotactic dorsomedian thalamotomy was used for psychosurgery as early as 1947 (Spiegel et al., 1947), and pallidotomy was performed for epilepsy in 1956 (Baird et al., 1956; Spiegel et al., 1958), so the precedent for stereotactic treatment of these disorders has long been founded, leading to the use of DBS for psychosurgery (Nuttin et al., 2003) and epilepsy (Theodore and Fisher, 2004). Velasco stimulated both the centromedian nucleus (Velasco et al., 1993) and the hippocampus (Velasco et al., 2000) for seizures. One use of DBS that is still unproved is its use in prolonged coma (Tsubokawa et al., 1990). Undoubtedly, additional indications that were not managed by lesions will be discovered for DBS. Several other types of stimulation outside of the central or peripheral nervous system are noteworthy, especially since the indications are similar to those discussed above. Chief among these is vagal nerve stimulation (VNS) for intractable epilepsy not amenable to surgical resection (Finesmith et al., 1999). Curiously, in the 1880s, Corning performed cutaneous stimulation in the area of the vagal nerve and observed a decrease in seizures (Lanska, 2002). In 1972, Zabara demonstrated that VNS could control emesis in the dog, a not unexpected finding (Zabara et al., 1972). In 1985, he demonstrated a decrease in strychnine seizure potentials, again in the dog, but he did not offer evidence in that paper about why he should perform such an experiment. Nevertheless, this led Terry et al. (1991) to design and produce a vagal nerve stimulator that has been approved for use in clinical epilepsy. Despite its long history, the mechanism for vagal nerve stimulation remains to this day obscure (Zabara, 1992). More recently, based on the observation of mood improvement in some of the patients who had VNS for epilepsy, there has been evidence that VNS may also be of benefit for severe depression (Shafique and Dalsing, 2006), although it has not been approved, as of this writing. Other indications for electrical stimulation of the central nervous system include stimulation of the conus of the spinal cord for bladder control, which was advocated by Nashold et al. as early as 1972. About a
17
decade later, Brindley developed a technique for stimulating sacral nerves for micturition (Brindley et al., 1982; Brindley, 1988), which has evolved as the preferred technique (Creasey et al., 2004). (For a complete review of sacral nerve stimulation, see Chapter 77.) The design of implantable stimulators has progressed to the point where any desired stimulation can be applied to almost any neural structure. At the meeting of the World Society for Stereotactic and Functional Neurosurgery in São Paulo in 1977, I remarked, “The engineers can give us any stimulation parameters we need. We just have to know what to ask for and where to put the electrode.” That has still not changed.
References Alberts, W.W., Feinstein, B., Levin, G. and Wright, E.W. (1966) Electrical stimulation of therapeutic targets in waking dyskinetic patients. Electroencephalogr. Clin. Neurophysiol. 20: 559–66. Aldini, J. (1804) Essai théorique et expérimental sur le galvanisme, avec une série d’expériences faites devant des commissaires de l’Institut national de France, et en divers amphitheâtres anatomiques de Londres. Paris. Anderson, T., Hu, B., Pittman, Q. and Kiss, Z.H. (2004) Mechanisms of deep brain stimulation: an intracellular study in rat thalamus. J. Physiol. 559: 301–13. Ashby, P., Strafella, A., Dostrovsky, J.O., Lozano, A. and Lang, A.E. (1998) Immediate motor effects of stimulation through electrodes implanted in the human globus pallidus. Stereotact. Funct. Neurosurg. 70: 1–18. Augustinsson, L.E., Carlsson, C.A., Holm, J. and Jivegard, L. (1985) Epidural electrical stimulation in severe limb ischemia. Pain relief, increased blood flow, and a possible limb-saving effect. Ann. Surg. 202: 104–10. Baird, H.W., III, Wycis, H.T. and Spiegel, E.A. (1956) Treatment of convulsions by pallidoansotomy. AMA Arch. 75: 446–7. Bakay, R.A. (1993) Neurotransplantation: a clinical update. Acta Neurochir. Suppl. (Wien) 58: 8–16. Bantli, H., Bloedel, J.R., Long, D.M. and Thienprasit, P. (1975) Distribution of activity in spinal pathways evoked by experimental dorsal column stimulation. J. Neurosurg. 42: 290–5. Bechtereva, N.P. (1969) Some crucial points in investigation of the neurophysiological basis of human mental activity. Electroencephalogr. Clin. Neurophysiol. 26: 545. Bechtereva, N.P., Bondarchuk, A.N. and Smirnov, V.M. (1972) Therapeutic electrostimulations of the deep brain structures. Vopr. Neurokhir. 1: 7–12. Benabid, A.L., Benazzous, A. and Pollak, P. (2002) Mechanisms of deep brain stimulation. Mov. Disord. 17 (Suppl. 3): S73–S74. Benabid, A.L., Koudsie, A., Benazzouz, A., Fraix, V., Ashraf, A., Le Bas, J.F. et al. (2000) Subthalamic stimulation for Parkinson’s disease. Arch. Med. Res. 31: 282–9. Benabid, A.L., Pollak, P., Gervason, C., Hoffmann, D., Gao, D.M., Hommel, M. et al. (1991) Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet 337: 403–6. Benabid, A.L., Pollak, P., Gross, C., Hoffmann, D., Benazzouz, A., Gao, D.M. et al. (1994) Acute and long-term effects of subthalamic nucleus stimulation in Parkinson’s disease. Stereotact. Funct. Neurosurg. 62: 76–84. Benabid, A.L., Pollak, P., Louveau, A., Henry, S. and de Rougemont, J. (1987) Combined (thalamotomy and stimulation) stereotactic
I. an introduction to neuromodulation
18
2. neuromodulation: a historical perspective
surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl. Neurophysiol. 50: 344–6. Brice, J. and McLellan, L. (1980) Suppression of intention tremor by contingent deep-brain stimulation. Lancet 1: 1221–2. Brindley, G.S. (1988) The Ferrier lecture, 1986. The actions of parasympathetic and sympathetic nerves in human micturition, erection and seminal emission, and their restoration in paraplegic patients by implanted electrical stimulators. Proc. R. Soc. Lond. B Biol. Sci. 235: 111–20. Brindley, G.S., Polkey, C.E. and Rushton, D.N. (1982) Sacral anterior root stimulators for bladder control in paraplegia. Paraplegia 20: 365–81. Cook, A.W. (1976) Electrical stimulation in multiple sclerosis. Hosp. Pract. 11: 51–8. Cooper, I.S., Riklan, M., Waltz, J.M., Amin, I. and Pani, K. (1974) A study of chronic cerebellar stimulation in disorders of sensory communication in the central nervous system. Bol. Estud. Med. Biol. 28: 347–90. Cosman, E.R., Nashold, B.S., Jr and Bedenbaugh, P. (1983) Stereotactic radiofrequency lesion making. Appl. Neurophysiol. 46: 160–6. Creasey, G.H., Ho, C.H., Triolo, R.J., Gater, D.R., DiMarco, A.F., Bogie, K.M. et al. (2004) Clinical applications of electrical stimulation after spinal cord injury. J. Spinal Cord. Med. 27: 365–75. Cushing, H. (1909) Faradic stimulation of postcentral gyrus in conscious patients. Brain 32: 44–53. Davis, R., Cullen, R.F., Duenas, D. and Engle, H. (1976) Cerebellar stimulation for cerebral palsy. J. Florida Med. Assoc. 63: 910–12. Davis, R., Gray, E., Engle, H. and Dusnak, A. (1983) Reduction of intractable seizures using cerebellar stimulation. Appl. Neurophysiol. 46: 57–61. Davis, R., Gray, E., Ryan, T. and Schulman, J. (1985) Bioengineering changes in spastic cerebral palsy groups following cerebellar stimulation. Appl. Neurophysiol. 48: 111–16. Dooley, D.M. and Kasprak, M. (1976) Modification of blood flow to the extremities by electrical stimulation of the nervous system. South. Med. J 69: 1309–11. Dooley, D.M. and Sharkey, J. (1977) Electrostimulation of the nervous system for patients with demyelinating and degenerative diseases of the nervous system and vascular diseases of the extremities. Appl. Neurophysiol. 40: 208–17. Finesmith, R.B., Zampella, E. and Devinsky, O. (1999) Vagal nerve stimulator: a new approach to medically refractory epilepsy. N. Engl. J. Med. 96: 37–40. Fritsch, G. and Hitzig, E. (1870) Über die elektrische Erregbarkeit des Grosshirns. Arch. Anat. Physiol. Wiss. Med. 37: 300–32. Gildenberg, P.L. (1977a) Treatment of spasmodic torticollis with dorsal column stimulation. Acta Neurochir (Wien) (Suppl. 24): 65–6. Gildenberg, P.L. (ed.) (1977b) Symposium on the Safety and Clinical Efficacy of Implanted Neuroaugmentive Devices. Appl. Neurophysiol. 40: 69–240. Gildenberg, P.L. (1977c) Neurosurgical statement on neuroaugmentive devices. Appl. Neurophysiol 40: 69–71. Gildenberg, P.L. (1993) “Stereotaxic” versus “stereotactic”. Neurosurgery 32: 965–6. Gildenberg, P.L. and Tasker, R.R. (eds) (1998) Textbook of Stereotactic and Functional Neurosurgery. New York: McGraw–Hill, pp. 1179–98. Giller, C.A., Dewey, R.B., Ginsburg, M.I., Mendelsohn, D.B. and Berk, A.M. (1998) Stereotactic pallidotomy and thalamotomy using individual variations of anatomic landmarks for localization. Neurosurgery 42: 56–62. Gol, A. (1967) Relief of pain by electrical stimulation of the septal area. J. Neurol. Sci 5: 115–20.
Gybels, J.M. and Sweet, W.H. (1989) Neurosurgical Treatment of Persistent Pain. Basle: Karger. Hassler, R., Riechert, T., Mundinger, F., Umbach, W. and Ganglberger, J.A. (1960) Physiological observations in stereotaxic operations in extrapyramidal motor disturbances. Brain 83: 337–50. Heath, R.G. (1958) Correlation of electrical recordings from cortical and subcortical regions of the brain with abnormal behavior in human subjects. Confin. Neurol. 18: 305–15. Heath, R.G. (1996) Exploring the Mind–Brain Relationship. Baton Rouge, LA: Moran Printing, Inc.. Heath, R.G., Monroe, R.R. and Mickle, W.A. (1955) Stimulation of the amygdaloid nucleus in a schizophrenic patient. Am. J. Psychiatry 111: 862–3. Hitchcock, E. (1994) Stereotactic neural transplantation. Stereotact. Funct. Neurosurg. 62: 120–33. Hoppenstein, R. (1975) Electrical stimulation of the ventral and dorsal columns of the spinal cord for relief of chronic intractable pain: preliminary report. Surg. Neurol. 4: 187–94. Horsley, V. (1909) The Linacre Lecture on the function of the so-called motor area of the brain. Br. Med. J. 21: 125–32. Horsley, V. and Clarke, R.H. (1908) The structure and functions of the cerebellum examined by a new method. Brain 31: 45–124. Hosobuchi, Y., Adams, J.E. and Rutkins, B. (1973) Chronic thalamic stimulation for the control of facial anesthesia dolorosas. Arch. Neurol. 29: 158–61. Houdart, R., Mamo, H., Dondey, M. and Cophignon, J. (1965) Results of subthalamic coagulations in Parkinson’s disease (apropos of 50 cases). Rev. Neurol. (Paris) 112: 521–9. Isaacson, W. (2003) Benjamin Franklin. An American Life. New York: Simon & Schuster. Johansson, G. and Laitinen, L. (1965) Electrical stimulation of the thalamic and subthalamic area in Parkinson’s disease. Confin. Neurol. 26: 445–50. Kelly, P.J. (1980) Microelectrode recording for the somatotopic placement of stereotactic thalamic lesions in the treatment of parkinsonian and cerebellar intention tremor. Appl. Neurophysiol. 43: 262–6. Kumar, R., Dagher, A., Hutchison, W.D., Lang, A.E. and Lozano, A. M. (1999) Globus pallidus deep brain stimulation for generalized dystonia: clinical and PET investigation. Neurology 53: 871–4. Laitinen, L.V., Bergenheim, A.T. and Hariz, M.I. (1992a) Ventroposterolateral pallidotomy can abolish all parkinsonian symptoms. Stereotact. Funct. Neurosurg. 58: 14–21. Laitinen, L.V., Bergenheim, A.T. and Hariz, M.I. (1992b) Leksell’s posteroventral pallidotomy in the treatment of Parkinson’s disease. J. Neurosurg. 76: 53–61. Lanska, D.J. (2002) Corning and vagal nerve stimulation for seizures in the 1880s. Neurology 58: 452–9. Larson, S.J., Sances, A., Cusick, J.F., Meyer, G.A. and Swiontek, T. (1975) A comparison between anterior and posterior spinal implant systems. Surg. Neurol. 4: 180–6. Lee, K.H., Chang, S.Y., Roberts, D.W. and Kim, U. (2004) Neurotransmitter release from high-frequency stimulation of the subthalamic nucleus. J. Neurosurg. 101: 511–17. Lindvall, O., Backlund, E.O., Farde, L., Sedvall, G., Freedman, R., Hoffer, B. et al. (1987) Transplantation in Parkinson’s disease: Two cases of adrenal medullary grafts to the putamen. Ann. Neurol. 22: 457–68. Loher, T.J., Hasdemir, M.G., Burgunder, J.M. and Krauss, J.K. (2000) Long-term follow-up study of chronic globus pallidus internus stimulation for posttraumatic hemidystonia. J. Neurosurg. 92: 457–60.
I. an introduction to neuromodulation
references
Lozano, A. (2001) Deep brain stimulation: challenges to integrating stimulation technology with human neurobiology, neuroplasticity, and neural repair. J. Rehabil. Res. Dev. 38: x–xix. Lozano, A. and Lang, A.E. (1998) Pallidotomy for Parkinson’s disease. Part II: The Toronto Hospital experience. In: P.L. Gildenberg and R.R. Tasker (eds), Textbook of Stereotactic and Functional Neurosurgery. New York: McGraw–Hill, pp. 1161–6. Lozano, A., Hutchison, W., Kiss, Z., Tasker, R., Davis, K. and Dostrovsky, J. (1996) Methods for microelectrode-guided posteroventral pallidotomy. J. Neurosurg. 84: 194–202. Mazars, G.J. (1975) Intermittent stimulation of nucleus ventralis posterolateralis for intractable pain. Surg. Neurol. 4: 93–5. Mazars, G., Merienne, L. and Cioloca, C. (1980) Control of dyskinesias due to sensory deafferentation by means of thalamic stimulation. Acta Neurochir. Suppl. (Wien) 30: 239–43. Melzack, R. and Wall, P.D. (1965) Pain mechanisms: a new theory. Science 150: 971–9. Meyer, D.J. and Price, D.D. (1976) Central nervous system mechanisms of analgesia. Pain 2: 379–404. Morgan, J.P. (1982) The first reported case of electrical stimulation of the human brain. J. Hist. Med. Allied Sci. 37: 51–64. Nashold, B.S.J., Friedman, H., Glenn, J.F., Grimes, J.H., Barry, W.F. and Avery, R. (1972) Electromicturition in paraplegia. Implantation of a spinal neuroprosthesis. Arch. Surg. 104: 195–202. Nuttin, B., Gybels, J., Cosyns, P., Gabriels, L., Meyerson, B., Andreewitch, S. et al. (2003) Deep brain stimulation for psychiatric disorders. Neurosurg. Clin. North Am. 14: 15–16. Ojemann, G.A. (1983) Neurosurgical management of epilepsy: a personal perspective in 1983. Appl. Neurophysiol. 46: 11–18. Olds, J. and Milner, P. (1954) Positive reinforcement produced by electrical stimulation of the septal area and other regions of the rat brain. J. Comp. Physiol. Psychol 47: 419–27. Parrent, A.G. (1998) Overview of the surgical treatment of movement disorders. In: P.L. Gildenberg and R.R. Tasker (eds), Textbook of Stereotactic and Functional Neurosurgery. New York: McGraw–Hill, pp. 995–1004. Penfield, W. and Jasper, H. (1954) Epilepsy and the Functional Anatomy of the Human Brain. Boston, MA: Little, Brown. Pool, J.L. (1954) Psychosurgery in older people. J. Am. Geriatr. Soc. 2: 456–65. Pruel, M.C. (1997) A history of neuroscience from Galen to Gall. In: S.H. Greenblatt, T.F. Dagi and M.H. Epstein (eds), A History of Neurosurgery. Park Ridge, IL: American Association of Neurological Surgeons, pp. 99–130. Reynolds, D.V. (1969) Surgery in the rat during electrical analgesia induced by focal brain stimulation. Science 164: 444–5. Rezai, A.R., Lozano, A.M., Crawley, A.P., Joy, M.L., Davis, K.D., Kwan, C.L. et al. (1999) Thalamic stimulation and functional magnetic resonance imaging: localization of cortical and subcortical activation with implanted electrodes. Technical note. J. Neurosurg. 90: 583–90. Richardson, D.E. and Akil, H. (1977a) Pain reduction by electrical brain stimulation in man. Part 1: Acute administration in periaqueductal and periventricular sites. J. Neurosurg. 47: 178–83. Richardson, D.E. and Akil, H. (1977b) Pain reduction by electrical brain stimulation in man. Part 2: Chronic self-administration in the periventricular gray matter. J. Neurosurg. 47: 184–94. Riechert, T. (1980) Stereotactic Brain Operations. Methods, Clinical Aspects, Indications. Berne: Hans Huber. Shafique, S. and Dalsing, M.C. (2006) Vagus nerve stimulation therapy for treatment of drug-resistant epilepsy and depression. Perspect. Vasc. Surg. Endovasc. Ther. 18: 323–7.
19
Shealy, C.N., Mortimer, J.T. and Reswick, J.B. (1967) Electrical inhibition of pain by stimulation of the dorsal columns. Preliminary clinical report. Anesth. Analg. (Cleve.) 46: 489–91. Shelley, M. (1818) Frankenstein. Oxford: Oxford University Press. Siegfried, J. (1986) Effect of stimulation of the sensory nucleus of the thalamus on dyskinesia and spasticity. Rev. Neurol. (Paris) 142: 380–3. Siegfried, J. and Lippitz, B. (1994a) Bilateral chronic electro stimulation of ventroposterolateral pallidum: a new therapeutic approach for alleviating all parkinsonian symptoms. Neurosurgery 35: 1126–9. Siegfried, J. and Lippitz, B. (1994b) Chronic electrical stimulation of the VL-VPL complex and of the pallidum in the treatment of movement disorders: personal experience since 1982. Stereotact. Funct. Neurosurg. 62: 71–5. Spiegel, E.A., Wycis, H.T. and Baird, H.W. (1952) Studies in stereoencephalotomy. I. Topical relationships of subcortical structures to the posterior commissure. Confin. Neurol. 12: 121–33. Spiegel, E.A., Wycis, H.T. and Baird, H.W., III (1958) Pallidotomy and pallidoamygdalotomy in certain types of convulsive disorders. AMA Arch. Neurol. Psychiatry 80: 714–28. Spiegel, E.A., Wycis, H.T., Marks, M. and Lee, A.S. (1947) Stereotaxic apparatus for operations on the human brain. Science 106: 349–50. Spiegel, E.A., Wycis, H.T. and Umlauf, C.W. (1950) Electro encephalographic studies before and after thalamotomy. Monatsschr. Psychiatr. Neurol. 120: 398–411. Spiegel, E.A., Wycis, H.T., Szekely, E.G., Soloff, L., Adams, J., Gildenberg, P. et al. (1964) Stimulation of Forel’s field during stereotaxic operations in the human brain. Electroencephalogr. Clin. Neurophysiol. 16: 537–48. Stillings, D. (1971) The first use of electricity for pain treatment. Medtronic Archive on Electro-Stimulation. Story, J.L., French, L.A., Chou, S.N. and Meier, M.J. (1965) Experiences with subthalamic lesions in patients with movement disorders. Confin. Neurol. 26: 218–21. Tasker, R.R., Organ, L.W. and Hawrylshyn, P.A. (1982) The Thalamus and Midbrain of Man. A Physiological Atlas Using Electrical Stimulation. Springfield, IL: C.C Thomas. Terry, R.S., Tarver, W.B. and Zabara, J. (1991) The implantable neurocybernetic prosthesis system. Pacing Clin. Electrophysiol. 14: 86–93. Theodore, W.H. and Fisher, R.S. (2004) Brain stimulation for epilepsy. Lancet Neurol. 3: 111–18. Tronnier, V.M. and Fogel, W. (2000) Pallidal stimulation for generalized dystonia. Report of three cases. J. Neurosurg. 92: 453–6. Toth, S. and Tomka, I. (1968) Responses of the human thalamus and pallidum to high frequency stimulations. Confin. Neurol. 30: 17–40. Tsubokawa, T., Yamamoto, T., Katayama, Y., Hirayama, T., Maejima, S. and Moriya, T. (1990) Deep-brain stimulation in a persistent vegetative state: follow-up results and criteria for selection of candidates. Brain Inj. 4: 315–27. Velasco, A.L., Velasco, M., Velasco, F., Menes, D., Gordon, F., Rocha, L. et al. (2000) Subacute and chronic electrical stimulation of the hippocampus on intractable temporal lobe seizures: preliminary report. Arch. Med. Res. 31: 316–28. Velasco, F., Jimenez, F., Perez, M.L., Carrillo-Ruiz, J.D., Velasco, A.L., Ceballos, J. et al. (2001) Electrical stimulation of the prelemniscal radiation in the treatment of Parkinson’s disease: an old target revised with new techniques. Neurosurgery 49: 293–306. Velasco, M., Velasco, F., Velasco, A.L., Velasco, G. and Jimenez, F. (1993) Effect of chronic electrical stimulation of the centromedian thalamic nuclei on various intractable seizure patterns: II. Psychological performance and background EEG activity. Epilepsia 34: 1065–74.
I. an introduction to neuromodulation
20
2. neuromodulation: a historical perspective
Vilensky, J.A. and Gilman, S. (2002) Horsley was the first to use electrical stimulation of the human cerebral cortex intraoperatively. Surg. Neurol. 58: 425–6. Wall, P.D. and Sweet, W.H. (1967) Temporary abolition of pain in man. Science 155: 108–9. Watts, R.L., Subramanian, T., Freeman, A., Goetz, C.G., Penn, R.D., Stebbins, G.T. et al. (1997) Effect of stereotaxic intrastriatal cografts of autologous adrenal medulla and peripheral nerve in Parkinson’s disease: two-year follow-up study. Exp. Neurol. 147: 510–17. Woolsey, C.N. (1964) Cortical localization as defined by evoked potential and electrical stimulation studies. In: G. Schaltenbrand and C.N. Woolsey (eds), Cerebral Localization and Organization. Madison, WI: University of Wisconsin Press, pp. 17–26.
Wycis, H.T. and Gildenberg, P.L. (1965) Further observations on campotomy in various extrapyramidal disorders. In: A. Barbeau, L. J. Doshay and E.A. Spiegel (eds), Parkinson’s Disease. Trends in Research and Treatment. New York: Grune and Stratton, pp. 134–48. Wycis, H.T. and Gildenberg, P.L. (1969) Long-range evaluation of the surgical treatment of spasmodic torticollis. Excerpta Med. Int. Congr. Ser. 193: 97. Zabara, J. (1985) Peripheral control of hypersynchronous discharge in epilepsy. EEG Clin. Neurophysiol. 61: 162. Zabara, J. (1992) Inhibition of experimental seizures in canines by repetitive vagal stimulation. Epilepsia 33: 1005–12. Zabara, J., Chaffee, R.B., Jr and Tansy, M.F. (1972) Neuroinhibition in the regulation of emesis. Space Life Sci. 3: 282–92.
I. an introduction to neuromodulation
C H A P T E R
3
Neuromodulation Technologies: Whom Do We Serve? Allen R. Dyer and Mary Pat Aardrup
o u tl i ne Introduction
21
Pain as Paradigm
23
Pain and Dependency
23
Psychiatric Overlay
24
24
How Do We Serve Whom We Serve?
26
The Healer’s Art
26
References
27
The American Heritage Dictionary (2000) confirms our historical orientation of patienthood:
In our quest to help patients, let us not forget the fundamental elements. John C. Oakley, MD*
patient — 1. adjective Capable of bearing affliction with calmness. 2. Tolerant; understanding. 3. Persevering; constant. 4. Capable of bearing delay and waiting for the right moment. –noun One under medical treatment. [from Latin patiens, to suffer]
Introduction
(Copyright © 2000 by Houghton Mifflin Company)
The answer to the question, “Whom do we serve?” is as simple as “We serve those who could benefit from the technology” and as complex as “We serve those who suffer from the afflictions which neuromodulation technologies might address.” The question, “Whom do we serve?” touches on scientific, technological, humanistic, ethical, and economic aspects of medicine.
Someone who is patient is capable of bearing affliction with calmness. One becomes a patient, that is comes under medical treatment, in order to bear affliction with calmness. The doctor’s role is defined by the patient. That is to say, the doctor or the healer in society exists in order to help people bear affliction with calmness. Technology, specifically neuromodulation technology, is one of the tools physicians use to help patients be patient. This chapter will address those patients whom we (the broad field of neuromodulation) serve as well as those whom we do not serve. Neuromodulation is the field of science, medicine, and bioengineering that encompasses implantable and
*
John Oakley (1945–2006) was a neurosurgeon neuroscientist, a pioneer in pain medicine. The fundamental elements he refers to in the above quote, which was an inscription on a photomicrograph of the brain, are nerve cells. This chapter is dedicated to Dr Oakley, colleague and friend, and is inspired by his scientific humanism.
Neuromodulation
Ethical and Economic Considerations: Whom Do We Not Serve?
21
2009 Elsevier Ltd. © 2008,
22
3. Neuromodulation Technologies: Whom Do We Serve?
non-implantable technologies, electrical and chemical, that improve life for humanity. Neuromodulation is technology that impacts upon the neural interface (see International Neuromodulation Society website, www. neuromodulation.com). Among the technologies that neuromodulation encompasses are the following: l l l l l l l
Neurostimulation Neuroaugmentation Neural prosthetics Functional electrical stimulation (FES) Assistive technologies Neural engineering Brain–machine interface
Neuromodulatory devices are used for a growing number of indications including: l l l l l l
l l
l
l
Pain (ischemic, visceral, and neurogenic) Angina pectoris Peripheral vascular disease Epilepsy Urinary disorders Spasticity from spinal cord injury, cerebral palsy, or multiple sclerosis Diabetes Abdominal disorders such as irritable bowel syndrome or dysmotility syndromes Psychiatric disorders such as depression, obsessive– compulsive disorder and Tourette’s syndrome Movement disorders such as dystonia
Neuromodulation therapies serve a broad array of problems, as indicated by Table 3.1. Neurostimulation and other neuromodulation technologies have emerged as effective means of controlling and/or improving many bodily functions. Today, the original neuromodulation technology from
pacemaker technology is being successfully applied to the nervous system to treat diseases as diverse as Parkinson’s disease (Green et al., 2006), disorders of cardiac pacing (Sutton et al., 1980) and epilepsy (Kuba et al., 2003), and a myriad of other disabling conditions that are expected to significantly increase due to the aging population. These conditions include Alzheimer’s disease (Eriksdotter Jönhagen et al., 1998), chronic pain syndrome (Leveque et al., 2001), treatment-resistant depression (www.wireheading. com, 2007), severe migraine (Oh et al., 2004), obesity management (Liu et al., 2005) and many others. More impressive than a tabulation of the technologies used for neuromodulation therapies are the personal stories of people who have benefited from these technologies, such as the following: One of my biggest regrets is that the chronic pain and medication stole the opportunity to be actively involved in my children’s lives. Prior to the spinal cord stimulation (SCS) surgery, the last meaningful involvement I can remember having with my 14-year-old son is when he was three years old. With the help of the SCS system, I have been given the opportunity to reclaim what I lost and can live a fulfilling and productive life again. (Mike, phantom limb pain; www.advancedbionics.com/2007) It’s amazing how many simple things you give up when you’re in pain, and don’t even realize it until you get them back. For example, picking up a pen and not having it hurt. Just having the day to day things change and not needing to think about if it’s going to hurt – that’s a great deal of freedom. (Jessica, RSD hands, shoulders and back; www.advancedbionics.com/2007) My family has been extremely supportive of me, though I know they were frustrated over the years with my inability to hear. Increasingly, my family became my telephone communicator, social communicator as well as moral supporter.
Table 3.1 Populations served by neuromodulation therapies Indication
US prevalence
Source
Pain
105 000 000 (35%)
American Pain Society
Interstitial cystitis
847 000–1 000 000
National Kidney and Urologic Diseases Clearing House
Migraine
29 500 000
Population Division, US Census Bureau NCEST 2005-01
Traumatic brain injury
1 500 000
Brain Injury Association of America
Tinnitus
12 000 000
National Institutes on Deafness
Parkinson’s disease
1 500 000
National Parkinson Foundation
Essential tremor
5 000 000
Neurology Channel
Depression
14 200 000–28 000 000
NIMH
Morbid obesity
10 000 000
American Obesity Association
Angina
6 000 000
National Heart, Lung, and Blood Institute, NIH
Source: Marketing data from Advanced Neuromodulation Systems/St. Jude Medical
I. An introduction to neuromodulation
23
Pain and dependency
The cochlear implant has been a true miracle for me, my family, my friends, my colleagues and my students. (Neina, progressive hearing loss over 30 years; www.advancedbionics.com/2007) After a diagnosis of Parkinson’s disease in 1986, Gary endured growing difficulty walking, freezing episodes and slowness of movement. Of his life now after receiving deep brain stimulation, he says “Every day when I get up it is like a new life. I can go out to dinner with friends and not embarrass them or myself by twitching all over the place.” (Gary, Parkinson’s disease; www.medtronic.com/2007) I could see the difference immediately. Within a day or two, I was amazed how easy things were like writing a check and signing my name. (Bryan, essential tremor; www.medtronic.com/2007) Spinal cord stimulation is not a universal remedy. But chronic pain sufferers whose conditions cannot be improved with surgery owe it to themselves to investigate the treatment, particularly if they are told like I was, that drugs are the only options. (Pat, failed back surgery; www.ans-medical.com/2007)
Pain as paradigm Chronic pain is not the only disability for which neuromodulation technologies are employed, but all disabilities share in some ways the issues that pain and suffering impose on people’s lives. Disabilities are subjective experiences; they involve biological, psychological, social, and even spiritual components. They may be excruciating to the individual and imperceptible to others except through the vehicles of language such as verbal language or possibly, but not necessarily, “body language,” such as the flinch or grimace. For these reasons, pain may serve as a paradigm of a number of related disorders and disabilities. The American Heritage Dictionary (2000) defines pain as follows: pain — n. 1. An unpleasant sensation, occurring in varying degrees of severity as a consequence of injury, disease, or emotional disorder. 2. Suffering or distress. 3. Plural. The pangs of childbirth. 4. Plural. Great care or effort: take pains with one’s work. 5. Informal A nuisance. [Middle English paine, from Old French peine, from Latin poena, penalty, from Greek poine, penalty.] (Copyright © 2000 by Houghton Mifflin Company)
Medically, pain is now considered to be the fifth vital sign (American Pain Society, 1995; Phillips, 2000) which should be monitored along with temperature, heart rate, respiratory rate, and blood pressure. Pain is a subjective perception, not able to be objectified, and can only be monitored by a patient’s report and, as such, is the only vital sign for which there is not an
objective measure. Properly speaking, the fifth vital sign is the perception of pain. For our purposes we use the definition of pain from the International Association for the Study of Pain: “pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage” (IASP, 1994). As such, it is the paradigmatic symptom of medicine. All medicine is ultimately about pain in its myriad manifestations, in varying degrees of severity and consequence. Physical pain is seldom isolated from emotional pain and, over time, pain interferes with one’s life to the extent that mood, as a result of this “ongoing pain,” is altered in a way that we often call “depression.” Conversely, a lifetime of distress may also contribute to depression, complicating the perception of pain caused by injury or disease. pain→depression→emotional pain All medicine attempts to relieve the suffering and impatience that disrupts the lives of human beings. In the case of specialized interventions such as pharmacological treatments (modern derivatives of ancient herbal remedies) and the newer neuromodulation technologies, treatment is directed at a particular anatomical and physiological aspect of what is clearly understood to be a complex phenomenon, the bio-psycho-social experience of distress. For the physician’s purposes, the available technologies serve the larger goal of relief of suffering; they are tools of the physician’s trade. And suffering, understood as pain, is appreciated as a consequence of injury, disease, or emotional disorder. This circularity locates the physician’s work at the heart of human experience.
Pain and dependency
Case example Paul occasionally experienced back pain at times of stress in his late twenties and early thirties. Though this could be excruciating and incapacitating for a few days, it usually resolved with rest and his use of over-the-counter analgesics. His doctor prescribed diazepam for muscle relaxation, but did not perform any particular diagnostic work-up. When he was 32, his back pain became chronic after what at first seemed like a relatively minor injury (lifting boxes at work). X-rays showed degenerative disc disease and a ruptured intervertebral disc. His
I. An introduction to neuromodulation
24
3. Neuromodulation Technologies: Whom Do We Serve?
doctor prescribed non-steroidal anti-inflammatory analgesics, renewed the diazepam, and recommended a period of rest, which helped but did not relieve the symptoms. He returned to work, but his performance suffered; his boss was unsympathetic, at times hostile. His analgesic use escalated. He became physically dependent and ultimately psychologically dependent (addicted) to the pills his doctor prescribed, then to drugs he received from his friends. He was now unable to do his job, and was fired. He became depressed and irritable. He isolated himself from family and friends and from his own feelings of anger and rage. He felt hopeless and considered suicide. Pain became his constant companion and the center of his existence. His doctor refused to see him because he was “non-compliant,” and without a job, he was without insurance. Eventually, he was granted disability. He was given a dorsal column stimulator and, for several months, it provided some intermittent relief.
account of disorders with a life of their own and must be considered when comprehensively assessing whom do we serve: l l l l l l
Anxiety Depression Psychosis Somatoform disorders Factitious disorders Axis II disorders (DSM–IV, Developmental and Personality Disorders)
The physician must deal with his or her own reactions to the feelings that these “difficult” patients bring to the table. It may be more useful to conceptualize these disorders as defenses, the characteristic way people deal with unpleasant affects and emotions, fear, anger, loss, sorrow. Such patients may have difficulty expressing their feelings directly or even recognizing them. If the physician can respond to the underlying feelings, it may be easier than responding to the behavior itself. Recognizing and responding to these disorders can significantly impact the success of the procedure and open receptivity to the healing mindset (Table 3.2).
Psychiatric overlay The ideal patient in the biomedical perspective is someone who has demonstrable organic dysfunction and no psychiatric overlay. In the real world, such a creature rarely exists. Practically speaking, the nonorganic aspects of symptom presentation complicate diagnostic evaluation and may frustrate physicians’ attempts to help the patient, both at a professional and personal level. Often such frustration may limit the care a patient receives from a healthcare giver, either from anger or misunderstanding. It may be useful to reconceptualize medicine to account for not only the anatomical and physiological aspects of disease in a reductionistic sense, but also the inter-relationships of the biological, the psychological, and the social. Philosophers of medicine call this new direction “complexity science,” acknowledging the multiplicity of variables that must be addressed in every clinical situation. Interdisciplinary teams are a practical and more or less efficient way of making sure that each aspect of a person’s problem gets the attention of a specialist prepared to consider each facet of such complex symptoms. Often in the busy clinical world, each specialist does his or her own thing. It is important that the teams be integrated at a working level and conceptually. The following list of symptoms commonly associated with disease states is intended to illustrate the complex nuance of conceptualizing human feelings and experiences as much as it is to be an exhaustive
Ethical and economic considerations: whom do we not serve? The complexities of the question “Whom do we serve?” can be appreciated by asking the question in the negative, “Whom do we NOT serve?” The answer to this form of the question opens consideration of a number of ethical and economic considerations of how we value health and how we fund health. It is obvious to all that we do not serve those whose symptoms do not indicate treatment with our technologies. We do not use neuromodulation technologies for those whose symptoms respond to less complex treatments. Similarly we do not employ these complex technologies for those who are unlikely to bene fit from them. Careful research, particularly outcome studies, will be needed to best predict and delineate those most likely to benefit. We do not serve those who choose not to receive surgery/treatment. In one survey of 212 implanting physicians, 40% of patients offered neurostimulation declined treatment (Table 3.3). There are many reasons for this relatively high number of refusals. Fear of the procedure itself and fear of having a foreign object implanted in one’s body top these reasons. For example, patients have concerns about paralysis due to the leads connecting
I. An introduction to neuromodulation
25
Ethical and economic considerations: whom do we not serve?
Table 3.2 Neurostimulation applications Condition [Treatment]
Prevalence/incidence
FDA Regulatory status
Estimated implants to date/per year
Chronic pain spinal cord stimulation [Peripheral nerve stimulation]
50 000 000/5 000 000
Cleared
110 000/16 000
Parkinson’s disease/essential tremor [Deep brain stimulation]
1 500 000/250 000
Cleared
30 000/5850
Epilepsy [Vagal nerve stimulation]
2 700 000/500 000
Cleared
22 500/1250
Chronic depression [Vagal nerve stimulation]
15 000 000/4 000 000
Cleared
22 500/1250
Urge urinary incontinence [Sacral nerve stimulation]
12 000 000/150 000
Cleared
25 000/3000
Pelvic pain [Sacral nerve stimulation]
N/A
In trials
N/A
Chronic intractable pain [Spinal cord stimulation]
N/A
In trials
N/A
Peripheral vascular disease [Spinal cord stimulation]
N/A
In trials
N/A
Obesity vagal nerve stimulation [Direct gastric stimulation]
5 000 000/250 000
In development
N/A
Pain, dystonia, epilepsy, OCD, depression, motor dysfunction, brain injury [Deep brain stimulation]
N/A
In trials
N/A
Source: Medtech Insights
Table 3.3 Patients recommended for a spinal column stimulator but not receiving surgery Approximate percentage agreeing to implant
Approximate percentage declining the implant?
No.
212
212
Mean
61.9
38.1
Median
60.0
40.0
Source: Medtronic, Inc data on file, January 2007
with the spinal column and therefore may not choose the therapy that might help their pain and disability. Hope is another significant barrier to receiving implantable technologies. Many of these individuals have been defined by their illness on average for 7–12 years. How will their lives change when they are no longer defined by their malady? Many are unready to give up the symptoms. The level of enthusiasm on the part of the physician will also dictate the patient’s receptivity to the procedure as will negative word of mouth regarding the procedure. Other possible issues may involve lack of information on outcomes measurements, misperceptions about what the treatment entails, and cosmetic considerations. More work needs to be done to better understand why people do and do not choose to receive these technologies and how best to match those wanting and needing the treatments with those most likely to benefit. The next group of people that we do NOT serve that must be considered is the uninsured. One in
six Americans are uninsured – all Americans are underinsured (National Health Interview Survey, 2006). According to the National Health Interview Survey, 43.6 million Americans are uninsured. This includes 19.8% of working-age adults and 9.3% of children. Ideally everyone who could benefit from these or other treatments should have access to them. Unfortunately, the uninsured or underinsured population has very limited opportunity for benefiting from expensive neuromodulation techniques. Individuals who are at the end stage of their lives who could potentially benefit from neuromodulation are often passed over as undeserving of this opportunity for relief because of the costs incurred for little time left. Like so many ethical issues, value is often calculated as a cost–benefit analysis. What is the greatest good for the greatest number? Many people who might benefit are denied opportunity for service because of cost. The limitations of resources for treatments of proven medical benefit are ethical and economic issues. It is a matter of distributive justice. Its resolution is ultimately a matter of science and a matter of politics. The scientific contribution must rest on good evidence and sound analysis of the benefits in relation to the cost. Increasingly questions of justice are receiving more attention. What does the principle of justice – understood as fairness – require of a just and equitable society? These considerations have led many to conclude that it isn’t right that healthcare isn’t a right. It isn’t right that people should suffer from disorders that are treatable. Our moral and ethical responsibilities will be greatly challenged as the field of neuromodulation expands to address additional disease states.
I. An introduction to neuromodulation
26
3. Neuromodulation Technologies: Whom Do We Serve?
Reimbursement issues are an ongoing challenge that requires everyone in the field of neuromodulation to be vigilant in participating in the process of educating insurers about the advances in the technology and clearly articulating success stories. Neuromodulation is a ground-breaking yet costly technique. It is difficult to receive reimbursement at the present time for those that are fully insured. Reimbursement and efficacy challenges have weighed down the field of neuromodulation since the beginning of the technology. Double blind studies are difficult to do, which makes it challenging to appreciate the true value of this technology. The most common reasons for the denial of coverage for neuromodulation procedures include: The therapy is investigational/experimental l There is a paucity of type A evidence for their efficacy l The therapy is not medically necessary l The therapy is not a standard of care
Often people with invisible illnesses blame themselves. However, irrational such blame may seem, it is understandable. It reflects a culture of individualism and self-reliance. It may reflect guilt from many unresolved sources. Many people think of illness as a burden of sin that is deserved. This perception of pain as penalty is reflected in the ancient Greek definition and is particularly prominent in people who consider themselves religious. In this sense even physicians must minister to the sick. Science and technology may come to aid, but not always to the rescue.
The healer’s art
l
Patients have a right to appeal these decisions. Coverage is often denied because the carrier does not have a clear understanding of the therapy and providing them with information about the success of neuromodulation therapy and the other therapies that have been tried with the patient in the past can be helpful.
How do we serve whom we serve? Chronic illness involves much more than the patient’s body. It involves the patient, the patient’s family, and the patient’s community. Unlike, say, an acute appendix, which can be removed and forgotten, chronic illness, by definition, is ongoing; it endures throughout time. It becomes and remains a focus of attention and consciousness. Chronic illnesses, whether they are understood to be physical illnesses or mental illnesses, become bio-psycho-social and spiritual illnesses. Serving a person with a complex chronic illness involves serving the person as a whole and serving the family-community system affected by the illness. It involves at the least, caring and acknowledging the reality the person confronts. Often people with invisible illnesses, diseases and illness that are not outwardly apparent, such as chronic pain will say, “It is important to be believed.” In a series of focus groups conducted in 1999 by the National Pain Foundation (NPF; www.NationalPainFoundation .org), lack of validation (belief that the patient was suffering what the patient said they were suffering) was identified as the most significant challenge faced by people in pain.
With impressive new technologies such as neuromodulation technologies, the physician is able to bring unprecedented interventions to patients who suffer some of the most excruciating disabilities. But treatment of human beings by human beings involves more than just applying technology. Listening to patients’ stories and validating their experience can be very important even when the problem can or can’t be fixed. This is especially true for patents whose symptoms have been minimized or doubted. Furthermore, just as illness entails a loss, loss of the healthy self, healing also involves a life change. Patients need to communicate their experiences to other human beings, and this too is an important aspect of the healer’s role and the healer’s art. Individuals considering neuromodulation may have exhausted pharmacologic, complementary, and manipulative therapies. Interventionalists hold open the door of hope for those seeking refuge from their life of suffering. It is a privilege to change the direction of an individual’s life. This privilege must be treated with great respect. Professionals, family, and friends may help people struggling with disease give voice to their experience and to focus on a life beyond the suffering. They partner with patients to make life better. Often they succeed. Always they must try. The ripple effect of health concerns on an individual’s life are far-reaching. Illness takes a toll on careers, family, friends, and finances. A person’s life can be forever changed because someone took the time hear their “story,” explored options, and determined the proper treatment. Neuromodulation is but one of those options. Sir William Osler, whose remarks have long reminded physicians of the complexities of their duties, may have had something like this in mind when he observed. “It is not nearly as important what disease the patient has as what patient has the disease.”
I. An introduction to neuromodulation
references
References American Heritage Dictionary of the English Language (2000) Fourth edn. Boston, MA: Houghton Mifflin. American Pain Society (1995) Pain: The fifth vital sign. www. ampainsoc.org/advocacy/fifth (accessed 22 April 2004). Eriksdotter Jönhagen, M., Nordberg, A., Amberla, K., Bäckman, L., Ebendal, T., Meyerson, B. et al. (1998) Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer’s disease. Dement. Geriatr. Cogn. Disord. 9 (5): 246–57. Green, A.L., Bittar, R.G., Bain, P., Scott, R.B., Joint, C. et al. (2006) STN vs. pallidal stimulation in Parkinson Disease: improvement with experience and better patient selection. Neuromodulation 9 (1): 21–7. IASP Task Force on Taxonomy (1994) Classification of Chronic Pain, 2nd edn (edited by H. Merskey and N. Bogduk). Seattle: IASP Press, pp. 209–14. Kuba, R., Brázdil, M., Novák, Z., Chrastina, J. and Rektor, I. (2003) Effect of vagal nerve stimulation on patients with bitemporal epilepsy. Eur. J. Neurol. 10 (1): 91–4.
27
Leveque, J.-C., Villavicencio, A.T., Bulsara, K.R., Rubin, L. and Gorecki, J.P. (2001) Spinal cord stimulation for failed back surgery syndrome. Neuromodulation 4 (1): 1–9. Liu, S., Hou, X. and Chen, J.D.Z. (2005) Therapeutic potential of duodenal electrical stimulation for obesity: acute effects on gastric emptying and water intake. Am. J. Gastroenterol. 100 (4): 792–6. Oh, M.Y., Ortega, J., Bellotte, J.B., Whiting, D.M. and Alo’, K. (2004) Peripheral nerve stimulation for the treatment of occipital neuralgia and transformed migraine using a C1-2-3 subcutaneous paddle style electrode: a technical report. Neuromodulation 7 (2): 103–12. Phillips, D.M. (2000) JCAHO pain management standards are unveiled. JAMA 284 (4): 428. Sutton, R., Perrins, J. and Citron, P. (1980) Physiological cardiac pacing. Pacing Clin. Electrophysiol. 3 (2): 207–19. www.wireheading.com/brainstim/antidepressant.htm (accessed 7 April 2008).
I. An introduction to neuromodulation
C H A P T E R
4
Challenges in Moving Toward Product Development Paul Meadows
o u tli n e Introduction
29
The Neurostimulation Market Patient Population Available Technology Proposed Technology – Intellectual Property Reimbursement
30 30 31 32 33
The Implantable Medical Device Development Process Planning Phase Product Identification and Market Analysis Marketing Requirements Feasibility Study Product Definition Design Phase
33 33
A Modern Day Success Story – Advanced Bionics and Alfred E. Mann The Spinal Cord Stimulation Market in 2000 The Design Approach Taken by Advanced Bionics Corp. The Impact Upon the Market and Lessons Learned
34 34 34 34 35
References
Introduction
36 37 38 39 40
and progressing through the applications of suppression of chronic pain, restoration of hearing, control of urinary incontinence , and suppression of the symptoms of Parkinson’s disease and other movement disorders such as cerebral palsy, dystonia, and epilepsy. Emerging applications to treat the problems associated with spinal cord injury, stroke, and vision are just beginning to make an impact on the lives of patients suffering from these debilitating conditions. While some neurostimulation methods and devices have been around since the early 1960s, there have only
Implanted neuromodulation systems have advanced greatly over the decades, but have greatly accelerated in their complexity and capabilities in the most recent years. Implantable stimulators are used for a variety of applications, beginning initially with cardiac pacing, Editors’ note: The views on products given within this chapter are the author’s opinions only and do not necessarily reflect the opinions of the Editors or other contributors of this book.
Neuromodulation
35 35 35 35 35 36 36 36
Module Design Design Verification and Validation System Integration Process Development Process Validation Manufacturing Acceptance Clinical Study Transfer/Acceptance Phase
29
© 2008, 2009 Elsevier Ltd.
30
4. Challenges in Moving Toward Product Development
been a small number of devices which have been introduced into the commercial marketplace and survived the test of time. The reasons for this limited presence of devices compared to the numerous potential applications are many, but primarily fall into a very few key categories: Market, Resources, and lastly, Technology. One might think that technology would be first in this list, but in fact it is, by itself, a rather small impediment to the introduction of new medical implants. It should be noted that our discussion of the field of implanted neurostimulation devices covers both commercially and academically produced devices. The latter have focused on some of the most difficult applications and have rarely been able to make the transition into the commercial arena. For the purposes of this discussion these academic institutional efforts will be discussed only briefly. The Market for an implanted neuromodulation system is perhaps one of the least appreciated elements in the development of a newly developed neurostimulation system. The implanted neurostimulation market consists of the following key participants: patients who will receive the new system physicians: – who determine that the conditions which can be addressed by the system exist in the patient – will refer the patient to an implanting surgeon – who can and will implant the system – who can program and maintain the system for the patient l third party payers who can pay for the system. l l
Factors that will affect the size of the market include the following key elements: alternative technologies, substitutes and treatment methods l scope of the application l acceptance by the patient l acceptance by the physician. l
A newly introduced product must provide a cost and risk effective result compared to alternative technologies and must use common sense regarding its outlook in addressing a clinical need. A 500 horsepower sports car with a joy-stick control may look appealing to someone with a mobility problem, but a motorized wheelchair may in fact be the best fit of technology for the application. The system developer must take careful stock of the needs of the patient and the limitations imposed upon the product by the marketplace and design their products accordingly. In this chapter I will briefly describe the product development process for implantable neurostimulation devices and describe the introduction of the most
advanced spinal cord stimulation system to date, and I will provide some guidance and process descriptions to be utilized in the development of a neuromodulation product.1
The Neurostimulation Market Patient Population The neurostimulation market can best be described by the patient population that can benefit from neurostimulation devices. In Figure 4.1 below it can be seen that neurostimulation may address both sensory and motor nerve dysfunctions, and that the sites of stimulation are literally every region of the body. In the sensory neurostimulation market one of the first commercial successes was the cochlear implant. In the USA there are roughly 1.2 million people who meet cochlear implant candidacy criteria with approximately 350 000 accessible candidates. Globally there are roughly 75 000 accessible candidates who will enter the market yearly, yet only 16 500 cochlear implants were sold in 2006 and the market penetration is at about 20%, while growing at 12–14% annually. Three major companies compete for this market: Cochlear Corporation of Australia, Advanced Bionics Corporation of the USA, and Medel of Austria. At this time Cochlear Corp. has approximately 120 000 patients implanted and Advanced Bionics has more than 28 000 patients implanted with their devices. The benefits of a cochlear implant to the patient are dramatic, but the benefits to society are also now widely appreciated. In a recent study (Mohr et al., 2000) it was determined that the lifetime costs for those with prelingual onset of profound deafness exceed $1 million, with the chances of gaining entrance into a college at 3% and a poor outlook for vocational opportunities. A child under the age of 12 months who receives a cochlear implant, however, at a cost of approximately $50 000, will very often be able to be mainstreamed into traditional educational environments with chances of college and vocation equal to their peers. Thus the cost savings to society and the chance for the child to lead a normal and productive life are greatly enhanced through cochlear implant technology. 1
Implanted neuromodulation should rightfully include electrical stimulation and pharmacological stimulation, as well as any future modalities that affect the operation or state of the nervous system. This chapter will constrain the discussion to electrical stimulation, but the general conditions and environment of product devel opment described here are common to both forms of implanted neuromodulation devices.
I. AN INTRODUCTION TO NEUROMODULATION
31
The Neurostimulation Market
Brain Disorders: Epilepsy Parkinson’s Cerebral palsy
Blindness Deafness
Pain: Peripheral neuropathy Angina pain Chronic low back pain
Respiratory: Sleep apnea Respiratory failure
Incontinence Paralysis: Stroke Spinal cord injury
Figure 4.1 Stimulation applications
Sensory neurostimulation for the restoration of sight is in its earliest stages. While investigated for many years in academic centers around the world using optic nerve multipolar cuff electrodes (Veraart et al., 1999), visual cortex (Brindley and Lewin, 1968), and retinal multicontact arrays and microelectrodes (Humayun et al., 2003), retinal stimulation is now being commercially developed by Second Sight in Sylmar, California. This newly developed system has been in clinical trials for two years using a cochlear implant stimulator with 16 current sources driven by an external video processing system. Next generation devices will increase the number of contacts and will reduce the size of the implanted components. Peripheral motor nerve stimulation, like visual prostheses, has been of academic interest for over 40 years. One of the first applications of peripheral nerve stimulation was the demonstration by Liberson (1961) in which he stimulated the peroneal nerve to dorsiflex the ankle of stroke patients. This early neuromodulation system was commercialized by Medtronic (Minneapolis, MN) as the Neuromuscular Assist and was implanted in thousands of patients in the USA. The device consisted of a radio frequency (RF) powered single channel voltage source and utilized a cuff electrode placed at the post-tibial branch of the peroneal nerve. A foot switch triggered when the heel left the floor at the initiation of the swing phase of gait. This caused a small shoe-worn transmitter to telemeter a signal to a waist-worn receiver which then transferred energy using a coil placed over the implanted stimulator, usually implanted into the medial thigh.
Stimulation of the peroneal nerve would then cause dorsiflexion of the ankle so that the foot could clear the floor more effectively than without the benefit of stimulation. Stimulation terminated when the heel switch again came into contact with the floor at the terminus of the swing phase removing the trigger and causing stimulation to cease. Spinal cord stimulation was one of the greatest field-changing technologies in the history of neuromodulation and was introduced by Medtronic in the late 1960s and early 1970s after the pioneering work of Shealy (Shealy et al., 1967). RF and battery-powered pulse generators were first employed to treat intractable pain and then were utilized for the treatment of peripheral nerve disorders and eventually for deep brain stimulation for Parkinson’s disease and other movement disorders. With the expansion of these products the neuromodulation market has grown to encompass many of the potential neurostimulation sites available with the opportunity to treat and correct an ever-increasing number of medical conditions.
Available Technology The development of implanted medical devices must carefully balance the desire to utilize the latest and most advanced electronic components, materials, and mechanical technologies while at the same time provide products that are both safe and reliable. Often new microelectronics are made available to the designers of consumer and other non-medical products and greatly
I. AN INTRODUCTION TO NEUROMODULATION
32
4. Challenges in Moving Toward Product Development
tempt the designer of medical devices to incorporate them into their new products. However, the risks of unproven technology having bugs or failure modes that have not yet been identified would place the products using those devices at risk of erratic behavior and potential explant before their intended useful service life is exhausted and so very often implanted technology utilizes the most conservative of technologies with, perhaps, reduced functionality, but with greater confidence in the reliability and function of the product. The risks associated with using the latest electronic devices are also similar to those pertaining to the use of new fabrication technologies. Traditional implanted electronic devices have gained much from the highreliability world of military electronics which have employed thick and thin film ceramic hybrid assemblies in which bare dice are epoxy attached to the substrate and gold wirebonded from die to substrate. Passive components such as resistors and capacitors are often conductive epoxy attached as well and the entire assembly is placed in a hermetically welded metal enclosure. This fabrication technology limits the types and varieties of components available to the designer but is a well understood and conservative method of device manufacture. When ball grid arrays and flip chip technologies were introduced to the electronics industry it heralded unprecedented opportunities to reduce circuit footprint and volume. However it has taken many years for the implanted medical device community to adopt and embrace these new technologies as the long-term reliability of these packaging methods were not well proven until only recently. The selection of components to be utilized in an implanted device requires not only conservatism on the type of technology but extraordinary levels of testing and screening. Failures in medical implants are rare, because of good design and meticulous manufacturing practices. Components are selected from suppliers who understand the requirements of high reliability (hi-rel), often from their experience in supplying components to the military and space programs. In fact, it is traditional for medical device companies to depend upon the military and space standards and performance guidelines in the testing and building of products. Few standards for neuromodulation devices exist outside of those originally developed for the cardiac pacing industry. The adherence to the military hi-rel methods adds tremendous expense to the production cost of an implanted device but ensures that the components selected and their fabrication into finished goods will result in devices that in some instances may last the life of the patient. This is especially critical in devices that are life-supporting, such as cardiac pacemakers and automatic defibrillators. Devices that
are not life-supporting must also be highly reliable, because premature device failure could mean significant harm or discomfort to the patient.
Proposed Technology – Intellectual Property Key to the introduction of new or improved medical devices is securing the rights to the intellectual property upon which it is based. Either new technology must be developed and patented, or licensing rights must be acquired to enable the legal and noninfringing introduction of products into the marketplace. This also ensures that the products introduced enjoy the fruits of their efforts for the maximum allowed period under law before they may be freely copied or utilized by others. Developers of new products would be well advised to conduct an exhaustive patent search performed by experts in the technology field of the product and applicable patent databases. A product that infringes upon the patents of others, no matter what improvements and performance enhancements might be provided, can nonetheless be prevented from entering the marketplace. Considering the monetary cost of bringing new products to market, this represents a significant risk to investors. Intellectual property (IP) can be broken down into four types: patent, trademark, copyright, and trade secret. The patent is the most visible form of IP, and (in the USA) is the grant of a property right to the inventor for a term of 20 years from the date of filing. The patent “confers the right to exclude others from making, using, offering for sale, or selling the invention in the US.” Of course, foreign patents must be considered for foreign product distribution as well. The trademark is a “word, name, symbol, or device which is used to indicate the source of the goods and to distinguish them from the goods of others” and in the medical device arena would most commonly be used in product labeling and sales materials. A copyright is “a form of protection provided to the authors of original works of authorship, both published and unpublished, giving the owner the exclusive right to reproduce or distribute copies of the original work” and has its relevance to software, labeling, and literature associated with neuromodulation products. Trade secrets are those pieces of information that are not generally known beyond the confines of the holder and have no legal protection but give the owner a competitive advantage, and which may be patentable or otherwise protected, but which it is in the best interests of the holder not to divulge to the public. The most appropriate course of action to protect the IP assets of the company is a difficult decision and one that cannot be taken lightly or after the fact.
I. AN INTRODUCTION TO NEUROMODULATION
The Implantable Medical Device Development Process
Reimbursement Reimbursement is a key element in the sales of new implanted medical technology that must be considered early in the development of a new product. Governmental regulation or insurance industry guidelines for billing and reimbursement for durable medical goods must fall into specific categories in order that they may be reimbursed by federal agencies or private insurers. Technologies that change the methods of reimbursement may need to address or seek changes in the reimbursement structure to be successful in the marketplace. An example of this can be seen by observing the manner in which spinal cord stimulators for chronic pain are delivered. In this application a patient typically receives an electrode lead, placed percutaneously, and which is attached externally to a trial stimulation device to test for several days to a week or more to determine if the stimulation ultimately provided by an implanted version of the trial stimulator can significantly relieve pain. This trial process is reimbursed separately from the permanent implant of a pulse generator, but the latter only occurs if the trial demonstrated significant pain relief for the patient. It is foreseeable that in the future technology could be developed that could be either so effective that the trial would not be required, or that the methods employed could demonstrate efficacy so quickly that a patient could go from testing to permanent implant in a single procedure. The reimbursement methods and codes might have to be modified to support this change and it would be expected that this could take a significant amount of time and effort to work with federal regulators and third party payers to make this happen.
The Implantable Medical Device Development Process The development of a new implanted medical device is a well-understood and highly regulated process. Only a few companies have the resources to embark on such a development and be able to provide the regulatory bodies with sufficient evidence of a safe and effective product. The development process may be broken into a series of phases during which initial product exploration occurs, product and manufacturing process designs are initiated, the transition to the manufacturing phase along with formal clinical trials, and finally the product launch and monitoring phase. The strict adherence to a consistent and logical development plan for an implanted product will not only help in the smooth submission of data to the regulatory
33
bodies and introduction to the market, but, more importantly, will result in the most safe and effective device possible with the available resources. Several books have been written on the development of medical products and are well worth the time to review for anyone contemplating the development of a new medical device. An excellent example of such a reference is by Elaine Whitmore as she writes from a quality design-in perspective and presents a very wellbalanced introduction to this topic (Whitmore, 2004). The development of implanted medical devices is governed by several internationally recognized standards. Two of these standards are tremendously important to product development in the USA: ISO 13485:2003 Medical Devices – Quality Management and the US FDA Quality System Regulation of 1996: 21CFR 820.30. As described by the International Organization of Standards (ISO), “ISO 13485:2003 specifies requirements for a quality management system where an organization needs to demonstrate its ability to provide medical devices and related services that consistently meet customer requirements and regulatory requirements applicable to medical devices and related services.” The primary objective of ISO 13485:2003 is to “facilitate harmonized medical device regulatory requirements for quality management systems.” This standard forms the basis of product development documentation and is the backbone for regulatory investigation guidance during FDA reviews. The 21CFR 820.30 regulations provide the structure for the development process and provide a means to both internally and externally review the product design, evaluation, and manufacturing procedures. The development process description that follows owes its structure to these two foundation standards, and its description, while admittedly somewhat dry, highlights the effort and documentation required to bring a new medical implant product to market. Implanted medical device development is not for the faint of heart and requires extreme diligence to detail lest the wrath of the regulatory agencies descend upon you and your hapless peers. Milton Friedman perhaps said it best: “Hell hath no fury like a bureaucrat scorned.”
Planning Phase The planning phase is the first phase of product development. It is during this phase that an idea for a new product is first examined; plans are made and executed to verify that a market exists for the product, and a proof of concept is developed and verified. Following the successful completion of these initial steps, the formal product definition is made.
I. AN INTRODUCTION TO NEUROMODULATION
34
4. Challenges in Moving Toward Product Development
Product Identification and Market Analysis Product identification and market analysis are extremely important activities in that they ultimately determine whether you have a product to sell. A careful review of the market can determine whether an existing market is being underserved, or if a nonexisting market may be developed. In most instances, the former is the easier market to enter as many of the clinical application and reimbursement issues have already been developed by your competitors allowing your company to bring improvements in function, cost, and implementation. Developing a new market requires the development of an education plan, establishment of new or modified reimbursement structures and a strong sales effort to convince the clinical and reimbursement structure that a change from existing practices will be beneficial and practical. These efforts become the design input for the development team and are consistent with the quality systems described above. In the initial product identification process the business benefits should be identified, a milestone schedule prepared, staffing and resource requirements determined and risk areas (business, technical, clinical) considered. It is important to acquire as many outside opinions as possible without jeopardizing the security of the development program to ensure that valid assumptions are being made about the ultimate clinical application. Sometimes a very small detail such as the impact upon other medical procedures can be a tremendous impediment to adoption by the market. Non-disclosure agreements are executed with key outside opinion leaders to help prevent the leakage of sensitive information to competitors. While these safeguards do help to prevent this leakage it may still occur so the amount of information dispensed should be just adequate enough to answer the internal questions about the market analysis and product requirements.
manufacturing, shipping, transfer from field representative to clinician, and explantation and return to the manufacturer. All of these conditions and environments must be considered for a complete understanding of the useful life of the product and its design requirements. Feasibility Study A feasibility study can be a very important step in the product development, as it can determine if any unresolved risks may or may not be mitigated by design changes. Feasibility studies will often require that a limited functional version of the product be developed and tested in a clinical environment or that adequate simulations and bench testing of product elements be conducted to reduce the risk of the product development process. If a feasibility study requires clinical input that involves direct patient involvement, then a very carefully prepared study with appropriate reviews and oversight is required to protect the interests of the patients and to produce valid and useful data. Product Definition Functional Specification The functional specification is the top level technical product requirements document and is drawn directly from the marketing requirements. Every feature of the product should have a traceable requirement and function so that the development of the product can be tracked and all features and functions realized in the final form of the system. Many software tools now exist for the tracking of these features, including software to track system requirements and the review process. The functional specification should be considered to be the primary design input document – all other documents refer back to this document and it should be used for all verification and validation testing of the product.
Marketing Requirements
Architectural Description
The result of the product identification and market analysis should lead directly to the development of a list of marketing requirements, the product specifications and functions that are directly tied to customer needs and the intended uses. Use cases should be defined for all of the users of the product – the surgeon, the patient, and the support clinicians who will all have to be convinced of the utility of the proposed product. The use of field clinical engineers and a medical advisory board are key to developing and identifying the important elements of product requirements. Often overlooked in the use models are the environments of
The architectural description is a document that describes all of the elements of the system and how they interact. Basic functional diagrams for each element may be defined with the interfaces to other elements so that project partition and team building may occur and be monitored. This document is typically prepared by a systems engineer who understands the inter-relationships and dependencies of the various sub-systems and the engineering teams that will be needed to create them. Further breakdown with milestones and program goals may be derived from this document.
I. AN INTRODUCTION TO NEUROMODULATION
The Implantable Medical Device Development Process
Risk Management Risk management is composed of the activities that are required to identify, analyze, and mitigate risks associated with the development of the product, its components, and the impact from the manufacture, shipping, implantation, daily use by the patient, and, if necessary, explantation and return to the company. This includes the evaluation and testing of components, as well as the detailed analysis of how they are utilized in the implanted system. This is one of the most often overlooked and least appreciated areas in implanted device development and contributes tremendous cost to the manufacture of an implanted device, but without adequate attention can lead to far greater costs downstream if its implications are not sufficiently appreciated.
Design Phase
35
conditions. Module testing is limited in scope in the absence of other modules or a complete system but is guided by the functional specification, architectural description and module specification for the element being tested, and should be sufficient to elucidate deficiencies in the design for proof of function. Failure of any module test would require re-design, review, and re-testing before the next phase of development may occur. Verification testing will utilize the functional specification primarily as the guideline while validation testing will utilize the marketing requirements specification. Often there is confusion about the difference between verification and validation testing. Put simply, verification determines if the product is made right, while validation determines whether you have made the right product. System Integration
Module Design The design phase occurs only after the successful completion of the previous phases. Every phase along the way is a gating and prerequisite phase for the next, and must not be skipped or left incomplete or the success of the final product in the marketplace would be jeopardized. In the design phase the essential design of the product development is carried out, using the information gathered in the feasibility studies and the marketing specification, functional specification, and architectural description, and the sub-modules are designed. Design reviews are extremely important during this phase and should include all persons involved in the design of the module as well as a sufficient representation of other groups involved in the program so that interface issues between modules may be adequately considered. The use of outside experts in the technology of the module is extremely helpful, because an outsider will invariably see issues and relationships that may not be apparent to those close to the project. This may require the use of paid consultants or representatives from other divisions, but is well worth the cost.
When the various modules have been designed and tested it is time to integrate all of the elements into a finished system and test it as a whole. This process should be extensively reviewed before and at the completion of testing to verify that all of the tests to be performed speak to the functional specifications of the product. All modes of operation must be tested and in all environments required and warranted. Failure of any element of the system test would necessitate a review to see what portions of the system test should be repeated once the failure is analyzed and mitigated. Process Development Prior to the start of manufacturing, the R&D staff must help to develop the processes that will be utilized in manufacturing the final product. While it is best that these processes be considered during the early stages of product development, it is imperative at the latter stages to ensure that the successful designs of R&D efforts translate to products that can be efficiently produced with high yields, low costs, and high reliability expectations.
Design Verification and Validation
Process Validation
As each module of the design is completed, both hardware and software, it is tested in a design verification and validation process. This process involves testing the module not just in the well-defined use cases and norms of operation, but at all possible extremes of use and preferably to the limits of operation to the point of failure. This will expose many of the design weaknesses and issues that should be considered to ensure that the product can survive and serve the patient in the presence of all foreseeable obstacles and
Process validation is the step that occurs after all of the product assembly procedures and manufacturing documentation have been created. The validation effort and report demonstrates that each process in the manufacture of the completed product will consistently produce devices that meet the marketing requirements and quality requirements of the company. All processes used in the fabrication of product must undergo this effort and reports for each process tested must be created and reviewed.
I. AN INTRODUCTION TO NEUROMODULATION
36
4. Challenges in Moving Toward Product Development
A product-specific validation plan is a master listing of all processes and required validations for a product. This along with a process map identifies all of the processes that must be validated and identifies each step that must be examined. It also helps to guide the process failure mode and effects analysis, which evaluates the risk involved in each process step. Each failure mode must be evaluated for the probability of occurrence, the likelihood that it could be detected, and its severity, or what its ultimate effect would be. These factors lead directly to statistical methods to be utilized in the testing of the processes and the assignment of a risk index. If a risk index is high then additional process controls need to be added to mitigate the risk or the processes modified or replaced until the resulting risk index is reduced to acceptable levels. Manufacturing Acceptance The manufacturing acceptance phase is controlled by a manufacturing acceptance plan, which defines the deliverables, tests, and activities that are necessary to confirm that a product, meeting all of the specification and quality requirements, can be manufactured. All of the processes, materials, documentation (both engineering and manufacturing), and training mater ials must be in their production release revision, operators must be trained and certified, and vendors qualified to complete this phase. The measures of manufacturing must demonstrate to the business review staff that build rate, yield, and capacity are all within expectations, as this will determine the amount of product available to sell and at what cost. This will provide key determinants of the return on investment and the timeline to profitability. Clinical Study The product should undergo a field clinical trial to collect product data that verify device function in a clinical setting. The study will obtain information associated with the proposed product (or change in the product) and is conducted independently by the clinical research, marketing, and R&D teams along with clinical partners identified early on in the development of the marketing requirements for the product. Studies must be conducted in FDA approved trials with institutional review board (IRB) approval and monitoring for both the protection of patient interests and the proper and useful collection of data. This is not to be confused with the final product clinical trial, which is the gating element in FDA approval prior to product release and distribution.
Transfer/Acceptance Phase The final phase prior to product release to the market is the transfer and acceptance phase. This phase focuses on transferring the developed production processes to the manufacturing division, generating production prototypes, executing process validation and design validation protocols and running pilot production to gather performance metrics in support of manufacturing acceptance. It is during this phase that formal regulatory submissions are made and final patient testing is performed. The elements of this phase are the fabrication of production prototypes, the validation of all final manufacturing processes, a complete design validation, a systematic review of risk and its management, the production and review of all market literature, manuals and labeling, pilot production, and culminating in a formal clinical study and the first human use review. Regulatory submission and approval would then occur and, if successful, product launch and the monitoring phase of the product. Market preference testing is conducted early in the life of the product to verify product performance and to uncover any unanticipated design deficiencies or improvements that could be made to the product.
A Modern Day Success Story – Advanced Bionics and Alfred E. Mann Alfred Mann is the founder of Advanced Bionics Corp. and arguably one of the greatest medical technology entrepreneurs of our time. Born in 1925 in Portland, Oregon, Mr Mann moved to Los Angeles in 1946 where he earned his Bachelor of Science and Master of Science degrees in physics from the University of California. Mr Mann’s business interests began with government contracts which eventually led to his development of two companies, Spectrolab and Heliotek, both major suppliers of high technology products for the aerospace industry. In 1960 he sold both companies to Textron but continued to manage them. Alfred Mann developed many relationships with universities during this time, but one in particular led to his interest in medical products. In his work with the Johns Hopkins Applied Physics Laboratory he became interested in power supply issues for cardiac pacemakers. This interest led to the development of PaceSetter Systems, which focused on rechargeable pacemakers and the development of the first such product on the market. This breakthrough device was also the first hermetic pacemaker on the market and
I. AN INTRODUCTION TO NEUROMODULATION
A Modern Day Success Story – Advanced Bionics and Alfred E. Mann
the first with bidirectional telemetry. There are still patients using these devices after more than 30 years of implanted service. PaceSetter was sold in 1985 and is now part of St. Jude Medical. The second medical device company developed by Alfred Mann was MiniMed Technologies, which developed the first implanted programmable rate insulin pump, as well as the most advanced external insulin pump to treat Type I diabetes. Medical Research Group, formed from the Alfred E. Mann Foundation for Scientific Research (AEMF), developed the artificial pancreas utilizing a long-term catheterbased implanted continuous glucose monitoring system and implanted programmable-rate insulin pump with a primary battery lasting up to seven years before requiring replacement. MiniMed and Medical Research Group were both later sold to Medtronic. Alfred Mann went on to found Advanced Bionics Corp., Second Sight, which is developing a visual prosthesis to restore sight to the blind, Implantable Acoustics, which is developing implantable hearing aids, NeuroSystec, which is exploring drug therapies to treat tinnitus, Bioness, which is developing prosthetics for neurostimulation to treat neurological dysfunctions, Quallion, which develops, manufactures, and markets advanced batteries for medical, aerospace, and military applications, and Stellar Microelectronics, which produces micro-circuit assemblies. Advanced Bionics Corp. was formed from members of both the AEMF and MiniMed Technologies and led to the first multichannel independent current source cochlear implant in 1994, the Clarion Implantable Cochlear Stimulator. The technology that Advanced Bionics brought to the market was revolutionary. To improve power transfer to the implanted electronics the electronics assembly was housed in a radio frequency transparent ceramic enclosure. This replaced the traditional metallic enclosure used by other companies and tremendously reduced the losses of energy due to eddy currents in the metal components of the implanted device. More important was the introduction of eight independent bipolar current sources that were directly controllable at very high speed allowing the simultan eous generation of either continuous analog, pulsatile or combinational approaches to auditory nerve stimulation. Other devices on the market at that time and continuing today were fabricated using a single pulse generator that was time multiplexed to the various output contacts that then would deliver stimulation current to the auditory nerve. Today Advanced Bionics Corp. sells the Harmony HiResolution Bionic Ear System, shown in Figure 4.2, which contains 16 independent current sources with 128 virtual channels of stimulation allowing unprecedented sound fidelity to our patients.
37
Figure 4.2 The Advanced Bionics (Valencia, CA) Harmony HiResolution Bionic Ear System. Left: Behind-the-ear processor with headpiece; right: implantable stimulator and electrode
Alfred Mann elucidated the basic tenets for his “Model for Success” as follows: l l l l l
Select a target market Identify underserved needs Evaluate barriers to entry Establish product specifications Create a business model Allocate development resources Organize market, sales, reimbursement, and support infrastructure l Validate, qualify, and transfer to manufacturing l Pursue clinical trials and regulatory approval l Unleash sales, marketing, and service. l l
Most important in the list above is resources. The availability of capital to commit to the program early on will dramatically affect the ability of the organization to deliver a product that changes the market. PaceSetter, MiniMed, and Advanced Bionics all radically changed the technology foundation of the markets they entered because sufficient resources were provided to develop truly groundbreaking technology. Had products been introduced that were merely equivalent or modest improvements in existing technology it is likely that these companies would never have seen the market share that they ultimately acquired.
The Spinal Cord Stimulation Market in 2000 In the year 2000 Advanced Bionics started the development of the world’s most advanced spinal cord
I. AN INTRODUCTION TO NEUROMODULATION
38
4. Challenges in Moving Toward Product Development
stimulation system. After reviewing the devices on the market, the intellectual property of competitors, and discussing with clinicians in the field the limitations of existing technology and their wishes for improvements in that technology, Advanced Bionics determined what technology was already in their existing products and what needed to be developed to advance the state of the art in this growing market. After four years of development and many millions of dollars expended, Advanced Bionics introduced the Precision Spinal Cord Stimulation System in 2004, and in less than two years on the market it displaced the number two company in the market and is quickly gaining market share. The market in 2000 was dominated by Medtronic followed by Advanced Neuromodulation Systems. Medtronic had two principal products on the market, the Itrel and the Extrel. The Itrel was a primary batterybased implantable pulse generator (IPG) product while the Extrel was an externally powered radio frequency (RF) product. Both devices used a single voltage source which was time multiplexed to four electrical contacts on a lead and the metallic case of the IPG. A batterypowered IPG was, of course, most desirable because it simplified the life of the patient – the device could be commanded to stimulate the spinal cord nerves and no external equipment would then be required. In some instances, however, where large amounts of energy were required because of poor electrode coupling with target nerves or other factors that increased the energy demand of the system, the battery-powered IPG would quickly be depleted, sometimes requiring surgical replacement in as few as three to six months. This obviously would not be desirable to the patient because of cost, pain, and the risk of infection due to additional surgery. To address this issue the RF powered Extrel was developed which supplied power to the IPG using a coil attached to the skin of the patient over the IPG and powered by a belt-worn external controller. This external controller had replaceable batteries thus extending the operation of the implanted IPG almost indefinitely. A serious drawback of both the Itrel and Extrel devices was the fact that they utilized a voltage source for their stimulation pulse generator, and second, that they multiplexed the stimulation pulses to the electrical contacts of the implanted lead. In the electrical excitation of nervous tissue it is current and not voltage that determines the population of neurons excited. Long expected was that the implanted environment presented a constant electrode/tissue impedance model and that as such the current delivered to the tissue would be consistent over time. This model was not accurate, however, as electrode movement, tissue growth, and electrode degradation over time would change the impedance seen by the pulse generator and thus
the current delivered to the tissue would change, thus changing the resultant clinical effect of the implanted system. Added to this was the design deficiency of utilizing a single stimulation generator and multiplexing it to multiple contacts and the case of the stimulator. When multiple contacts were connected in parallel with the single voltage source, their individual electrode/tissue impedances determined the distribution of current to the nearby neurons, thus therapy could not easily be predicted from the simple assumption that current would be divided equally amongst the connected electrodes. If it was desirous to distribute current in a nonuniform manner to each of the electrodes this was of course not controllable with this design. Advanced Neuromodulation Systems products offered to the market the introduction of the first current source stimulation system and increased the number of stimulation contacts, but like Medtronic, used the multiplexed connection of this pulse generator source to the lead electrodes. So, while it was possible to exactly control the current delivered to a nerve using a single contact, when multiple contacts were connected together using the multiplexer the distribution of current was actually controlled by the electrode/tissue impedance, so again, there was a severe limitation in the technology delivered to the clinical environment.
The Design Approach Taken by Advanced Bionics Corp. The design team at Advanced Bionics looked first at the science of neural excitation and using its experience in the cochlear implant design determined that what was truly needed in the field of spinal cord stimulation was a design utilizing multiple independent current sources. Only in this manner could the amount of current delivered to each contact be precisely controlled. This had the added benefit that now non-uniform current distributions could be obtained, uniquely delivering the required stimulation energy to each population of nerves adjacent to the electrode contacts. This meant that multiple regions of the spinal cord could be stimulated with their own unique stimulation parameters, and that no longer would produce compromised stimulation patterns that non-optimally treated them together with the same stimulation parameters. This advanced technology came at a price. First, the delivery of current control of stimulation is more difficult than voltage control – added circuitry is required and energy is lost due to the regulation of current in addition to the current delivered to the tissue. Second, in the Advanced Bionics design there were 16 independent current sources, thus dramatically increasing the complexity
I. AN INTRODUCTION TO NEUROMODULATION
A Modern Day Success Story – Advanced Bionics and Alfred E. Mann
of the implanted circuitry, its development cost, and cost to goods sold in the final product. Advanced Bionics also looked at the size of the implanted device and was determined to deliver the smallest IPG but still have 16 times the number of current sources. The dilemma that this complex design presented was that of providing sufficient power while still providing a device that was still smaller than the competition. The solution chosen was to develop a rechargeable device which could power the IPG for a reasonable period of time and yet be recharged easily through the skin and have a reasonable cycle life such that the product would provide many years of service before replacement. The Precision SCS system uses a unique secondary lithium ion battery designed and supplied by Quallion of Sylmar, California that can withstand complete depletion of its voltage and yet have negligible loss of cycle life when abused in such a manner. The Advanced Bionics Precision IPG was the first rechargeable device introduced into the SCS market, although both Medtronic and ANS now offer rechargeable IPGs. For those applications where a small neurostimulation device is desired or where a larger device and leads are simply not an option, a groundbreaking device was developed by Advanced Bionics Corp. called the Bion (bionic neuron). This device measures a mere 3 mm in diameter and 20 mm in length, contains a full custom
39
integrated circuit, a rechargeable lithium battery and a bidirectional telemetry system allowing programming and rechargeable stimulation in a package that is extremely small and weighing about a gram.
The Impact Upon the Market and Lessons Learned The impact of the introduction of the Precision and Bion products on the neuromodulation market
Figure 4.4 The Boston Scientific Neuromodulation/Advanced Bionics (Valencia, CA) RF Bion microstimulator
Figure 4.3 The Boston Scientific Neuromodulation/Advanced Bionics (Valencia, CA) Precision SCS system. On the left is the remote control, in the center is the cordless charger, and on the right is the implantable pulse generator with two 8-contact epidural leads
I. AN INTRODUCTION TO NEUROMODULATION
40
4. Challenges in Moving Toward Product Development
has been tremendous. Medtronic and ANS have been producing devices for spinal cord stimulation for close to 40 years, and in less than two years’ time the Precision system became the number two player in the market and before its third year on the market has already over 13 000 patients implanted and at the time of this chapter’s writing enjoys greater than 30% market share. Advanced Bionics has realized tremendous growth in sales, corporate structure, manufacturing capability, and has expanded the possibilities for treatment of patients utilizing this extremely capable technology. The introduction of the Precision system sparked the release by both Medtronic and ANS of their own rechargeable pulse generators, albeit larger and similar in electronic design to their previous products, but improvements nonetheless. It has proven, again, that the significant introduction of advanced technology in a well-designed and ambitious yet highquality manner can result in rapid market acceptance and improvement in the treatment of patients.
References 21CFR 820.30, Title 21: Food and Drugs, Chapter I – Food and Drug Administration, Department of Health and Human Services,
Subchapter H: Medical Devices. Rockville, MD: US Food and Drug Administration. Brindley, G.S. and Lewin, W.S. (1968) The sensations produced by electrical stimulation of the visual cortex. J. Physiol. (Lond.), 196 (2): 479. Humayun, M.S., Weiland, J., Fujii, G., Greenberg, R.J., Williamson, R., Little, J. et al. (2003) Visual perception in a blind subject with a chronic microelectronic retinal prosthesis. Vis. Res. 43 (24): 2573. ISO 13584 (2003) Medical devices – Quality management systems – Requirements for Regulatory Purposes. Geneva: International Organization for Standardization. Liberson, W.T. et al. (1961) Functional electrotherapy: stimulation of the peroneal nerve synchronized with the swing phase of the gait of hemiplegic patients. Arch. Phys. Med. Rehab. 42: 101–5. Mohr, P.E., Feldman, J.J., Dunbar, J.L., McConkey-Robbins, A., Niparko, J.K., Rittenhouse, R.K. et al. (2000) The societal costs of severe to profound hearing loss in the United States. Int. J. Technol. Assess. Health Care 16 (4): 1120–35. Shealy, C.N., Mortimer, J.T. and Reswick, J.B. (1967) Electrical Inhibition of pain by stimulation of the dorsal columns: Preliminary Clinical Report. Anesth. Analg. 46: 489–91. Veraart, C., Delbeke, J., Wanet-Defalque, M.C., Vanlierde, A., Michaux, G., Parrini, S. et al. (1999) Selective Stimulation of the Human Optic Nerve; 4th Conference of the International Functional Electrical Stimulation Society, August 1999. Japan: Sendai, pp. 57–9. Whitmore, E. (2004) Development of FDA-Regulated Medical Products – Prescription Drugs, Biologics, and Medical Devices. Milwaukee, WI: ASQ Quality Press.
I. AN INTRODUCTION TO NEUROMODULATION
C H A P T E R
5
The Birth of an Industry James Cavuoto
o u tli n e Early Neuromodulation Devices
41
Competitive Landscape
46
The 21st Century Neuromodulation Industry 2001 2002 2003 2004 2005 2006 2007
42 43 43 44 44 44 45 45
Commonality with Cardiac Devices
46
New Product categories
47
Future Outlook
47
References
47
This chapter is devoted to the birth and growth of the neuromodulation industry and the maturation of commercial products that accompanied the industry’s development. We will first take a look at some of the key events that highlighted the early years of the industry. Next we will examine how the industry matured in the first eight years of the 21st century. Then we will examine some of the business and marketing factors affecting the industry. The chapter will conclude with a look forward on what lies ahead for the neuromodulation industry.
addressed by today’s neuromodulation industry are quite distinct from those of the cardiac device industry, much of the basic technology, including electrodes, batteries, leads, and packaging, is common to both industries. The first implantation of a cardiac pacemaker in a human patient took place in 1958, but the first long-term successful implant took place in 1960, when William Chardack, Andrew Gage, and Wilson Greatbatch implanted a device that remained in operation for a year. In 1957, Earl Bakken (Figure 5.1), the founder of Medtronic, Inc. (Minneapolis, MN), had invented a functional battery-powered pacemaker and Bakken and Greatbatch would later collaborate on the manufacture of a commercial device. The earliest implanted pacemakers were simple two-transistor circuits powered by mercury-zinc cells. Later, Greatbatch switched to a lithium iodide cell, which provided much longer lifetimes.
Early neuromodulation devices In many ways, the neuromodulation industry traces its roots to the birth of the cardiac pacing industry. Although many of the indications and clinical specialties
Neuromodulation
41
© 2008, 2009 Elsevier Ltd.
42
5. the birth of an industry
Figure 5.2 Thomas Mortimer, PhD, developed the first dorsal column stimulator that Dr Norman Shealy used
Figure 5.1 Earl Baaken, the founder of Medtronic, Inc.
Medtronic remained the dominant player in the cardiac pacemaker for the next four decades, and leveraged its expertise in cardiac pacemakers to emerging applications in neurological diseases and disorders. The company’s first forays into neuromodulation in the 1960s involved early deep brain stimulation (DBS) systems and spinal cord stimulation (SCS) systems. The first clinical use of SCS for treatment of pain took place in 1967, when C. Norman Shealy implanted an SCS (at that time, called dorsal column stimulation or DCS) system in a 70-year-old man (Shealy et al., 1967) based on the gate control theory of Melzack and Wall (1965) and the pioneering clinical work of Wall and Sweet (1967). J. Thomas Mortimer (Figure 5.2), from Case Western Reserve University, constructed the first device for Shealy. The external stimulator was connected to the electrodes via a subcutaneous jack. SCS systems went through a series of enhancements over the next four decades, including the development of single-electrode radio-frequency controlled systems in 1972 by Avery Labs (Avery Laboratories, Inc., Comack, NY) and Medtronic, and the development of epidural electrodes in 1978. In 1981, Cordis (Miami Lakes, FL), now a Johnson & Johnson company, introduced the first totally implantable SCS system. It was powered by a lithium battery. The IPG was packaged in a hermetically sealed titan ium case and allowed control of stimulation parameters. In 1984, Medtronic introduced its Itrel IPG for spinal cord stimulation. Originally, SCS systems used unipolar electrodes. Later more complex electrode systems were developed, starting with a four-contact electrode, the
Quad electrode, introduced by Neuromed in 1981. In 1986, Neuromed, which later became Advanced Neuromodulation Systems, Inc. (Plano, TX) and is now part of St. Jude Medical (St Paul, Minnesota, MN), introduced an eight-contact radio frequency controlled SCS system. In 1999, ANS introduced its 16-contact Renew RF system and Medtronic introduced its Synergy IPG, which featured eight contacts with two channels of stimulation. Outside of SCS, one of the first commercial neuro modulation devices to reach the market was the breathing pacemaker system from Avery Labs, which received FDA approval in 1986. The company’s founder, Roger Avery, had built several prototypes in the 1970s based on the work of William Glenn from Yale University. Medtronic has been the only manufacturer to market a DBS device for neuromodulation, though other vendors are expected to enter the market shortly. The first implantation of a DBS system took place in Grenoble, France in 1987 and Medtronic received approval to market its system in Europe in 1995. The US Food and Drug Administration (FDA) approved thalamic DBS for treatment of tremor in 1997. In 2001, the FDA approved DBS in the subthalamic nucleus and in 2002 the FDA approved Medtronic’s Activa therapy for bilateral treatment of Parkinson’s disease.
The 21st century neuromodulation industry After the year 2000, the neuromodulation industry was marked by increased competition, the development of new forms of stimulation, and a wide expansion
I. an introduction to neuromodulation
the 21st century neuromodulation industry
in the number of neurological diseases and disorders treated. The first seven years of the 21st century produced a number of key milestones for the neuromodulation industry. A look back at some of the articles published in Neurotech Business Report since its inception yields an enlightening overview of important developments, which are summarized below.
2001 One of the key industry events in 2001 was the sixth annual conference of the International Functional Electrical Stimulation Society (IFESS) meeting in Cleveland. The five-day event, themed “Envisioning a New Century of Breakthroughs,” highlighted six “millennium” papers on key areas of neurotechnology, a truly international assembly of presenters, a small but solid core of manufacturers and sponsors, and several unique attributes not often found at a scientific or engineering meeting. These “millennium papers” were published in Neuromodulation: Technology at the Neural Interface, Journal of the International Neuromodulation Society (INS) and IFESS. Exhibitors and sponsors at the event included several of the early manufacturers of neuromodulation products and systems. NeuroControl Corp. (Valley View, OH) showed its FreeHand hand grasp prosthesis, the VoCare bladder stimulation system, and a new miniaturized multichannel programmable stimulator call StIM. The device was targeted at stroke patients suffering from shoulder pain caused by the separation of the shoulder joint and weak muscles after stroke. Medtronic, the largest corporation in the business, promoted its InterStim urinary control system and DBS product line. Cleveland Medical Devices (Cleveland, OH) showed its BioRadio 110, a compact and wireless brain monitoring device. EIC Laboratories in Norwood, Massachusetts, exhibited its range of electrode coating products and services, which work with gold, platinum, silicon, iridium, and other materials. Empi (Empi, Inc., St Paul, MN) showed its line of stimulators for pain treatment and neuromuscular rehab ilitation. NeuroStream Technologies (Anmore, British Columbia, Canada), a Canadian manufacturer that would later be acquired by Victhom Human Bionics (Saint-Augustin-de-Desmaures, Quebec, Canada), showed its line of implantable NeuroCuff interfaces, which accommodate electrodes as well as catheters for fluid infusion. Neopraxis Pty Ltd, an Australian firm (Sydney, New South Wales, Australia), promoted its 22-channel Praxis stimulator, targeted at paraplegic patients. Advanced Bionics Corp. (Valencia, CA), one of the leaders of the cochlear implant business, promoted its line of Bion leadless stimulators.
43
2002 As 2002 came to a close, the neuromodulation industry looked back on a paradoxical year, a year filled with exceptional triumphs in technology developments and depressing financial and economic news from the commercial enterprises in the field. For example, the latter months of 2002 witnessed staff reductions at Aspect Medical Systems, Inc. (Norwood, MA) and Axon (Newton, MA), flat sales at Bio-logic Systems (Mudelein, IL), and the demise of Symphonix (San Jose, CA). Other examples of bad news in the industry were microHelix’ (Tualatin, OR) decreased revenues and 4-D Neuroimaging’s (San Diego, CA) failed merger with Neuromag (Helsinki, Finland). And the functional electrical stimulation field was still reeling from NeuroControl Corp.’s decision to discontinue marketing its FreeHand hand-grasp stimulator. But 2002 was not without bits and pieces of good economic news. Several start-up neuromodulation firms received first- or second-round infusions of venture capital at a time when other technology industries were hard-pressed to get attention from VCs. The most noteworthy examples: Vertis Neuroscience, now Northstar Neuroscience (Seattle, WA), received $37 million in funding, Optobionics Corp. (Wheaton, IL) received $20 million, Sleep Solutions, Inc. (Palo Alto, CA) received $7 million, and Cyberkinetics, Inc. (Foxborough, MA) received $5 million. Several public companies also showed improving financial results – some with record performance – including Advanced Neuromodulation Systems, Cyberonics, Cochlear Ltd (Lane Cove, New South Wales, Australia), and Integra NeuroSciences (Plainsboro, NJ). Merger and acquisition activity during the year included Compumedics’ (Abbotsford, Australia) purchase of Neuroscan Labs (Sterling, VA), Bionic Technologies’ (Salt Lake City, UT) merger with Cyberkinetics, and Encore Medical Corp.’s (Austin, TX) purchase of Chattanooga Group (Hixson, TN). Significant FDA product approvals reported during the year were Vertis Neuroscience’s percutaneous stimulation system, Medtronic’s Activa deep brain stimulation therapy for Parkinson’s, and ANS’ Genesis implantable pulse generator. Some good news also came on the reimbursement front, including favorable Medicare decisions or recommendations on magnetoencephalography, functional electrical stimulation, and implanted stimulators. Still, the overall financial picture for the neuromodulation industry in 2002 was not as favorable as was the technology development outlook. Significant progress was made in a number of early-stage and
I. an introduction to neuromodulation
44
5. the birth of an industry
more mature product categories, including micro stimulation systems, electrode development, cortical control systems, visual prostheses, and stroke rehabilitation devices.
2003 In 2003, the editors of Neurotech Business Report chose to single out a few individuals and organizations for special recognition. The result was the somewhat impromptu “Gold Electrode” Awards, which were intended to add some profile to the industry. Synapse Biomedical’s (Oberlin, OH) diaphragm pacing system was selected as the best new product of the year, and Afferent Corp. (Providence, RI) was named the most promising start-up firm. There were several events in 2003 that stood out as significant developments for the neuromodulation industry. The first was the implantation of a diaphragm stimulation system in actor/activist Christopher Reeve in February. Reeve was just one user, and the potential market for the device was not huge. But the fact that he was willing to undergo the procedure, and became a vocal proponent of the device, is significant if for no other reason than that he had previously not been a major proponent of functional electrical stimulation devices as a treatment for paralysis. Another key event of 2003 was Medicare’s decision to cover deep brain stimulation for treatment of tremor and Parkinson’s disease. Reimbursement continued to be a major hurdle confronting the neuromodulation industry, but the relative speed with which this decision followed FDA approval of DBS treatment for Parkinson’s disease was a positive sign. Still another major development in 2003 was the progress Cyberonics made in obtaining FDA approval of its VNS therapy for treatment of drug-resistant depression. Though, as later years would reveal, the process was far from over, the positive research results and the indication from the FDA that a timely decision was forthcoming were encouraging signs. Aside from the sheer market size of this application, it was significant because in penetrating even a portion of the mood disorder market, Cyberonics may well have proven to other neuromodulation device manufacturers that they can compete in markets where the pharmaceutical industry appears to have a firm grip. While venture capital investment was not rampant in 2003, there were enough deals done to give hope to start-up firms. Perhaps more significant was the fact that major medical device manufacturers, including Boston Scientific (Natick, MA), Medtronic, Guidant (St Paul, MN), and Johnson & Johnson (New Brunswick,
NJ), showed signs that they were looking closely at this market.
2004 As years go, 2004 was better in many respects than the three that preceded it. From a financial standpoint, the biggest news was undoubtedly Boston Scientific Corp.’s purchase of Advanced Bionics Corp., a deal that would prove to be worth more than $2 billion. This valuation profoundly affected the venture capital community’s perception of the neuromodulation industry. Probably the biggest disappointment of the year was the FDA’s decision to ignore its own neurological devices panel recommendation and deny Cyberonics’ PMASupplement for VNS treatment for resistant depression. But between these two extremes, there were a number of significant developments in 2004 that continued to highlight the maturation of the industry. The establishment of the National Science Foundation Engineering Research Center for Biomimetic Microelectronic Systems (Los Angeles, CA) was one such development, as was the announcement of a new advanced prosthetics program at DARPA’s Defense Sciences Office. The National Institutes of Health’s first Neural Interfaces Workshop, which merged the Neural Prosthesis Workshop with the DBS Consortium, was another highlight. On the technology front, there was significant progress in areas such as EEG interpretation, brain– computer interfaces, cortical stimulation for stroke rehabilitation, deep brain stimulation, magnetic stimulation, neural-silicon hybrids, retinal implants, neurorobotics, and controlling neural growth. New product categories that emerged in 2004 included occipital nerve stimulation systems, rechargeable spinal cord stimulation systems, and navigated brain stimulation. New entrants in the industry were prosthetics vendor Innovative Neurotronics, Inc. (Bethesda, MD), implantable probe supplier NeuroNexus Technologies (Ann Arbor, MI), cortical plasticity firm Restorative Therapies, Inc. (Baltimore, MD), and neurorehabilita tion firm Bioness, Inc. (Valencia, CA). Initial public offerings included NeuroMetrix (Waltham, MA), which brought in $24 million, and Stereotaxis (St Louis, MO), which fetched $40 million.
2005 The year 2005 was a banner year for the neuromodulation industry in many respects. Overall, financial performance of both public and private companies trended in the direction of black ink. There were a large number of new products receiving FDA approval during the year. Plus there were several healthy mergers
I. an introduction to neuromodulation
the 21st century neuromodulation industry
and acquisitions, and several start-ups in the space obtained venture-capital funding during the year. Certainly the most significant financial development of 2005 was the acquisition of Advanced Neuro modulation Systems by St. Jude Medical in a $1.3 billion deal. Though perhaps overshadowed by that merger, other noteworthy deals were Medtronic’s purchase of Transneuronix (Mt Arlington, NJ) and Natus Medical’s (San Carlos, CA) merger with Biologic Systems. Though the multi-billion dollar deals like the ANS acquisition dominated the landscape, the smaller ones are important too, if for no other reason than demonstrating to investors a path to liquidity for start-ups in this space. And the numerous cooperative agreements and collaborations that neuromodulation firms enter into were a sign for all observers of the industry’s vitality. Another notable trend in 2005 was the continued forays of orthopedic industry players into the neuromodulation space. Encore Medical, with its purchase of Compex Technologies (New Brighton, MN) complementing its prior acquisitions of Empi and Chattanooga Group, was one example, as was Otto Bock’s (Duderstadt, Germany) purchase of Neurodan (Aalborg, Denmark). These two firms joined Hanger Orthopedic (Bethesda, MD), which set up a neuromodulation unit called Innovative Neurotronics (Bethesda, MD), and Ossur (Reykjavik, Iceland), which is developing neural prostheses with Victhom Human Bionics. Notable start-ups of 2005 included Andara Life Science Inc. (Indianapolis, IN), which began developing a spinal cord regeneration stimulator, Medtrode, Inc. (London, Ontario, Canada), which developed novel DBS electrodes, NeuroSystec Corp. (Valencia, CA), which developed a device to treat tinnitus, and BioNeuronics, Inc. (now NeuroVista Corp., Seattle, WA), which began developing a series of implantable neuromodulation devices for treatment of neurological disorders. The latter firm secured $6 million in funding. On the new product front, the FDA’s long-awaited approval of Cyberonics’ VNS system for treating treatment-resistant depression stands out as significant, as does the heightened competition in the DBS and spinal cord stimulation markets.
2006 The year 2006 was neither the watershed year that 2005 was for the neuromodulation industry, nor was it the depressing time seen in the early years of the decade. The business experienced a number of promising technology and market developments, and a few disappointments. But overall, the industry appeared to be on a stronger footing than it was the previous year.
45
From a financial standpoint, there were no multibillion dollar mergers in 2006, or anything even coming close. But the deals that were consummated, including Cyberkinetics’ purchase of Andara, Encore Medical’s purchase of Compex, and Bioness’ purchase of NESS Ltd (Ra’anana, Israel), point out the continuing viability of the $100-million-and-under segment of the industry. And while the only significant IPO activity of 2006 was Northstar Neuroscience, which fetched more than $100 million, at least two public neurotech companies, VSM MedTech (Vancouver, British Columbia, Canada) and Encore Medical went private during the year. Venture capital investment in neurotech start-ups continued to be robust in 2006. VC firms were particularly generous to firms in the obesity stimulation market segment, with EnteroMedics (St Paul, MN), IntraPace (Menlo Park, CA), and GI Dynamics (Watertown, MA) securing $87 million total. Other noteworthy fundings during the year included Intelect Medical’s (Cleveland, OH) $3 million seed round, NBI Development’s (now Nevro Corp., Palo Alto, CA) $5.5 million round, Intelligent Medical Implants’ (Zug, Switzerland) €15 million round, and Posit Science’s (San Francisco, CA) $24 million round. On the technology front, one of the most exciting developments was a dramatic increase in understanding of the mechanisms of action of deep brain stimulation, not just for treating movement disorders, but psychiatric disorders as well. Transcranial magnetic stimulation got a considerable bit of attention during the year, particularly after Neuronetics (Malvern, PA) presented promising clinical trial data at the American Psychiatric association meeting in Toronto. The year was also a good one for neurorehabilitation, with several new devices from Bioness, Innovative Neurotronics, Victhom, and Otto Bock achieving some form of regulatory approval, and with new government initiatives such as the DARPA Advanced Prosthetics Program. But challenges remained for the industry, and probably the biggest one pertains to reimbursement. Slowness and difficulty in getting CMS coverage decisions is affecting nearly every segment of the neuromodulation industry. Cyberonics, which otherwise would have been riding high from its 2005 FDA approval of VNS for treatment-resistant depression, saw limited growth in this market, and the problem was a factor in the management shake-up that afflicted that company in 2006.
2007 In 2007, a number of technological and financial developments helped move the neuromodulation industry forward. On the technology front, Northstar
I. an introduction to neuromodulation
46
5. the birth of an industry
Neuroscience was awarded a patent for its cortical stimulation technology, and Aculight Corp. (Bothell, WA) signed a licensing agreement with Vanderbilt University for optical stimulation technology. On the financial side, Synapse Biomedical raised $4 million in venture capital funding, Apnex Medical Inc. (Minneapolis, MN) completed a $16 million funding round, Intelect Medical closed a $7 million round, and Afferent Corp. received an investment from orthopedic manufacturer Stryker Corp. (Kalamazoo, MI). Also in 2007, Greatbatch, Inc. (Clarence, NY), a manufacturer of batteries for implanted devices, acquired Enpath, Inc. (Minneapolis, MN) for $102 million, a few months after acquiring the assets of Biomec, Inc. (Cleveland, OH).
Competitive landscape Today, the competitive landscape of the neuromodulation industry is marked by the presence of a small number of large medical device firms, and a large number of smaller, upstart companies. Undoubtedly, the market leader at this point is Medtronic. The company’s neuromodulation group, which incorpor ates offerings in spinal cord stimulation, deep brain stimulation, sacral nerve stimulation, and a number of related applications, still represents a minority of overall annual revenues of $12 billion. But neuromodulation represents one of the fastest-growing segments of the company’s business. Boston Scientific is another major player in the neuromodulation industry of today. Boston Scientific’s initial venture into neuromodulation was in 2002, when it formed a strategic alliance with Advanced Neuromodulation Systems, Inc. The agreement called for Boston Scientific to market ANS’s neuromodulation products in Japan. That year Boston Scientific also signed a strategic alliance agreement with Aspect Medical Systems that included purchasing 1.4 million shares and providing $5 million in revolving credit. In 2003, Boston Scientific purchased 14.7% Cyberonics, Inc. for $50 million. In June 2004, Boston Scientific made its biggest move yet into neuromodulation by acquiring Advanced Bionics for $740 million in cash plus future payments based on performance milestones. Over a 72-month period, the performance payments could have reached a maximum of about $1.3 billion. However, in 2007, Boston Scientific amended its merger agreement with Advanced Bionics, eliminating shared management provisions and modifying the schedule of earnout payments. The amendment granted Boston Scientific sole management and control of the pain management
business, including the emerging indications program. The company agreed to sell the auditory business and drug pump development program to principals of Advanced Bionics, thereby heading off pending litigation between Boston Scientific and former Advanced Bionics shareholders. The pain management business Boston Scientific retains includes spinal cord stimulation technologies, as well as emerging technologies such as the Bion microstimulator. St. Jude Medical, Inc. entered the neuromodulation market in 2005 as a major player with the $1.35 billion cash purchase of Advanced Neuromodulation Systems. St. Jude, well-established in the multibillion dollar cardiovascular medical device market, regards the field of neuromodulation as a segment of the medical device industry with “enormous long-term growth potential.” In a report to investors, St. Jude noted that “the technologies used in pacemakers and in neurostimulation systems are extremely complementary. The ANS technologies complement our cardiac rhythm management expertise in microelectronics, batteries, leads, and programmers, which should benefit the flow of new products in both organizations.” The acquisition of ANS was completed as a merger, and the ANS subsidiary now operates as one of St. Jude’s six divisions. St. Jude was founded in 1976 as a heart valve company by Manuel Villafana, who named the company after the patron saint of desperate cases as a thank you for the successful corrective surgery at Mayo Clinic on his newborn son, who was named Jude. The first St. Jude mechanical heart valve was implanted in 1977 and its continuing success over the years made it the gold standard in the industry. In 1994, St. Jude acquired Pacesetter, Inc. from Siemens AG, which marked the company’s entry into the cardiac rhythm management market. The acquisition doubled St. Jude’s salesforce and tripled its workforce. Today, cardiac therapies are shifting from mechanical heart valves to tissue valve and repair products, which St. Jude also markets.
Commonality with cardiac devices Since the inception of the neuromodulation industry, many market observers, analysts, and investors have compared the emerging market for implanted neuro devices to the growth of cardiac devices 20 years earlier. One of the most prominent individuals to make that comparison is Alan Levy, founder of Northstar Neuroscience. Levy is in a position to know. Prior to founding Northstar, he was CEO of Heartstream, a manufacturer
I. an introduction to neuromodulation
47
future outlook
of automatic external defibrillators that was eventually sold to Hewlett–Packard. Before that, he was president of Heart Technology, a manufacturer of coronary devices that was sold to Boston Scientific. Many of Northstar’s venture capital investors were no doubt betting that Levy could turn that trick again. Any doubt that investors may have had about the long-term viability of the neuromodulation market should have been put to rest with St. Jude’s purchase of ANS in 2005. Coming on the heels of Boston Scientific’s purchase of Advanced Bionics in 2004, the stage was set for a showdown in neuromodulation devices among three medical device giants, Medtronic, Boston Scientific, and St. Jude, who just happen to be competitors in the cardiac device market. The comparison of neuromodulation devices to cardiac devices is certainly a flattering one. A research report published by Neurotech Reports, The Market for Neurotechnology: 2008–2012, projects the worldwide neurotech device market will exceed $3.8 billion in 2008; the cardiac market will likely be 10 times that. Still, the comparison may be limiting in the long run, given the much larger number of clinical applications, medical specialties, and patient populations that can be served with neuro devices.
New product categories With all the attention given to the big three’s competition in neuromodulation devices, there are several other very promising categories of neurotech devices that have yet to gain the same level of investor and analyst interest. Neurorehabilitation devices, such as muscle stimulators, neurorobotic systems, and neural regeneration stimulators, are poised for dramatic growth. And new types of neural prostheses, including motor prostheses and new FES devices, have already attracted the attention of device makers such as Otto Bock, Hanger, and Ossur. And although most individuals in the neuromodulation industry would consider cardiac pacing outside
its borders, even though these devices control excitable tissue, the industry has much to gain by studying, and perhaps annexing, concepts from the cardiac device industry. Recent journal articles about neural stimulation as a potential treatment for cardiovascular disorders remind us that the nervous system and the circulatory system are connected – literally. Stimulation of the vagus nerve or the greater splanchnic nerve can elicit response in cardiac muscle, much as stimulation of the phrenic nerve or the ulnar nerve produces response in the lungs or skeletal muscle. Surely it would be narrow-minded to exclude such neuromodulatory applications just because the end organ is the heart. Given the industry’s background and success at fine-tuning stimulation parameters, the cardiovascular market may well represent a ready and lucrative opportunity for neuromodulation companies.
Future outlook The neuromodulation industry is poised for considerable growth in coming years. There will also likely be continued consolidation as large medical device and biotechnology firms acquire smaller companies and make investment in start-up firms. New technology areas such as optical stimulation, magnetic stimulation, and nanotechnology will no doubt produce more new companies competing in the neuromodulation device industry. And there will be numerous opportunities for neuromodulation firms to partner with other life sciences companies, such as pharmaceutical firms.
References Melzack, R. and Wall, P. (1965) Pain mechanisms: a new theory. Science 150: 971–8. Shealy, C., Mortimer, J. and Reswick, J. (1967) Electrical inhibition of pain by stimulation of the dorsal columns: preliminary report. Anesth. Analg. 46: 489–91. Wall, P.D. and Sweet, W.H. (1967) Temporary abolition of pain in man. Science 155: 108–9.
I. an introduction to neuromodulation
C H A P T E R
6
Beginnings of the Societies Ross Davis, Philip L. Gildenberg, Giancarlo Barolat, Elliot S. Krames, Dejan Popovic, and Paul Meadows
o u t l i n e A: History of the Societies of Stereotactic and Functional Neurosurgery
49
FES History
56
References
52
Advances in External Control of Humans Extremities (ECHE) Meetings
57
B: History of the International Neuromodulation Society
52
Rehabilitation Engineering Society of North America (RESNA)
58
Formation of International Chapters
53
Membership
54
Vienna International Workshop on Functional Electrical Stimulation
58
Mission Statement of the INS
54
The Development of IFESS
58
References
60
C: History of the International Functional Electrical Stimulation Society
55
A: History of the Societies of Stereotactic and Functional Neurosurgery
In the animal, the apparatus was secured to the animal by ear plugs and tabs that held it to the inferior orbital rim which also served to localize the head to stereotactic (stereotaxic, as it was spelled then) space. Although this provided reasonable accuracy in animals, it was not accurate enough for patients. It was not until 40 years later that Ernest Spiegel and Henry Wycis (Spiegel et al., 1947) used intraoperative X-ray to identify landmarks around the third ventricle that stereotactic guidance could be used safely in patients. Their report drew immediate worldwide attention. Soon neurosurgeons from throughout the world visited them at Temple Medical School in Philadelphia to learn their technique. Since, at that time, there was
Philip L. Gildenberg The technique of stereotaxic surgery began in 1908 when Horsley and Clarke (1908) published a detailed description of their apparatus and technique, along with the first stereotaxic atlas and the results of investigating cerebellar physiology in the monkey. Their system was based on a Cartesian principle that defines a target by three coordinates: AP, lateral, and vertical.
Neuromodulation
49
© 2008, 2009 Elsevier Ltd.
50
6. beginnings of the societies
Figure 6.1 Henry T. Wycis and Ernst A. Spiegel with Model V 1959 stereoencephalotome, which they used for the duration of their practice
no commercially available stereotactic apparatus, each neurosurgeon designed their own version or copied by hand one that had already been developed. This event resulted in a flurry of information exchange and by the early 1950s meetings were called at many stereotactic centers. Most of these meetings were relatively informal. These early pioneers of stereotaxis had sufficient comradeship to speak freely and frankly and the field blossomed. I (Philip Gildenberg) was a medical student when I began to work with Spiegel and Wycis in 1956 while the field was in its infancy and returned to their service when I was a neurosurgical resident from 1962 to 1967. My meeting these early stereotacticians as they visited Temple provided to me a unique opportunity to learn of this exciting new field. In 1961, at one of those informal meetings, the decision was made to form a professional society through which meetings could be better organized. The Inter national Society for Research in Stereoencephalotomy was chartered in Philadelphia in that year. The term “stereoencephalotomy” was coined by Spiegel to acknowledge that the target was defined in three dimensions, using the landmarks within the encephalon from which to measure the target. At this early juncture there existed an American Branch and a European Branch. The first meeting of the International Society for Research in Stereoencephalotomy was held in Philadelphia in 1963, and was designated as the First International Symposium on Stereoencephalotomy.
The Second International Symposium on Stereoencephalotomy was held in 1965. Part of the meeting was held in Copenhagen and part in Vienna to coincide with the location of the Meeting of the World Federation of Neurosurgical Societies (WFNS). To this day, the meeting every four years of the World Society for Stereotactic and Functional Neurosurgery (WSSFN) is held just before the meeting of the WFNS in a location selected to facilitate traveling from one meeting to the next. The Third International Symposium on Stereoencephalotomy was held in Madrid in 1967. Meanwhile, the continental societies began to have their own meetings. The American Branch of the International Society for Research in Stereoencephalotomy was founded in 1968 and held its first formal meeting in Atlantic City in that year. The main topic at the meeting was Parkinson’s disease, but, because L-DOPA was introduced at approximately the same time (Cotzias et al., 1967), there was a sudden disappearance of patients with Parkinson’s disease being referred to neurosurgeons. Meetings of the societies, however, were still held, but the emphasis at these meetings changed to pain management, epilepsy, and non-Parkinson movement disorders. Because of this introduction of L-DOPA, many neurosurgeons left the field and only a cadre of academically oriented neurosurgeons remained. The Societies, however, continued to function. The Fourth International Symposium on Stereoen cephalotomy was held in 1969 in New York, just before the meeting of the WFNS. The Fifth International Symposium, hosted by Tragott Riechert in Freiburg, Germany, was held the next year in 1970 and coincided with the founding of the European Branch of the Society for Research in Stereoencephalotomy, the precursor of the European Society for Stereotactic and Functional Neurosurgery, which will be discussed below. A significant turning point occurred at the Sixth International Symposium on Stereoencephalotomy hosted by Hirotoro Narabayashi that was held in Tokyo in 1973. The society was reorganized into more distinct components. The word “Stereoencephalotomy” had never caught on and was not used except in the name of the organization and it was decided to adopt a more recognizable name. The International Society for Research in Stereoencephalotomy was renamed the World Society for Stereotactic and Functional Neurosurgery (WSSFN) in 1973. A discussion and vote were held to decide how to spell “stereotactic” in the name of the organization. Sometime, in the late 1950s and early 1960s, human “stereotaxic” surgery became named by some neurosurgeons, particularly in Europe, as “stereotactic.” The origin of that spelling is unknown at present. Nevertheless, enough neurosurgeons used
I. an introduction to neuromodulation
A: History of the Societies of Stereotactic and Functional Neurosurgery
that spelling, so a vote was taken as to how to spell the name of the Society (Gildenberg, 1993). In 1973, Spiegel passed on to me the editorship of the journal affiliated with the stereotactic societies, Confinia Neurologica. In subsequent years the name of the journal was changed to Applied Neurophysiology, which more closely stated the purpose of functional neurosurgery in English. Several years later when the introduction of image guided surgery came about, the name of the journal was again changed to Journal of Stereotactic and Functional Neurosurgery. The proceedings of the meetings of the WSSFN and ASSFN continued to be published in that journal until the editorship changed to David W. Roberts, in 2002. The atmosphere at the meetings was always cordial and informal with members freely exchanging information. The International 1973 Tokyo meeting also forced a name change in the continental branches from the American Branch to the American Society for Stereotactic and Functional Neurosurgery (ASSFN) and the European branch to the European Society for Stereotactic and Functional Neurosurgery (ESSFN). A four-year cycle was established, whereby the WSSFN would meet one year, the ESSFN the following year, the ASSFN the next, and then the ESSFN, once again, to complete the cycle. This pattern continued with a few exceptions until 2002 when the ASSFN felt the need to meet every two years. The next quadrennial meeting of the WSSFN was held in 1977 in Saõ Paulo and hosted by Raul Marino (Gildenberg and Marino, 1978). Although still affiliated with the WSSFN, the ASSFN was declared an independent society in 1973 and it was not until 1980 that the first separate meeting was held in Houston with myself (P.L. Gildenberg) as the host. Although this meeting was held during the time that stereotactic surgery was relatively quiescent, it was attended by stereotacticians from throughout the world. Twenty-seven papers were presented on basic neurophysiology, movement disorders, epilepsy and pain. Interestingly, although the use of computers in surgery was still in its infancy, 11 papers were presented on that topic, a true reflection of the influence of this small group of surgeons on subsequent developments, which has led us to image guided surgery. The 1981 meeting held in Zurich and hosted by Jean Siegfried (Gildenberg et al., 1982) was declared by the ESSFN to be a joint meeting between the WSSFN and the ESSFN and furthermore that the ESSFN was no longer a component society of the WSSFN, but an independent society. As interest in frameless stereo tactic surgery grew, it became a major topic in the 1983 Meeting of the ASSFN, held in Durham, North Carolina and hosted by Blaine Nashold. The Ninth Meeting of the WSSFN, hosted by Ronald Tasker, was held in Toronto in 1985 (Tasker
51
et al., 1985), the Tenth Meeting, hosted by Chihiro Ohye, was held in Maebashi, Japan (Ohye et al., 1990), and the Eleventh Meeting, hosted by this author, was held in Ixtapa, Mexico (Gildenberg et al., 1994). In 1995, the ASSFN Meeting was held in Los Angeles and hosted by Michael Apuzzo and David Roberts (Roberts et al., 1996). At this meeting there was a resurgence of reports about pallidotomy for Parkinson’s disease and other functional neurosurgery, which constituted half of the program, an indication of the resurgence of that field. There were also reports of stereotactic radiosurgery, imaging, and computer guidance. In 1997, the WSSFN Meeting was held in Lyons, France, with Marc Sindou as host (Sindou et al., 1997). It was outstanding in several ways. It was by far the largest meeting held to date. The meeting included a large number of French scientists working in functional neurosurgery. Neuromodulation had become a particularly active field, and several of its most active proponents were amongst the French colleagues in attendance. Deep brain stimulation (DBS) was particularly well represented in this program. The Thirteenth Meeting (perhaps a prophetic number) of the WSSFN, hosted by Brian Brophy, was held in Adelaide, Australia, in September, 2001. During that meeting, the attack on the World Trade Center occurred in New York. All flights to the USA were canceled, so many of the speakers scheduled to appear at the meeting of the WFNS in Sydney the following week could not attend, nor could the WSSFN members return home. The ASSFN Meeting in 2003 was held shortly after the FDA approved the use of DBS for movement disorders. Patrick Kelly was the host of that meeting, held in New York. At this meeting there was a rush of early papers on experience with DBS, which was certainly the topic of discussion throughout the meeting hall. Many of the papers were on the intraoperative use of computers and image guidance. The most recent meeting of the WSSFN, hosted by Mario Meglio, was held in 2005 in Rome and was held to coincide with the meeting of the International Neuromodulation Society (INS). The next meeting of the WSSFN is scheduled for 2009 in Toronto, hosted by Andres Lozano, who is the current President. The 2006 meeting of the ASSFN, hosted by G. Rees Cosgrove, was held in Boston. DBS and epilepsy surgery were the most active topics. The last meeting of the Society, before the writing of this chapter, was held in 2008, in Vancouver, Canada, and was hosted by Chris Honey of Vancouver. In July, 2006, the WSSFN sponsored and organized, for the first time, an interim meeting that was held
I. an introduction to neuromodulation
52
6. beginnings of the societies
Figure 6.2 A gathering of the present and past presidents of the WSSFN on 30 October 2000. Left to right: Marc Sindou, Chihiro Ohye, Brian Brophy, Philip Gildenberg, and Sang Sup Chung
in Shanghai, China concerning movement disorders, pain, psychiatric disease, and epilepsy. There was great interest in neuromodulation and DBS. It was hosted by Bomin Sun from the Shanghai Jiao Tong University, Rui Jin Hospital, and Andres M. Lozano was the meeting chairman. As the need to accommodate non-English-speaking and junior colleagues has grown, several other national stereotactic societies have been formed including the Japanese, the Korean, the Argentinian, and more recently the Chinese Societies for Stereotactic and Functional Neurosurgery. Regional Societies have also been formed and include the Sociedad Latinoamericana de Neurocirugia Funcional y Estarerotaxia (SLANFE) and the Asian Society for Stereotactic, Functional and Computer Assisted Neurosurgery (ASSFCN). Acknowledgment The author wishes to thank Prof. Joachim Krauss, Hanover, Germany, for providing much of the information about the ESSFN.
Society for Stereotactic and Functional Neurosurgery. Stereotac. Funct. Neurosurg. 63: 1–301. Gildenberg, P.L., Siegfried, J., Gybels, J. and Franklin, P.O. (eds) (1982) Eighth Meeting of the World Society and the Fifth Meeting of the European Society for Stereotactic and Functional Neurosurgery. Appl. Neurophysiol. 45: 1–554. Horsley, V. and Clarke, R.H. (1908) The structure and functions of the cerebellum examined by a new method. Brain 31: 45–124. Ohye, C., Gildenberg, P.L. and Franklin, P.O. (eds) (1990) Proceedings of the Tenth Meeting of the World Society for Stereotactic and Functional Neurosurgery. Stereotac. Funct. Neurosurg. 54–55: 1–564. Roberts, D.W., Apuzzo, M.L.J., Gildenberg, P.L. and Franklin, P.O. (1996) Proceedings of the Meeting of the American Society for Stereotactic and Functional Neurosurgery, Part II. Stereotac. Funct. Neurosurg. 66: 1–156. Sindou, M., Martens, F., Gildenberg, P.L. and Franklin, P.O. (eds) (1997) Proceedings of the Twelfth Meeting of the World Society for Stereotactic and Functional Neurosurgery. Stereotac. Funct. Neurosurg. 68: 1–318. Spiegel, E.A., Wycis, H.T., Marks, M. and Lee, A.J. (1947) Stereotaxic apparatus for operations on the human brain. Science 106: 349–50. Tasker, R.R., Turnbull, I.M., Gildenberg, P.L. and Franklin, P.O. (eds) (1985) Proceedings of the Ninth Meeting of the World Society for Stereotactic and Functional Neurosurgery. Appl. Neurophysiol. 48: 1–498.
References www.assfn.org. www.essfn.org. www.wssfn.org. Cotzias, G.C., VanWoert, M.H. and Schiffer, L.M. (1967) Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med. 276: 374–9. Gildenberg, P.L. (1993) “Stereotaxic” versus “stereotactic.” Neurosurgery 32: 965–6. Gildenberg, P.L. and Marino, R. Jr (eds) (1978) Seventh Symposium of the International Society for Research in Stereoencephalotomy. Conf. Neurol. 41: 1–250. Gildenberg, P.L., Franklin, P.O., Escobedo, F.R. and Garcia Flores, E. (eds) (1994) Proceedings of the Eleventh Meeting of the World
B: History of the International Neuromodulation Society Giancarlo Barolat and Elliot S. Krames Neuromodulation is defined by the International Neuromodulation Society (INS) as a field of science, medicine, and bioengineering that encompasses implantable and non-implantable technologies, electrical
I. an introduction to neuromodulation
Formation of international chapters
or chemical, that impact upon neural interfaces to improve life for humanity. Currently, the involved clinical specialists come from anesthesiology, neurosurgery, neurology, neurophysiology, cardiology, physical medicine and rehabilitation, gastroenterology, urology and orthopedics; however, this relatively new discipline of medicine will most likely encompass or influence most medical specialties. The INS was founded in 1990, because of the increasing frustration of neurosurgeons involved with “Functional Neurosurgery.” Until the mid-1980s, most of the neuro-implantation procedures were for pain management and were performed by neurosurgeons with anesthesiologists making some inroads. These implantation procedures included epidural dorsal column stimulation (DCS), peripheral nerve stimulation (PNS), and stereotactic deep brain stimulation (DBS). In the 1970s and 1980s, the use of medications helped control Parkinson’s symptoms, which resulted in a marked decrease in the use of stereotactic procedures. In the mid-1980s on, there was a radical shift for the utilization of stereotactic surgery for brain biopsy and irradiation brain lesions for the neuro-oncologists. As a result, by the late 80s most of the meetings and publications of the Stereotactic and Functional Neurosurgery Societies were dedicated to reporting the success of stereotactic brain biopsies and treatments, with functional neurosurgery being relegated to a minor part of these meetings and activities. However, in 1990 an active group of neurosurgeons, specializing in therapeutic stimulation, decided, in Paris, to create a new society inclusive of other disciplines that were related to neuromodulation. The founding members of the new International Neuromodulation Society (INS) were: l l l l l l
Lee Illis (Neurology, UK, President 1990–94) Mario Meglio (Neurosurgery, Italy) Daniel Galley (Cardiology, France) J.U. Krainick (Neurosurgery, Germany) J.C. Sier (Vascular Surgery, The Netherlands) Michiel J. Staal (Neurosurgery , The Netherlands)
The first official meeting of the Society, organized by Mario Meglio, a neurosurgeon from Rome, was held in Rome in 1992. Further successful meetings, held every two years, were as follows: 1994, Gotenburg, Sweden, hosted by Lars Augustinsson l 1996, Orlando, Florida, USA, hosted by Giancarlo Barolat l 1998, Lucerne, Switzerland, co-hosted by Claus Naumann and Ross Davis for the first combined l
l
l l l
53
meeting of INS with the International Functional Electrical Stimulation Society (IFESS) 2000, San Francisco, California, hosted by Elliot Krames, combined three different world societies into one comprehensive multidisciplinary symposium 2003, Madrid, Spain, hosted by Enrique Reig 2005, Rome, Italy, hosted by Mario Meglio 2007, Acapulco, Mexico, co-hosted by Elliot Krames, President of the INS, and Joshua Prager, President of the North American Neuromodulation Society (NANS), the INS’s largest country/regional chapter
Initially, the Society encountered difficulties in asserting its role to speak for its members involved with implantable and non-implantable technologies at the “neural interface” because of competition with the various pain societies, both internationally and nationally, within each country. Because the INS membership was, by its very nature, multidisciplinary, there was difficulty in bringing its members of disparate interests together. However, the use of neurostimulation for peripheral vascular disease and angina, in Europe, helped the Society attract a substantial number of vascular specialists and cardiologists. While Giancarlo Barolat was President of the Society from 1994 to 2000, Elliot Krames was brought onto the INS Board and undertook the task of creating the journal Neuromodulation. The journal’s first issue was published in January 1998, and has become the authoritative publication in this area. Tia Sofatzis was brought into the Society in 1998 as Managing Editor of Neuromodulation, and in 2001, she was elected Executive Director of the INS, a position she has held since. In 1999, the International Society for Functional Electrical Stimulation (IFESS) started publishing their scientific papers in Neuromodulation, in a special section devoted to Functional Electrical Stimulation (FES). In 2001, the IFESS agreed to adopt Neuromodulation as their official publication. This collaboration between Societies has fostered a healthy relationship between clinicians, engineers and scientists involved in the restoration of neurological function through implanted devices. In January 2007 the journal was renamed as Neuromodulation: Technology at the Neural Interface.
Formation of international chapters In 1994 a group of implantation specialists with interest in pain control from the USA and Canada convened in Atlanta, Georgia to form the American
I. an introduction to neuromodulation
54
6. beginnings of the societies
Figure 6.3 INS Board of Directors in March 1993. On the left: Mike DeJongste, Sherri Kae Calkins, Bengt Linderoth, John Oakley. On the right: Richard North, Robert Foreman, Giancarlo Barolat, Elliot Krames
Table 6.1 International Societies and formation dates Australian Neuromodulation Society – 2004 Benelux Neuromodulation Society – 2002 Brazilian Neuromodulation Society – 2007 Canadian Neuromodulation Society – 2007 German Neuromodulation Society – 2005 Italian Neuromodulation Society – 1999 Japanese Neuromodulation Society – 2005 Korean Neuromodulation Society – 2007 North American Neuromodulation Society – 1995 Neuromodulation Society of the United Kingdom and Ireland – 2005 South Eastern Europe Neuromodulation Society – 2007 Spanish Neuromodulation Society – 2007
Neuromodulation Society. While originating as an independent Society, it, in 1995, became the first chapter of the INS under the name of the North American Neuromodulation Society (NANS). Under the tutelage of the INS Presidencies of Giancarlo Barolat, Brian Simpson, Mario Meglio, and Elliot Krames, 11 more international chapters have been created (Table 6.1). Chapters currently under differing stages of development include the Argentine Neuromodulation Society, the Chinese Neuromodulation Society, the French Neuromodulation Society and the South African Neuromodulation Society.
accounts for about 50% of the total membership of the INS and other countries outside of the USA, accounts for 50%. The INS has grown about 300 new members each year since 2005. The largest interest group is of members from the medical, scientific and industry world who are primarily interested in the specialty of pain medicine (anesthesia background), followed by neurosurgery. Other members include neuroscientists, neurologists, engineers, nurses and members of industry. In the year 2008, Daryl Kipke, Professor and Chairman of the Department of Bioengineering, University of Michigan, USA and Hunter Peckham, Professor and Chairman of the Department of Biomedical Engineering, Case Western Reserve University, Cleveland, USA will start a biomedical engineering special interest group (SIG) for the INS.
Mission statement of the INS The INS exists to “promote, disseminate and advocate for the science, education, best practice and accessibility of all aspects of neuromodulation. Our multidisciplinary Society is established to be inclusive of all scientists, physicians, bioengineers, members of industry and other professionals who have a primary interest in the field of neuromodulation.” To accomplish this mission the INS will: Expand the community by bringing together, on a national level, practitioners and other interested stakeholders of neuromodulation into national chapters of the INS. l Protect the community by partnering with industry to expand present technologies, by advocating for l
Membership Currently the INS has approximatley 1200 members. The North American Neuromodulation Society
I. an introduction to neuromodulation
C: History of the international functional electrical stimulation society
55
Figure 6.4 INS Board of Directors Meeting in Acapulco, Mexico, December 2007: Back row: Simon Thomson, UK, INS Secretary and President-Elect; Jon Valentine, UK, President NS of UK & Ireland; Eduardo Barretto, Brazil, President Brazilian NS; Ross Davis, USA, INS Director-at-Large; Athanasios Koulousakis, Germany, Past-President German NS; Francisco Robaina, Spain, President Spanish NS; Brian Simpson, UK, former INS President, Liaison Officer for IFESS; Jung-Kyo Lee, South Korea, President Korean NS; Bart Nuttin, Belgium, President Benelux Chapter. Middle row: Takamitsu Yamamoto, Japan, representative of Japanese NS; Luan Guoming, China, President Chinese NS; Damianos Sakas, Greece, President South-Eastern European NS; Mario Meglio, Italy, INS Immediate Past President; Giancarlo Barolat, USA, INS Director-at-Large, and former INS President; Paolo Poli, Italy, President Italian NS; Krishna Kumar, Canada, President Canadian NS; Joshua Prager, USA, Past-President of NANS; Liong Liem, The Netherlands, Treasurer-INS Executive Board. Front row: Tia Sofatzis, USA, INS Executive Director; Elliot Krames, USA, INS President
Table 6.2 The INS Executive Officers Presidents 1989–1994 Lee S. Illis, UK 1994–2000 Giancarlo Barolat, USA 2000–2003 Brian Simpson, UK 2003–2006 Mario Meglio, Italy 2006–2009 Elliot Krames, USA Secretaries 1989–1994 J.C. Sier, The Netherlands 1994–2000 Claus Naumann, Switzerland 2000–2003 Michael J.L. DeJongste, The Netherlands 2003–2008 *Simon J. Thomson, UK
government acknowledgement of the technologies used by the field, and for advocating for reasonable remuneration to practitioners of the clinical science of neuromodulation and reasonable reimbursement to industry for the research and development of the devices used by the field. l Disseminate the knowledge base of the field of neuromodulation through national and international scientific meetings and the journal of the INS, Neuromodulation: Technology at the Neural Interface. l Expand the knowledge base through fostering education and research germane to the field of neuromodulation and encouraging scientific discourse.
Treasurers 1989–1994 Michiel J. Staal, The Netherlands 1994–2000 Michael J.L. DeJongste, The Netherlands 2000–2006 Robert D. Foreman, USA 2006–2009 Liong Liem, The Netherlands
C: History of the International Functional Electrical Stimulation Society
Editor-in-Chief of Neuromodulation 1998– Elliot S. Krames, USA IFESS liaison 2004– Brian Simpson, UK Executive Directors 1994–2001 Sherri Kae Calkins, USA 2001– Tia Sofatzis, USA *
President Elect 2008–2009
Dejan Popovic and Paul Meadows The International Functional Electrical Stimulation Society (IFESS) was first conceived in 1993 and founded in 1995 at the 5th Vienna International Workshop on Functional Electrostimulation, in Vienna, Austria. To fully appreciate the inspirations for this society, the history of IFESS must first be preceded with a brief history
I. an introduction to neuromodulation
56
6. beginnings of the societies Neurostimulation addressable population (000s patients) 16 000 14 000 12 000 10 000 8000 6000 4000 2000 0
2300 3069 1635
645
401
123
657
768 13850
850
200
2625
ta l To
tit is D
ep
re s
gi na
re a
nc
An
pa ic hr on C
si Er o Ep n ec Irr t i le ile ita ps bl dy y e sf bo un w ct el sy ion M nd ov ro em m e en M td ig ra is in or e de rs (P D N ) ec k pa O in ve O ra b es ct iv ity e bl Pe ad rip de he r ra lp ai Pe n lv ic pa in
118
460
Figure 6.5 Diseases amenable to neuromodulation therapies and prevalence of the disease in the USA alone (Source: US qualitative research with referrers and potential implanters, literature search, internal discussions, and data analysis) Table 6.3 FES Societies, Workshops and Conferences, starting 1963 Advances in External Control of Humans Extremities
Meetings every 3 years, 1963–1990
Society of Neuroscience Meetings
1970 on
US National Institute of Health NINDS Neural Prosthesis Workshops Neural Interfaces Workshops Engineering Foundation: Neural Prostheses; Motor Systems Meetings
1972–2003 2004–2006, 2008 on Every 3 years, 1985–2000
Case Western Reserve University Biomedical Engineering Department Applied Neuro-Control Research Day Neuro Engineering Research Lecture
1986–2002
Japanese FES Society
1989 on
Vienna International Workshop on FES
Every 3 years from 1983
International Functional Electrical Stimulation Society (FESS) formed 1993–4
Meetings yearly from 1996
2003 on
of functional electrical stimulation (FES) research and the contributions of other societies and various conferences/workshop series (Table 6.3).
FES history Since the original work of Luigi Galvani (1780), who discovered animal electricity, through to the
magnificent work of Guillaume B.A. Duchenne de Boulogne (1872) who was the first to describe the controlled use of faradizing current electricity in the human nervous system, scientists have sought ways to treat human diseases with electrical stimulation. In 1875, it was reported that Duchenne applied electrical stimulation to the lower extremities of a paraplegic subject as reported in a Paris newspaper: “Who does not recollect the astonishment exhibited in the clinic at that experiment of Duchenne of drawing from his bed a patient regarded as absolutely paraplegic, and loading him with the weight of a man of ordinary size, without him ever flinching under it?” Since then, the goal of many researchers has been to assist the disabled individual through the use of electrical stimulation. It was not until the advent of the heart pacemaker that the world began to appreciate what technology could provide to individuals with disabilities on a broader scale. The early work of the Canadian engineer John A. Hopps in 1950, with simple technology by today’s standards, nonetheless opened a completely new page in the treatment of people with heart disease. The development of small electronic devices, especially the transistor and followed later by the computer in the 1950s, enabled many researchers to investigate the effects of controlled bursts of electrical charge to the sensory-motor system and the applications in the domain of what is today called “neuromodulation.” However, early foundation technology came from the work at the Case Institute of Technology, Cleveland, Ohio, where a group of very enthusiastic young people led by James Reswick and Thomas Mortimer in the early 1960s started suggesting that it might be possible to tap into the nervous system and provide the connection between the higher and lower neural substrates that were interrupted due to the
I. an introduction to neuromodulation
Advances in external control of humans extremities (ECHE) meetings
57
Figure 6.6 (A) Rajko Tomovic; (B) Jim Reswick; (C) Dejan Popovic; (D) Tadej Bajd; (E) ECHE Conference in Dubrovnik (1975): Lojze Vodovnik, W.T. Liberson, Alojz Kralj, Primoz Strojnik, Uros Stanic
injury or disease. This coincided with the patent and publication of W.T. Liberson (Liberson et al., 1961) and his application of a simple device to treat drop-foot during gait in hemiplegic individuals. FES has been applied to the lower extremities of paraplegic persons since 1963, when A. Kantrowitz raised a paraplegic subject into a standing position using surface applied electrodes. In parallel, much interest was paid to the development of powered artificial prosthetics that would help amputees to walk, reach and grasp by using control signals that are coming from the muscles volitionally controlled by the amputee.
Advances in external control of humans extremities (ECHE) meetings In 1962, Rajko Tomovic started a unique series of triennial meetings called Advances in External Control of Humans Extremities (ECHE). The first meeting took place in the beautiful summer resort of Opatija, Yugoslavia (now Croatia). The meeting was a fantastic and rare opportunity for scientists from East and West to meet at one place and spend one week of productive and pleasant time together to present their novel and promising ideas. The first meeting attracted, among others, Norbert Wiener, who gave an interesting overview of what computers could do in the future in the domain of controlling extremities, and how cybernetics would resolve the man–machine
interface problem. The first meeting was also the occasion where the great mind of Lojze Vodovnik (University of Ljubljana, Slovenia) met Jim Reswick and decided to spend some time at Case (became Case Western Reserve University). The success of the first meeting motivated the new group of scientists who dedicated their time, knowhow and intelligence to the development of electrical stimulation principles and applications. Tomovic decided to move the location for the ECHE Symposium to Dubrovnik on the Adriatic coast. During the last week of August, every third year from 1966, Dubrovnik became home to about 100 hot minds willing to share in what they had accomplished in the domain of new systems for rehabilitation of individuals with disability. The discussions and presentations shifted from the symposium room to the round tables at the beach, long debates in the restaurants and under the clear sky and stars. The Dubrovnik meeting became synonymous with the latest technology introductions in the field of electrical stimulation. The efforts of the Ljubljana group, led by engineers Lojze Vodovnik, Alojz Kralj, Tadej Bajd, Uros Stanic and physicians Milan Dimitrijevic and Franjo Gracanin, resulted in bringing excellent scientists and many young people with great ideas together. The Dubrovnik meeting was the best forum to place seeds for excellent collaborations between North American, Japanese, Russian, Polish, Austrian, German, French, English, Scottish, Dutch, Yugoslav and other researchers and clinicians and indeed many future collaborations can trace their roots to this international gathering of renowned scientists
I. an introduction to neuromodulation
58
6. beginnings of the societies
and clinicians. Dejan Popovic, one of the organizers of the ECHE meetings since 1978, followed the idea of Tomovic of providing information to many generations of researchers to come by collecting all ten proceedings of the ECHE Meeting and publishing them on a CDROM that is available today. This CDROM brings important information that could help provide a better understanding of the foundation of the field of modern prosthetics and neural prostheses, especially applied to sensory-motor systems, and provides easy access to information that is not available through the Internet regarding this pioneering work.
Rehabilitation engineering society of north america (RESNA) Jim Reswick, along with Douglas Hobson, Colin McLaurin, Anthony Staros and Joseph Traub, organized a conference in Rehabilitation Engineering, and initiated the development of the RESNA, which held its first meeting in Toronto in 1980. Since that time, RESNA has changed its name to the Association for the Advancement of Rehabilitation Technology; and in 1995 it changed its name, once again, to the Rehabilitation Engineering and Assistive Technology Society of North America – RESNA. RESNA is an interdisciplinary organization dedicated to promoting the transfer of science, engineering and technology to meet the needs of individuals with disabilities, and its members include a broad range of disciplines. Key to the development of this organization was the Special Interest Groups (SIGs), one of which was dedicated to Electrical Stimulation. The SIGs solicited papers for presentation in conference sessions and held ad hoc meetings to discuss and promote their specialties. Comprised of engineers, physical therapists, and other interested parties, the group successfully integrated disparate interest groups into this single session topic. Over time, however, the electrical stimulation special interest group was unable to maintain itself and is now inactive.
Vienna international workshop on functional electrical stimulation An international tri-annual conference organized by the Department of Biomedical Engineering and
Physics of the Medical University of Vienna, Vienna Medical School, and associated with the International Federation for Artificial Organs (IFAO), which emerged and originated from the International Society for Artificial Organs (ISAO), has for many years addressed the medical application of electrical stimulation. The first of these meetings was held in 1984 in Vienna and has been held in or around Vienna every three years since. The participants at this meeting were not required to be members of the ISAO or IFAO, and the meeting has attracted engineers, medical researchers, and manufacturers. The Vienna Workshop continues on to this day and is one of the greatest contributors to the ongoing development and presentation of research in electrical stimulation.
The development of IFESS The last in the series of ten ECHE meetings took place in 1990. The tragic events in the Balkans prevented the continuation of this great tradition. Many among the original organizers of the Dubrovnik meetings strongly believed that the tradition and achievements of this great series of meetings should be remembered and continued. The need to continue this activity was recognized by Slovenian researchers and they suggested that a new Society should be organized that would have the major task of contributing to better use of electrical stimulation. In 1993, at a meeting devoted solely to electrical stimulation, in Ljubljana, which was organized by the Institute Josef Stefan and the Faculty of Engineering at the University of Ljubljana, with a follow-up meeting that was held in the seaside village of Portoroz, the formation of a new society was discussed. At this meeting the participants met to determine how the field of electrical stimulation could best be advanced. In brief, it was decided that existing meetings and professional societies were not sufficiently focused on functional electrical stimulation, and that only with the formation of a new international society that was solely focused on this topic could the field be properly represented, promoted, and clinical development accelerated. This then was the impetus behind the formation of the International Functional Electrical Stimulation Society (IFESS). An organizing team consisting of Uros Stanic, Ross Davis, Peter Veltink, Robert Jaeger, and Thomas Sinkjaer was formed, and the team of Bob Jaeger, Thomas Sinkjaer, and Peter Veltink were assigned to draft the first Bylaws of the Society. At the following
I. an introduction to neuromodulation
59
The development of IFESS
Vienna FES Workshop in 1995, the Bylaws were presented and the Foundation Meeting of the Society was held. At this meeting elections were held and the first IFESS Executive Board and Board of Directors were elected. Elected to the Executive Board for three-year terms were: Uros Stanic, President; Ross Davis, VicePresident; Paul Meadows, Secretary; and Peter Veltink, Treasurer. Elected to the Board of Directors were Helena Benko, Gudrun Sigurjonsdottir, and Moshe Solomonow (each to hold office for one year), Stanley Salmons, Byron Marsolais, and Nick Donaldson (each to hold office for two years), Bob Jaeger, Alojz Kralj, and Dejan Popovic (each to hold office for three years). Thereafter, on a yearly basis, three new Directors would be elected and three would retire, and on a triennial basis a new Executive Board would be elected. The first Annual Conference of IFESS was organized by Hunter Peckham and held at Case Western Reserve University in Cleveland, Ohio, in 1996. The conference was well attended and served as a template for future meetings. In 1995 there were 138 members world-wide who joined IFESS as Founding Members. The 2nd through 12th conferences are described briefly in Table 6.4. In 1998 a key event in the history of IFESS occurred. At a joint conference held in Lucerne, Switzerland, with the International Neuromodulation Society (INS), a meeting was held between the Executive Boards of the two societies. At this meeting, it was agreed that, due to the mutual benefits that each Society would derive from the other, the IFESS and INS should become officially related, they should share a common official journal, and they should endeavor to have representation at each other’s Annual Conferences. As a result of this meeting, there have been official combined sessions at each of the INS and IFESS Annual Conferences, where key representatives from the complementary
Table 6.4 IFESS Conference venues and chairmen, 1996 through 2011 Year
Location
Chairmen
1996
Cleveland, Ohio, USA
Hunter Peckham
1997
Vancouver, British Columbia, Canada
Andy Hoffer, Dejan Popovic
1998
Lucerne, Switzerland
Claus Naumann (INS), Ross Davis
1999
Sendai, Japan
Yasunobu Handa, Nozomu Hoshimiya, Kouzou Satou, J. Thomas Mortimer
2000
Aalborg, Denmark
Thomas Sinkjær, Dejan Popovic, Johannes J. Struijk
2001
Cleveland, Ohio, USA
Ronald J. Triolo, Primoz Strojnik, Peter Veltink
2002
Ljubljana, Slovenia
Uros Stanic, Tadej Bajd
2003
Brisbane, Australia
Glen Davis, James Middleton
2004
Bournemouth, UK
Ian Swain, Paul Taylor
2005
Vancouver, Canada
Mohamed Sawan
2006
Mount Zao, Japan
Itaru Kimura, Nozomu Hoshimiya, Yasunobu Handa, Takashi Imai, Kazunori Seki
2007
Philadelphia, Pennsylvania, USA
Randy Betz, Brian Smith
2008
Freiburg, Germany
Thomas Stieglitz, Martin Schuettler, Thomas Becks
2009
Seoul, Korea
Gon Khang, Younghee Lee
2010
Vienna, Austria
Manfred Bijak, Winfried Mayr
2011
São Paulo, Brazil
Alberto Cliquet
Table 6.5 Executive Board of IFESS, 1996 to 2010 Term
President
Vice-President
Secretary
Treasurer
1996–1998
Uros Stanic
Ross Davis
Paul Meadows
Peter Veltink
1999–2001
Ross Davis
Thomas Sinkjaer
Aleks Kostov/ Paul Meadows
Peter Veltink
2002–2004
Thomas Sinkjaer
Paul Meadows
Manfred Bijak
Jimmy Abbas
2005–2007
Paul Meadows
Manfred Bijak
Nico Rijkhoff/ Andy Hoffer
Milos Popovic
2008–2010
Manfred Bijak
Jane Burridge
Glen Davis
Thierry Keller
I. an introduction to neuromodulation
60
6. beginnings of the societies
Figure 6.7 IFESS Past Presidents: Paul Meadows, Ross Davis, and Uros Stanic
Society would present scientific oral presentations to the entire assembly. It was also agreed that the journal Neuromodulation would be adopted as the official journal of IFESS, with the IFESS logo placed on the journal, and an Editorial Board was established for IFESS member submissions. Ross Davis has served as the Head of the Editorial Board since its inception, and is a key proponent of the relationship between IFESS and INS.
IFESS continues to have successful Annual Conferences, attended by a broad mix of engineers, physical therapists, doctors of physical medicine and rehabilitation, orthopedic surgeons, neurosurgeons, and many other representatives of medical specialties. The collective works of all of these Conferences were compiled by Paul Meadows and were made available through the IFESS website and on a DVDROM which contains all of the proceedings of all of the IFESS meetings from 1996 to the present, along with proceedings of the Vienna FES Workshops and abstracts and papers from the INS and World Stereotactic and Functional Neurosurgery Society conferences. FES and IFESS’s future is bright and in good hands and promises to provide the world with many more developments in electrical stimulation as we partner with our sister organization, the INS.
References Liberson, W.T., Holmquest, H.J., Scott, D. and Dow, M. (1961) Functional electrotherapy: stimulation of the peroneal nerve synchronized with the swing phase of the gait of hemiplegic patients. Arch. Phys. Med. Rehab. 42: 101–5. www.ifess.org.
I. an introduction to neuromodulation
C H A P T E R
7
Clinical Study Design Daniel B. Carr and Anthony Eidelman
o u t l i n e Introduction
61
Quality of the Current Literature
65
Hierarchy of Clinical Study Design
61
Future Clinical Trials of Neuromodulation
65
Clinical Objective
62
Future Areas of Research
66
Study Design
63
Conclusion
66
Study Population, Intervention, and Setting
63
Summary Points
67
Assessment of Outcomes
64
References
67
Analysis of Results
64
Hierarchy of clinical study design
Introduction An understanding of clinical trial design is necessary for physicians or scientists who conduct clinical research on neuromodulation. It is also essential that practitioners who will ultimately translate clinical evidence into clinical practice understand how to critically appraise the evidence. Moreover, the language of evidence-based medicine (EBM) is increasingly used by regulators, insurers and other policy-makers to restrict payment for many medical interventions. The present chapter surveys clinical trial design, with a particular focus on investigations of neuromodulation. We review the attributes of methodologically sound clinical studies that reduce both investigator bias and confounding variables.
Neuromodulation
Proponents of EBM grade the quality of literature based on the type and quality of research study design (Carr et al., 1992; Wittink et al., 2003). An example of the hierarchy of study designs is displayed in Box 7.1. Each category of trials is considered methodologically superior to those found below it. In practice, most expert opinions may be countered by an equally vehement opinion from an equally qualified expert. Therefore, while anecdotal evidence certainly influences our medical practice, it cannot replace systematic scientific study. The next higher tier of evidence includes uncontrolled, descriptive trials, including case reports and series. Such trials are
61
© 2008, 2009 Elsevier Ltd.
62
7. clinical study design
Box 7.1
Hierarchy of individual study types Systematic reviews of RCTs One or more well designed RCTs Observational controlled trials Uncontrolled trials (case reports or series) Expert opinion Source: Carr et al., 1992; Wittink et al., 2003
necessary when a treatment is initially introduced in order to establish its effectiveness, practicality, and safety. However, observational studies with control groups, including cohort and case–control studies, are superior to those that lack controls because the former allow estimates of therapeutic effect that may be differentiated from placebo effects, which have long been observed to have potential importance in trials with subjective outcomes such as pain relief and satis faction with care. A prospective cohort study involving neuromodulation would consist of a longitudinal trial that compares patients with a specified condition who were assigned to either the therapeutic arm or a matched control group. However, observational studies have inherent limitations, most notably the possibility of factors that influence the distribution of patients between the active treatment (e.g., neuromodulation) or control groups (Miller et al., 1989a, b). Accordingly, randomized controlled trials (RCT) are considered the least biased method of study design to determine the efficacy of medical interventions. Through the process of randomization, the allocation of subjects between the neurostimulation arm and control group is theoretically accomplished without bias, particularly when allocation is concealed and outcome assessment is conducted by third parties blinded to the intervention each patient received. However, it is common to find that RCTs of the same intervention yield disparate conclusions (LeLorier et al., 1997). The specific study design, patients enrolled, disease severity, concurrent treatments or particular therapeutic intervention may be heterogeneous between RCTs. Moreover, a single RCT cannot be expected to be generalizable to all clinical situations. Therefore, systematic reviews of multiple RCTs are considered to offer the highest level of medical evidence. A systematic review is a summary of the evidence that answers a specific clinical question using an explicit method ology to select, appraise and consolidate the literature
(Cook et al., 1997). When the trials that address a specific clinical question employ sufficiently similar methods and outcome measurements, their results may be synthesized quantitatively into a meta-analysis. One of the most extensive evidence-based collections is The Cochrane Database of Systematic Reviews, a nonprofit effort in which the results of systematic reviews performed by dozens of collaborative review groups around the world are coordinated through a central office in Oxford, England. As of February 2007 the Cochrane Library contains almost 3000 systemic reviews and 1700 protocols. For the reasons just mentioned, the hierarchy of clinical study design should be considered a “general framework” rather then an absolute ranking system and clinicians should consider the results of the best available evidence (that may comprise trials other than RCTs, if such trials provide strong, consistent evidence) when making evidence-based decisions. For instance, a well-constructed, large-scale observational study may be of greater clinical value than a poorly designed, small-scale RCT. Further, the historically accepted notion that observational studies overestimate the magnitude of treatment effects (Sacks et al., 1982; Colditz et al., 1989; Miller et al., 1989a, 1989b) has recently been challenged (McKee et al., 1999; Benson and Hartz, 2000; Concato et al., 2000). Observational studies conducted in the past 20 years likely have superior methodological design, enhanced data set selection and improved statistical analysis compared to earlier trials (Benson and Hartz, 2000). Therefore, in situations where RCTs are not practical or feasible, observational trials that are rigorously designed may be an appropriate alternative to RCTs for determining therapeutic efficacy (McKee et al., 1999).
Clinical objective The clinical objective is perhaps the most critical aspect of a research trial. The recent Nobel Prize winner in literature, Naguib Mahfouz, stated “you can tell whether a man is clever by his answers, you can tell whether a man is wise by his questions.” Likewise, every clinical study should explicitly frame a well-defined research question. An appropriately constructed objective should describe characteristics of the study population, disease condition, intervention and outcome measures. For example, it is not sufficient to pose the general question “Is spinal cord stimulation (SCS) effective for complex regional pain syndrome (CRPS)?” A more meaningful objective was presented by Kemler and associates: “In adult patients
I. an introduction to neuromodulation
study population, intervention, and setting
with CRPS, are SCS with physical therapy superior to treatment with physical therapy alone after six months, with regard to pain relief, patient rated global perceived effect and functional status?” (Kemler et al., 2000). The latter study question astutely includes most of the important elements for a well-framed clinical question.
Study design Biased studies can lead to over-, or, more commonly, underestimation of the effect of a therapeutic intervention. Methodologically sound studies are less likely to be flawed by bias or confounding variables. A critical component of any trial is the method by which participants are assigned to either the intervention or control group. Selection bias may occur when one or more influencing variables are unevenly distributed among the study groups, whether or not these influencing variables are explicitly documented. For example, co-morbid depression is recognized to increase the likelihood of a poor response to any treatment for chronic pain (Bair et al., 2003). Hypothetically, if patients allocated to receive SCS had a greater incidence and severity of depression than those receiving medical management alone, then the observed benefit of SCS could be falsely underestimated. An advantage of the RCT design compared to observational and uncontrolled studies is its ability to minimize selection bias through the processes of randomization and allocation concealment. Random allocation in a 1:1 paradigm means that study participants have an equal and arbitrary chance of being assigned to the treatment or control groups. This paradigm reduces the likelihood of a disproportionate distribution of factors between study groups that could influence the clinical outcome. Appropriate methods of random allocation include computer-generated assignment or use of a table of random numbers. Allocation concealment means that investigators and participants are unaware of study assignments. Trials that lack allocation concealment overestimate treatment effect by as much as 41% (Schulz et al., 1995). Double-blinded, placebo-controlled trials are the most appropriate method of analgesic study design because suggestibility, patient or investigator expectation, and other contributors to placebo effects may introduce significant bias. However, in trials evaluating interventional therapies, including neuromodulation, blinding is more challenging to accomplish and often impractical. Double-blinding during SCS is impossible because of the associated paresthesiae.
63
However, blinding of other types of neuromodulation, including deep brain stimulation (DBS), may not produce conscious sensations and therefore concealment of treatment is feasible. For instance, Kupsch and associates (2006) conducted a double-blinded RCT evaluating the efficacy of bilateral pallidal neuro stimulation for 3 months for primary generalized or segmental dystonia. Permanent quadripolar electrodes were implanted bilaterally in the internal globus pallidus under general anesthesia. Postoperatively, the patients were randomized to receive either neurostimulation or sham stimulation. Both the patients and study investigators who assessed the outcome measures were unaware of the treatment allocations. The study concluded that bilateral pallidal stimulation was more effective then sham stimulation.
Study population, intervention, and setting The trial outcome may be influenced by subject selection. The characteristics of the study participants should be representative of the target general population that is eligible to receive neuromodulation. The study should have clear inclusion and exclusion criteria with well-defined demographics including age, gender, ethnicity, co-morbidities, functional status, current medications, and previous therapeutic intervention. As described above, prognostic factors between the study and control groups should be similar, to minimize confounding variables that could alter the apparent efficacy of the therapeutic intervention. Furthermore, it is essential to examine the methods by which prospective trials participants are recruited for the study. If the recruitment techniques result in only certain subsets of eligible patients being enrolled there may be selection bias, especially if participants with characteristics associated with poor clinical outcomes are selectively included or excluded. A well-designed and well-reported study should include a description of the prospective patients who were considered for the trial, but did not meet inclusion criteria. General aspects of patient screening and patient flow within the study are typically provided in a flow diagram according to the recommendations of the QUORUM statement (Altman et al., 2001). The report of the trial should provide a detailed description of the intervention, so that the study can be precisely duplicated. In studies of SCS, the trialing procedure and criteria for implantation should be reported. Additional relevant details include the
I. an introduction to neuromodulation
64
7. clinical study design
device model, description of the leads (type, number, and location), implantation technique, and stimulation settings. For studies involving neuromodulation, it is important that study clinicians have adequate exper ience with surgical and implantation techniques. In multicenter trials, there should be consensus among the site concerning the trial and implant methods. Despite having a similar protocol, consensus centerand investigator-specific effects are possible, that may potentially cause bias. Also, concurrent therapies that may influence outcome measures should be described, including medical management, physical therapy or cognitive-behavioral therapy.
Assessment of outcomes The primary and secondary outcome measures should be clearly defined, reliable, and previously validated. Both the methods of how outcomes will be determined and the timeframe of when endpoints will be determined should be explicitly reported. For studies evaluating therapies for chronic pain, recommended outcomes include pain intensity, physical and emotional function, patient self-reported ratings of global improvement and satisfaction with treatment, adverse effects, and participant recruitment process through the trial (Dworkin et al., 2005). Rogers et al. have emphasized that generic quality of life instruments such as the SF-36 are likely to be insensitive to detect clinically meaningful outcomes of interventions for chronic pain, unless such generic instruments are augmented by specific, validated questions that are relevant to the population with chronic pain (Rogers, Wittink, Ashburn et al., 2000; Rogers, Wittink, Wagner et al., 2000). Klomp and associates (1999) randomized patients with critical peripheral vascular disease, who were not candidates for revascularization surgery, to receive either SCS with maximum medical management or the latter therapy alone. The primary endpoint was limb survival at two years, and mortality was also documented. Mannheimer et al. (1998) compared electrical stimulation versus coronary artery bypass surgery in patients with severe angina pectoris despite optimal medical management (ESBY study). The primary outcomes were (1) effect on symptoms (frequency of angina, consumption of short-acting nitrates, self-estimated symptoms relief) and (2) myocardial ischemia (exercise stress test prior and 6 months post surgery). In the Klomp and Mannheimer studies the endpoints were clearly specified, but if the outcomes are vague, then the paper may selectively report the outcomes with the greatest
magnitude of response, which could lead to overestimating the effects of the therapeutic intervention studied.
Analysis of results Data analysis and statistical testing are essential components of any clinical trial. Although a comprehensive description of statistical calculations is beyond the scope of the present chapter, we provide brief discussion of this topic. A priori statistical power calculation should be performed to determine appropriate study sample size. The statistical power, which is usually specified at 0.80 or greater, is the probability that there will not be a false-negative (type II) error. In the study of SCS for CRPS by Kemler and associates (2000), statistical power was set at 90% to detect a 2.3 cm difference in visual analogue scale assessment of pain intensity between the two groups. A power of 90% (0.9) means that there is a 10% chance of concluding that there is no difference between the groups, when in fact a difference does exist. Not only should the outcome measures be carefully selected and well defined, but it is essential that the results are appropriately analyzed. Before enrolling patients into a trial, the investigators should provide detailed description of the statistical methods used to assess the results. It is possible to perform multiple stat istical tests until one uncovers a “significant” P-value. Therefore, estimation of the size of outcome effects is often more important then whether the effects are statistically significant. Therefore, outcomes of anal gesic trials are most appropriately reported by providing both mean results and measures of variability, such as standard deviations or confidence intervals. The value of potentially insensitive outcome measures, such as the number needed to treat (NNT), has been questioned (Cepeda et al., 2005; Gray et al., 2005). In the context of pain therapies, NNT refers to the number of patients required to receive the therapy in order to detect a single patient who met criteria for improvement (e.g., 50% reduction in pain intensity) who would not have shown such improvement if treated with a placebo. Furthermore, the reported results should document the incidence and nature of adverse events. Complications that occurred during the neurostimulation trial, surgical implant procedure and after permanent implantation should be described in detail. A clinical trial should account for participants who were non-compliant with follow-up or were withdrawn. Typically, dropouts are associated with poor outcomes, up to and including death. There are strategies to reduce the bias associated with withdrawals.
I. an introduction to neuromodulation
future clinical trials of neuromodulation
An “intent to treat” analysis means that all patients are included in their original assignment groups regardless of whether they completed the study or not. A “worst case scenario” principle is then applied, which assigns the worst possible outcomes to missing patient data.
Quality of the current literature Although there is abundant literature evaluating the efficacy of neurostimulation, there is a paucity of high-quality studies. The clear majority of such trials are retrospective, underpowered and methodologically flawed. This is especially true for the literature evaluating neuromodulation for chronic pain (Turner et al., 1995; Grabow et al., 2003; Cameron, 2004; MailisGagnon et al., 2004; Turner et al., 2004; Taylor et al., 2006). In 1995 Turner and associates published a systematic review of SCS for failed back surgery syndrome. At that time the world’s evidence was limited to 39 published case series, most of which were retro spective. Few of these papers included data on functional capacity, employment status, and adjuvant analgesic consumption. Nine years later Turner and colleagues published another systematic review of the efficacy of SCS in providing analgesia and increasing functional capacity for both failed back surgery syndrome and complex regional pain syndrome (CRPS). Although the aggregated literature suggests benefit with SCS, the article identified only a single well-designed RCT that met the inclusion criteria for the review. Several evidence-based reviews have assessed the utility of SCS for CRPS (Grabow et al., 2003; Cameron, 2004; Turner et al., 2004; Taylor et al., 2006). In 2003 Grabow and colleagues performed a critical review of the literature that identified 15 relevant trials, including one RCT and 14 observational studies (2 prospective and 12 retrospective). Although the evidence supports the use of SCS for CRPS, the authors acknowledged the limited quantity and quality of the literature. Similarly a Cochrane Review, most recently updated in 2004, identified only two RCTs that assessed SCS for chronic pain (Mailis-Gagnon et al., 2004). The authors of this Cochrane Review concluded that although there is limited high-quality evidence evaluating the effectiveness of SCS for chronic pain, it remains a viable treatment option in appropriately selected patients for neuropathic pain involving the trunk or extremities. High-quality evidence does support the use of neuromodulation for other pathological conditions.
65
A systematic review of multiple well-designed RCTs is available for SCS for inoperable critical peripheral vascular disease (Ubbink and Vermeulen, 2005). At least two high-quality RCTs have evaluated the efficacy of vagal nerve stimulation for partial seizures (Privitera et al., 2002). Moreover, well-designed, multicenter randomized trials have recently been published in the New England Journal of Medicine that demonstrated efficacy of pallidal neurostimulation for dystonia (Kupsch et al., 2006) and deep brain stimulation for Parkinson’s disease (Deuschl et al., 2006). EBM is a valuable tool, and there is no denying that the literature on pain treatments has not historically been a high-quality one. However, the recent disturbing trend to deny payment on the basis of an absence of statistically significant differences between group means in generally underpowered trials, particularly of invasive pain therapies, is a misapplication of EBM. Such misapplication may well lead to denial of care for individuals or subgroups whose beneficial responses are not evident, when pooled data alone are used as a criterion for payment (Carr, 2008).
Future clinical trials of neuromodulation It is essential that the neuromodulation community, especially those involved with chronic pain management, develop innovative studies with improved methodological quality in order to determine the value of this therapy. Unquestionably additional RCTs are necessary. Ideally, placebo or sham-stimulator controlled trials should be conducted. However, it seems clear that certain types of neurostimulation therapy are impossible to conceal from the patient or investigator. Therefore, creative strategies should be developed to reduce bias caused by lack of blinding. If RCTs are not feasible then well-designed observational trials, including rigorous case-controlled trials or prospective cohort studies, are an appropriate alternative (Benson and Hartz, 2000; Concato et al., 2000). Collaborative multicenter trials are generally necessary to accrue sufficient sample sizes. We describe additional recommendations for prospective neuro stimulation trials in Box 7.2. Furthermore, Turner and associates recently made several astute suggestions for future clinical studies of implantable intrathecal delivery systems and many of their recommendations are also applicable to neuromodulation (Turner et al., 2007). The article suggested that the published RCTs comparing lumbar back surgery with non-surgical treatment of chronic back pain
I. an introduction to neuromodulation
66
7. clinical study design
Box 7.2
Suggestions for future clinical trials
Study design
l
Additional RCTs, if possible with placebo or sham stimulator controlled trials l Rigorous observational trials (case-controlled trials or prospective cohort studies)
Outcomes
l
Adequate experience with trial and surgical technique
Well-defined, validated, reliable endpoints Outcomes explicitly reported prior to start of study l Outcomes measurements over interval time points with sufficient duration of follow-up l If possible the treatment allocation could be undisclosed to the outcome assessors l Report mean results and standard deviations or confidence intervals l Description of adverse effects and complications l l
Study participants Adequately powered trials Well defined inclusion and exclusion criteria l Similar baseline demographics between study groups l Details of recruitment process l Description of subject flow through each stage of study, including withdrawals and dropouts l l
Intervention Details of trial and implant proceedings Description of implanted device
l l
could be used as models to guide the development of RCTs to evaluate the efficacy of intrathecal delivery systems. Moreover, they recommended additional well-designed non-randomized comparisons of intra thecal delivery systems with either alternative therapy or “treatment as usual.”
Future areas of research Future clinical trials of neurostimulation will no doubt focus on emerging therapeutic applications, including SCS for treatment of cerebrovascular disease (Isono et al., 1995), occipital nerve stimulators for chronic headaches (Schwedt et al., 2007) and deep brain stimulation for psychiatric disorders (Giacobbe and Kennedy, 2006). Interestingly, significant interindividual variability has been observed in the efficacy of neuromodulation, even in patients with apparently similar pathology and demographics. Certainly psychological morbidity, including personality disorders or intractable depression, is associated with poor outcome. However, insufficient attention has been given to the possibility that genetic determinants influence individual responses to neuromodulation. Recently,
much attention has been focused on pharmacogenetics as an explanation for inter-individual (Mogil, 1996) and inter-ethnic (Cepeda et al., 2001) differences in drug response. It is conceivable that, in the future, genetic profiling may lead to modifications in neurostimulation treatment planning and provide prognostic information on long-term outcome. Innovative research could be directed towards the identification of possible genetic determinants of clinical response to neuromodulation.
Conclusion Neuromodulation is a relatively novel field that incorporates clinical medicine and scientific technology. As knowledge of neuromodulation becomes more refined, its effectiveness will likely improve and the indications for this intervention will undoubtedly continue to expand. Over the past several decades we have seen electrical stimulation progress from an experimental concept to a widely practiced medical therapy. However, the available evidence to guide use of the therapy remains limited. We therefore must strive to improve the quality of clinical studies, not only to advance this technology, but also to better
I. an introduction to neuromodulation
summary points
inform the translation of technology to benefit individual patients according to tomorrow’s evidencebased practice paradigms.
Summary points The current consensus hierarchy of clinical study design stratifies the scientific literature based upon its type and quality. l Randomized, double-blinded, controlled trials (RCT) are historically considered the least biased method of study design for assessing the efficacy of medical interventions. l However, in trials evaluating the efficacy of interventional therapies, including neuromodulation, blinding is more challenging to accomplish. In fact, double-blinded trials of spinal cord stimulation are not feasible because of the paresthesiae normally present during such treatment. Therefore, creative strategies are required to reduce bias caused by the inability to conceal treatment in this setting. l Although the available evidence generally supports the use of neurostimulation, there is a paucity of high quality literature. l Misapplication of EBM (i.e. to deny payment for invasive therapies on the basis of absence of significant differences in groups means, in generally underpowered studies) may well lead to denial of care for certain individuals. l It is essential that those involved with neuromodulation, especially for chronic pain management, develop innovative studies with improved methodological quality, in order to determine the value of this emerging therapy. l
References Altman, D.G., Schulz, K.F., Moher, D. et al. (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann. Intern. Med. 134: 657–62. Bair, M.J., Robinson, R.L., Kayton, W. et al. (2003) Depression and pain comorbidity: a literature review. Arch. Intern. Med. 163: 2433–45. Benson, K. and Hartz, A. (2000) A comparison of observational studies and randomized, controlled trials. N. Engl. J. Med. 242: 1878–86. Cameron, T. (2004) Safety and efficacy of spinal cord stimulation for the treatment of chronic pain: a 20-year literature review. J. Neurosurg. 100: 254–67. Carr, D.B. (2008) When bad evidence happens to good treatments. Reg. Anesth. Pain Med. 33: 229–40. Carr, D.B., Jacox, A.K., Chapman, C.R. et al. (1992) Acute Pain Management: Operative or Medical Procedures and Trauma. Clinical
67
Practice Guideline. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, US Department of Health & Human Services, AHCPR Pub No. 92-0032. Cepeda, M.S., Carr, D.B., Miranda, N. et al. (2005) Comparison of morphine, ketorolac, and their combination for postoperative pain: results from a large, randomized, double blind trial. Anesthesiology 103: 1225–32. Cepeda, M.S., Farrar, J.T., Roa, J.H. et al. (2001) Ethnicity influences opioid pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 70: 351–61. Colditz, G., Miller, J. and Mosteller, F. (1989) How study design affects outcomes in comparisons of therapy. II. Medical. Stat. Med. 8: 455–66. Concato, J., Shah, N. and Horwitz, R. (2000) Randomized, controlled trials, observational studies, and the hierarchy of research designs. N. Engl. J. Med. 342: 1887–92. Cook, D., Mulrow, C. and Haynes, B. (1997) Systematic Review: synthesis of best evidence for clinical decisions. Ann. Intern. Med. 126: 376–80. Deuschl, G., Schade-Brittinger, C., Krack, P. et al. (2006) A randomized trial of deep-brain stimulation for parkinson’s disease. N. Engl. J. Med. 355: 896–908. Dworkin, R., Turk, D., Farrar, J. et al. (2005) Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 113: 9–19. Giacobbe, P. and Kennedy, S. (2006) Deep brain stimulation for treatment-resistant depression: a psychiatric perspective. Curr. Psychiatry Rep. 8: 437–44. Grabow, T.S., Tella, P.K. and Raja, S.N. (2003) Spinal cord stimulation for complex regional pain syndrome: an evidence-based medicine review of the literature. Clin. J. Pain 19: 371–84. Gray, A., Kehlet, H., Bonnet, F. et al. (2005) Predicting postoperative analgesia outcomes: NNT league tables or procedure-specific evidence? Br. J. Anaesth. 94: 710–14. Isono, M., Kaga, A., Fujiki, M. et al. (1995) Effect of spinal cord stimulation on cerebral blood flow in cats. Stereotact. Funct. Neurosurg. 64: 40–6. Kemler, M.A., Barendse, G.A., Van Kleef, M. et al. (2000) Spinal cord stimulation in patients with chronic reflex sympathetic dystrophy. N. Engl. J. Med. 343: 618–24. Klomp, H.M., Spincemaille, G.H., Steyerberg, E.W. et al. (1999) Spinal-cord stimulation in critical limb ischaemia: a randomised trial. ESES Study Group. Lancet 353: 1040–4. Kupsch, A., Benecke, R., Müller, J. et al. (2006) Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N. Engl. J. Med. 355: 1978–90. LeLorier, J., Grégoire, G., Benhaddad, A. et al. (1997) Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N. Engl. J. Med. 337: 536–42. Mailis-Gagnon, A., Furlon, A., Sandoval, J. et al. (2004) Spinal cord stimulation for chronic pain. Cochrane Database of Systematic Reviews, Issue 3. Art. No. CD003783. DOI: 10.1002/14651858. CD003783.pub2. Mannheimer, C., Eliasson, T., Augustinsson, L. et al. (1998) Electrical stimulation versus coronary artery bypass surgery in severe angina pectoris: the ESBY study. Circulation 97: 1157–63. McKee, M., Britton, A., Black, N. et al. (1999) Methods in health services research: interpreting the evidence: choosing between randomised and non-randomised studies. BMJ 319: 312–15. Miller, J., Colditz, G. and Mosteller, F. (1989a) How study design affects outcomes in comparisons of therapy. I. Medical. Stat. Med. 8: 441–54. Miller, J., Colditz, G. and Mosteller, F. (1989b) How study design affects outcomes in comparisons of therapy. II: Surgical. Stat. Med. 8: 455–66.
I. an introduction to neuromodulation
68
7. clinical study design
Mogil, J.S. (1996) The genetic mediation of individual differences in sensitivity to pain and its inhibition. Proc. Natl Acad. Sci. 93: 3048–55. Privitera, M., Welty, T., Ficker, D. and Welge, J. (2002) Vagus nerve stimulation for partial seizures. Cochrane Database of Systematic Review, Issue 1, Art. No. CD002896. DOI: 10.1002/14651858. CD002896. Rogers, W.H., Wittink, H.M., Ashburn, M.A. et al. (2000) Using the “TOPS”, an outcomes instrument for multidisciplinary out patient pain treatment. Pain Medicine 1: 55–67. Rogers, W.H., Wittink, H.M., Wagner, A. et al. (2000) Assessing individual outcomes during outpatient, multidisciplinary chronic pain treatment by means of an augmented SF-36. Pain Med. 1: 44–54. Sacks, H., Chalmers, T.C. and Smith, H., Jr. (1982) Randomized versus historical controls for clinical trials. Am. J. Med. 72: 233–40. Schulz, K.F., Chalmers, I., Hayes, R. et al. (1995) Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273: 408–12. Schwedt, T.J., Dodick, D.W., Hentz, J. et al. (2007) Occipital nerve stimulation for chronic headache – long-term safety and efficacy. Cephalalgia 27: 153–7. Taylor, R.S., Van Buyten, J.P. and Buchser, E. (2006) Spinal cord stimulation for complex regional pain syndrome: a systematic
review of the clinical and cost-effectiveness literature and assessment of prognostic factors. Eur. J. Pain 10: 91–101. Turner, J., Sears, J. and Loeser, J. (2007) Programmable intrathecal opioid delivery systems for chronic noncancer pain: a systematic review of effectiveness and complications. Clin. J. Pain 23: 180–95. Turner, J.A., Loeser, J.D. and Bell, K.G. (1995) Spinal cord stimulation for chronic low back pain: a systematic literature synthesis. Neurosurgery 37: 1088–95. Turner, J.A., Loeser, J.D., Deyo, R.A. et al. (2004) Spinal cord stimulation for patients with failed back surgery syndrome or complex regional pain syndrome: a systematic review of effectiveness and complications. Pain 108: 137–47. Ubbink, D. and Vermeulen, H. (2005) Spinal cord stimulation for non-reconstructable chronic critical leg ischaemia. Cochrane Database of Systematic Reviews, Issue 3. Art. No. CD004001. DOI: 10.1002/14651858.CD004001.pub2. Wittink, H., Wiffen, P. and Carr, D.B. (2003) Evidence-based medicine in pain management. Chapter 2. In: S. Berman (ed.), Approaches to Pain Management: An Essential Guide for Clinical Leaders. Oakbrook Terrace, IL: Joint Commission on Accreditation of Healthcare Organizations, pp. 21–33.
I. an introduction to neuromodulation
C H A P T E R
8
Psychological Issues and Evaluation for Patients Undergoing Implantable Technology Daniel M. Doleys
o utli n e Background
69
Psychological Test(s) and the Evaluation Process
74
Brief Review of Psychological Variables
70
How to Make What Works Work Better
76
When are Psychological Factors Most Likely to Influence Outcomes?
Summary
77
71
References
77
Relevant Psychological Factors
73
Shealy and his colleagues (Shealy et al., 1967) intro duced spinal cord stimulation (SCS) for the treat ment of chronic pain based on Melzack and Wall’s Gate Control Theory (Melzack and Wall, 1965). Shealy reportedly recommended emotional stability, no ele vations on the Minnesota Multiphasic Personality Inventory (MMPI: Keller and Butcher, 1991) except for the depression scale, and involvement with a rehab ilitation program, as selection criteria. Indeed, Long (1980) noted the psychological status of the patient to be the most common reason for the failure of stimula tion techniques. A number of studies since then have attempted to identify the relevant psychological fac tors and the most appropriate evaluation (see Doleys, 2006 for a review). Although a variety of psychologi cal variables have emerged, there is yet to be a con sensus as to which variables have the most reliable and predictable impact.
Only 20% of healing involves technology. Earl Bakken, founder Medtronic (personal communication, 2006) Pain cannot be reduced simply to neurophysiology or phar macogenomics. Pain is at the other end, the whole human being. It is a conscious experience that emerges from our very complex brains. People suffer in complicated ways. C. Richard Chapman, 2005
Background Neuromodulation in the form of electrical stimula tion of the brain for intractable pain was reported in the 1950s (Leone, 2006). The potential for psychologi cal variables to impact the outcome of neuromodula tion therapies was recognized as early as 1967 when
Neuromodulation
69
© 2008, 2009 Elsevier Ltd.
70
8. psychological issues and evaluation for patients undergoing implantable technology
Although there is a general agreement that a psy chological evaluation should be undertaken, what it means to “clear” a patient psychologically for a trial or internalization remains somewhat ill-defined. A recent summary of the literature on intrathecal therapy (IT) for pain summarizing studies from 1990 to 2005 con cluded that a psychosocial evaluation should explore patient expectations, quality and “meaning” of the patient’s pain, presence of psychological disease, and barriers to patient and family compliance with the treatment (Raffaeli et al., 2006).
Brief review of psychological variables The following is a review of some of the stud ies that have examined psychological factors in neuromodulation. Most studies involved SCS ther apy. A more detailed account can be found elsewhere (Doleys and Klapow, 1997; Doleys, 2000a, 2006). In 1981, Long et al. reported a 33% success rate in “unscreened” patients and a 70% rate in “screened” patients. Daniel et al. (1985) stated that “electrode placement can serve as the initial step in a treatment plan followed by psychotherapy (to address psy chological factors influencing pain)” (p. 776). North et al. (1996) found that certain psychological vari ables tended to be associated with pain relief dur ing the trial and post-implant, but not at a 3 month follow-up. Studies utilizing the MMPI have revealed a number of findings. Shealy (1975) felt that elevations of up to two standard deviations on scales 1 (hypochon driasis), 2 (depression), and 3 (hysteria) should not be considered as a contraindication for treatment. However, elevations in four or more of the ten MMPI clinical scales was thought to reflect a seriously dis turbed patient. Long et al. (1981) stated that elevations in scales 2 (depression) and 7 (anxiety) should not be considered as criteria for exclusion. High scores on scales 1 (hypochondriasis) and 2 (depression) have been associated with negative outcomes (Blumetti and Modesti, 1976; Brandwin and Newman, 1982). Patients with high scores on scales 1 (hypochondria sis) and 3 (hysteria) frequently have a successful trail and proceed to internalization, but scale 3 (hysteria) was correlated with diminished therapeutic effect at a 3 month follow-up (North et al., 1991). Contrary to conventional wisdom, Brandwin and Newman (1982) reported positive outcomes with patients demonstrating a “conversion V” profile wherein scales 1 (hypochondriasis) and 3 (hysteria) are elevated
relative to scale 2 (depression). Several others (Burchiel et al., 1996; North et al., 1996; Olson et al., 1998) also noted such patients tended to have a successful trial. Olson et al. (1998) reported that lower elevations on depression (scale 2) and mania (scale 9) were associ ated with a positive response to SCS. Doleys and Brown (2001) found that patients with mildly elevated scores on scales 1 (hypochondriasis), 2 (depression), 3 (hyste ria), 7 (anxiety), and 8 (schizophrenia) reported greater pain relief at 4 year follow-up compared to those with “normal” levels in a group of patients treated with intrathecal therapy (IT). While Meilman et al. (1989) failed to find a correlation between MMPI scores and outcomes, they did note the accuracy of prediction was greater than 71% in “simple mononeuropathies” versus 32% in the more complicated arachnoiditis. This finding suggests an interaction between the complexity of the physical pathology, psychological factors, and psycho logical test scores. Depression and anxiety or common psychologi cal co-morbidities are associated with pain and dis ability (Covington et al., 2005). Olson et al. (1998) found patients scores approximating 12/63 on the Beck Depression Inventory (BDI; Beck et al., 1988) to be successful while those with a score of 16/63 were not. He also reported that patients proceed ing to SCS trial had State Trait Anxiety Inventory scores (STAI; Spielberger et al., 1997) of 23/80 and 19/80, respectively, while those that did not pass the trial had scores of 25/80 and 21/80. Long et al. (1996) noted scores exceeding 37/80 on STAI in his population, and Doleys (2000a) 46/80 and higher. The higher STAI scores in these latter two popu lations appear to reflect a different and more dis tressed group of pain patients than those of Olsen et al. Higher scores on the Affective scale of the McGill Pain Questionnaire (MPQ; Melzack, 1975), 3.7 versus 1.9, tended to predict unsuccessful SCS trials (Olsen et al., 1998). Of interest is the reporting of a greater reduction in affective compared to sensory scores on the MPQ in patients successfully treated with IT ther apy (Winkelmuller and Winkelmuller, 1996). Block et al. (2003) have developed a somewhat com prehensive model for pre-surgical evaluation of patients in pain undergoing corrective spinal surgery. They have created an algorithm incorporating a variety of “risk factors.” These risk factors are assigned a value of 0, 1, or 2 based upon the strength of the association with sur gical outcomes in the literature and identified through a clinical interview and psychological testing. Scores are combined with the number of “adverse clinical features,” i.e. deception, personality disorder, medica tion seeking etc. and patients rated as having a “good,” “fair” or “poor” prognosis. This pre-surgical behavioral
I. AN introduction to neuromodulation
When are psychological factors most likely to influence outcomes?
medicine evaluation (PBME) has only recently been applied to implantable therapies (Schocket et al., in press). It will be interesting to note its relative applica bility to implantable versus surgical therapies. Most of the studies reviewed above were con ducted on patients with chronic low back and/or extremity pain utilizing SCS or IT therapy. The role of psychological variables in other areas such angina (DeVries et al., 2006) and deep brain stimulation (DBS) for movement disorders (Yamada et al., 2006) has received some attention. One would expect that any disorder likely to be affected by “stress,” i.e. headache, angina, gastrointestinal and genitourinary dysfunc tion, would rely heavily on multidisciplinary assess ments and concomitant treatments. The next section reviews some of the work concerning movement dis orders, primarily deep brain stimulation (DBS) for Parkinson’s disease (PD). Stereotactic ablative neurosurgery was used in the 1960s for various neuropsychiatric conditions and movement disorders. After being abandoned in the 1970s because of the improvement in medication man agement for these disorders, it has returned to some prominence (Wichman and Delong, 2006). The relative success of DBS for Parkinson’s disease (PD) has also reawakened an interest in its application for obses sive–compulsive disorders (OCD), Tourette’s syn drome, depression and pain (Skidmore et al., 2006). Randomized controlled and sham controlled studies (Kupsch et al., 2006; Wojtecki et al., 2006) have docu mented the efficacy of DBS and that the effects can be “dose related,” i.e. 10 Hz versus 130 Hz versus no stim ulation. The treatment is not, however, without adverse effects or complications. These may include hardware, physiological and psychological/cognitive adverse effects or complications (Bergamasco and Lopiano, 2006; Paluzzi et al., 2006). Because of these adverse effects/complications, there has been a call for more stringent evidentiary standards (Prehn et al., 2006). Primary outcome measure(s) for DBS often involve a reduction in observable motor activity. Quality of life (QoL) studies have employed the Parkinson’s Disability Questionnaire (PDQ-36; Bushnell and Martin, 1999; Damian et al., 2000). Deuschi et al. (2006) reported improvement in mobility, ADLs (activities of daily living), emotional well-being, stigma, and bodily discomfort. Although positive changes have also been found in depression and anxiety, these occurred in the absence of any changes in “personality traits” or social adjustment (Houeto et al., 2006). Interestingly, in one study (Gronchi-Perrin et al., 2006), patients tended to overestimate their preoperative level of function ing, when asked to rate it retrospectively, compared to their responses on a pre-treatment questionnaire.
71
Negative psychological sequelae have been noted despite positive changes in motor behavior. Schupbach et al. (2006) reported the absence of change in cognitive status but noted improvement in ADLs, 18–24 months post implant. In addition, social adjust ment failed to improve, highlighted by problems affecting patients’ perception of themselves and their body, marital situation, and professional life. Indeed, 71% (17/24) of couples had marital problems and only 56% (9/16) working preoperatively returned to work. Likewise, Castelli et al. (1999) noted a “small” improvement in mood as measured by the Beck Depression Inventory (BDI; Beck et al., 1988), OCD and paranoid personality traits, but worsening of thought disorders, with no change in suicidal idea tion, anxiety, and apathy scores. Some 20% (15/65) of patients reported a decline in cognitive function or an increase in depression and anxiety, while another 20% of patients reported improvement in mood and 12% in anxiety. These types of negative changes have also been documented in patients with cancer pain despite a decrease in pain (Cahana, 2002). The data would seem to emphasize not only the need for proper patient selection, but pre-trial preparation and postimplant follow-up as well. Even the best preparation cannot mimic the actual experience. Nonetheless, a multidisciplinary approach would seem to be advan tageous (Schupbach et al., 2006).
When are psychological factors most likely to influence outcomes? Table 8.1 illustrates the conditions under which psychological factors are most likely to exert more or less influence on outcomes. These areas include pain, etiology of target symptom, patient, practice, proce dure, and outcomes. The table outlines the various aspects of pain and pain therapies and shows the con ditions under which psychological factors are more or less likely to impact the outcome of therapy. Regarding pain, the influence of psycho/social factors may be related to the degree to which the “pain” can be shown to be well localized and speci fic versus generalized and nonspecific. For example, Wallis et al. (1997) selected patients to undergo radio frequency neurotomy (RF) of cervical facets on the basis of response to double-blinded placebo control injections of a local anesthetic. Furthermore, the “pain generator” had to be very specific and well localized. Psychological co-morbidities, as measured by the Symptom Checklist-90 (SCL-90; Derogatis, 1983),
I. AN introduction to neuromodulation
72
8. psychological issues and evaluation for patients undergoing implantable technology
Table 8.1 Influence of psychological factors Probably less
Probably more
Pain
Specific; well localized
Generalized; multifactorial
Etiology
Well defined
Multifactorial
Patient
Psychologically “intact”; concordant symptoms; acceptance high
Axis I/II Dx; psychological symptoms disproportionate; dependent, deferring
Procedure
Free from medical system; non-interactive; no sensation
Dependent on medical system; patient interactive; detectable sensation
Practice
Multidisciplinary/ modality; psychological support; physician attitude
Single discipline; interventional; disease/ “pain generator” oriented
Outcomes
Functional, objective, QoL; functionally related (dose/response) i.e. spasticity
Perceptual; experiential
resolved when the pain dissipated after RF therapy and returned along with the pain. The authors concluded that, in this situation, psychological factors were sec ondary to the pain and played no role in its develop ment or maintenance. This observation, however, has not been replicated in other studies, especially those involving less specific and more generalized pain, such as low back pain (Sator-Katzenschlager et al., 2003; Doleys et al., 2006). It appears that the more gen eralized and nonspecific the “pain” or other symptom, i.e. headache, tremor etc., and the less responsive the symptom to a targeted treatment, the more likely it will be that psychosocial factors are involved. Likewise, the more specific and physiologic the etiology, such as in urinary disorders (Craggs and McFarlane, 1999) or spasticity from spinal cord damage, the less influential psych/social factors may be. Obviously, this is a “gen eral” rule and may vary from case to case. In some instances resolution or improvement in the primary symptom may result in exacerbation of other problems. Cahana (2002) observed increased depres sion and marital conflicts in cancer patients follow ing improvement in pain and cognitive functioning using IT. Likewise, Schupbach et al. (2006) reported worsening of relationships with family, spouses, and social-professional environment in PD patients ben efiting from DBS. Seemingly, some patients and their support systems adapt to certain circumstances and may not be prepared or able to cope with change, no matter how positive or desirable these changes may appear. This may be akin to the patient with low back pain who comes to prefer freedom from work and responsibilities. Patients thus motivated may be more
likely to have a “false-positive” trial. That is, the pain improves enough to warrant implantation but not enough for increased activity or return to work. The above observation raises the question as to what constitutes an appropriate trial and criteria for internalization. Pain relief, reduction in medication(s), improvement in function, and patient satisfac tion have been used individually or in combination (Follett and Doleys, 2002). Ultimately, of course, these criteria may have to be individualized. We have come to prefer a “functionally oriented” trial preceded by a reduction in opioid medications in those cases where increased function and medication reduction are treat ment goals for the patient (Doleys and Kraus, 2007). The mere presence of a negative mood state (depression or anxiety) or specific personality disor der does not imply that it is functionally related to the problem to be treated. Indeed, an underlying mood state or personality disorder may have been camou flaged by adaptive coping, i.e. highly structured life and job, only to be revealed when the patient’s life is altered by pain or disease. Deuschi et al. (2006), in fact, reported the absences of change in personality traits in PD patients successfully treated with DBS. Verdolin et al. (2007) found that the presence of post-traumatic stress disorder (PTSD) in Iraq and Afghanistan war veterans did not negatively impact the treatment of neuropathic pain secondary to war related injuries with SCS. In addition, there was no change in PTSD symptoms despite the improvement in pain. The emergence of pathological states, including schizophrenia and conversion disorder, has been reported following the introduction of neuromodula tion therapies (Zdanowicz et al., 1999; Loughrey and Nedeljkovic, 2002; Ferrante et al., 2004). Without a thor ough psychological evaluation, it is difficult to deter mine whether such psychological conditions somehow emerged as a result of neuromodulation therapy or “pre-existed” in some form and made manifest by changes in the targeted symptom. These types of nega tive or maladaptive outcomes may be observed in the minority of patients. However, in the absence of pre– post psychological testing, especially of the treatment “failures,” many such cases could be inadvertently assumed under the “lost to follow-up” or technical failure categories. The attitude and expectations of the physician may also impact outcomes (Graz et al., 2005). The evidence of this is no more apparent than in the remarkable out comes from various “sham” surgeries (Flum, 2006). The involvement of different practitioners in patient selection, pre-implant trial, and post-implant management reduces the opportunity to take full advantage of any positive “placebo” effect. Patient satisfaction is determined in
I. AN introduction to neuromodulation
Relevant psychological factors
part by the perceived interest and participation of the “attending” physician (Yamshita et al., 2006). The more dependent, obsessive, and suggestible the patient, the greater effect expectations are likely to have. Others may be more influenced by information on the Internet, patient testimonials, or information in the public media. The degree to which the patient, support persons, physician and his/her practice adopt a multifactor ial and multidisciplinary approach to the problem and therapy, can mitigate the effects of psychologi cal factors (Schupbach et al., 2006). As pointed out by Doleys (2002), psychological assessments/interven tions can and may need to be carried out during pretreatment patient selection/preparation, pre-implant trialing, and post implant management. The emphasis on “prognostication” has diverted our attention away from identifying therapeutic algorithms that consider a detailed description of the patient and disease vari ables which may need to be addressed post implan tation to obtain the maximum treatment effect and minimize “relapse” (Turk and Rudy, 1991). We should also be aware of the potential additive and synergistic effects of psychological and medical interventions (Holroyd et al., 2001; Molloy et al., 2006). This is particularly true in the area of “pain,” wherein the search for the “pain generator” can result in over looking crucial psycho-social factors that could impact long-term outcomes. This philosophy may or may not be responsible for the reported loss of clinical efficacy 18–24 months post implantation of SCS for pain (see Doleys, 2006). Two final considerations of importance are those of the procedure carried out and outcome measure(s) selected. Some treatments result in a perceptible par esthesia, i.e. SCS, others do not (DBS for PD). The abil ity of the patient to tolerate these sensations or other treatment adverse effects, such as opioid-induced con stipation, long term is likely to vary. Those who tend toward somatic preoccupation and/or emotional reac tivity may be most vulnerable and more likely to yield a “false-positive” trial (North et al., 1996). Over time the paresthesiae, especially if combined with posi tional sensitivity, may become more annoying then the baseline problem. Although the response to transcutaneous electrical nerve stimulation (TENS) does not necessarily corre late with SCS outcomes, we have found the procedure useful. When TENS is applied for a month prior to the SCS trial, we have identified patients who could not tolerate the stimulation over time. This seems to be particularly true for those with high scores on meas ures of somatic preoccupation, hysteria, obsessive– compulsive tendencies, irritability, and/or anxiety upon psychological testing. In addition, though some
73
therapies such as SCS are favored because they may “free” the patient from the medical system, regular intermittent office visits could provide an opportun ity to assess for the absence of desirable concomitant changes, i.e. medication reduction, increased func tion, and the introduction of appropriate treatments. This more comprehensive approach imparts greater responsibility to the patients rather then success or failure being determined solely by the implant. It is much like reinforcing the importance of diet, weight control and exercise to the diabetic or hypertensive patient as opposed to an over-reliance on medication. The significance of the outcome measure(s) chosen has been demonstrated by Doleys et al. (2006). They reported on disease-specific and generic outcomes in a retrospective study comparing intrathecal therapy (IT), behavioral-functional restoration, and oral opioids in chronic low back pain patients. The treatment judged to be the most effective after four years was determined in large part by the particular outcome emphasized, i.e. pain, mood, function, satisfaction, opioid level, etc. A consensus panel (Turk et al., 2003) suggested using patient-reported outcomes (PROs), clinician-reported outcomes (CROs), and “third party” outcome, i.e. medical utilization, as sources to evaluate clinical pain trials. The desirable domains included pain, physical/ emotional functioning, participant ratings of improve ment/satisfaction, symptoms and adverse events, and participant disposition. Deyo et al. (1998) have recom mended assessing pain, mood, function, and personal ity pre and post intervention in treatments for painful disorders. Obviously, the more subjective, perceptual and experiential the outcome measure, i.e. “pain” (Price, 1999), satisfaction, mood etc., the more influen tial psychosocial variables are likely to be.
Relevant psychological factors Evaluating the role of psychological factors can be complicated. First, their presence or absence needs to be identified. The majority of patients are likely to show one or more indicators of psychological distress, i.e. anxiety, depression, emotional reactivity, somatic preoccupation. Some of these will be preexisting and perhaps causally related (Rome and Rome, 2000), others will be a consequence of the disorder. Second, it is difficult but necessary to establish a functional rela tionship between the target symptom(s) and existing psychological state(s) whenever possible. Not all psy chological tests have equal sensitivity or specificity in their ability to identify psychopathology (Doleys and
I. AN introduction to neuromodulation
74
8. psychological issues and evaluation for patients undergoing implantable technology
Doherty, 2000). Furthermore, there appears to be an association between the complexity of the disorder and the magnitude of psychological factors. Dworkin et al. (1990), for example, noted the more widespread the pain the greater the degree of psychological dis tress. Third, psychological factors may be mediators, modulators or maintainers of symptoms (Doleys, 2000b). As noted above, when the pain was very speci fic, psychological states tended to be a consequence and not a cause of the pain. Early histories of physical and/or sexual abuse and victimization have been found to be relevant in pain ful disorders (Schofferman et al., 1992; McMahon et al., 1997; Rome and Rome, 2000). However, their influence is not always apparent during “acute” procedures or brief trialing periods but can make the “pain” more recalcitrant to long term change. Mood disorders such as depression and anxiety are among the most commonly cited psychologi cal co-morbidities associated with disabling medical conditions and illnesses. (Covington et al., 2005). These are particularly relevant to “pain” disorders given the complexity of “pain processing,” which includes sen sory/discriminative, affective/motivational, and cog nitive/evaluative mechanisms (Melzack and Casey, 1968). Use of a single numerical pain rating (NPR) on a 0–10 scale may obscure the differences between “pain intensity” and “pain unpleasantness” (Price, 1999). Numerical ratings of pain tend to be associated with the sensory component, i.e. its severity or perceived intensity. Unpleasantness focuses more on the patients “affective” response to the pain. That is, how much does the pain “bother him/her.” Most of us can prob ably recall patients reporting that a particular treatment did not change the pain intensity very much but made it such that the pain was “less bothersome” and easier to cope with. Personality disturbances (PerD; elaborated below) have been relatively overlooked. These patients, espe cially those with a borderline personality disorder, may pose significant management problems. Patients with more somatic or histrionic personalities often need frequent reassurance and monitoring. The abuse of alcohol and/or illicit drugs can undermine an oth erwise successful trial and implant. In such cases the primary symptom may be the “excuse” for substance abuse. The potential impact of family and social sup port cannot be underestimated. Symptoms may serve to modulate marital/family discord. In some cases the “medical system” becomes the convenient scapegoat for misdirected hostility. Patient and family expecta tions clearly contribute to long-term outcomes. All too often, significant others are not intimately involved
in the evaluation and therapeutic process, yet they can exert significant positive or negative influence by being overly solicitous or non-reinforcing of desirable behavior (Flor et al., 1995). The correlation between patient expectations and outcomes is a main factor in determining patient sat isfaction (Yamashita et al., 2006). For this reason, it may behoove the physician to be conservative and encourage expectations which can be supported by the evidence-based literature rather than personal experience or treatment “outliers.” The patient’s goals and motivation are obviously crucial but not always easily quantified. This of course relates to quality of life (QoL) measures. Patient and physician goals may not be in concert and should, as much as possible, become part of the pre-implant trial discussion. For example, if a goal is to be independent in activities of daily living (ADLs), or able to shop for two hours, or sit through a religious service or dinner, these can be directly assessed in a functionally oriented trial.
Psychological test(s) and the evaluation process There is a plethora of psychological tests and assess ment tools/questionnaires (Doleys and Doherty, 2000). Some are general measures of personality (MMPI) and others assess general psychological status (SCL90). There are specific measures of mood such as the Beck Depression Inventory (BDI, Beck et al., 1988) and State–Trait Anxiety scales (Spielberger et al., 1997). Those patients exhibiting high levels of depression or anxiety might benefit from cognitive behavioral ther apy, relaxation or other stress management treatments pre-trial. A certain amount of anxiety or depression is to be expected and should be considered as nor mal. Some tests can evaluate perceived “readiness for change” (Kerns and Habib, 2004) and level of chronic pain acceptance (McCracken et al., 2004). There are any number of “disease-specific” ques tionnaires such as the Seattle Angina Questionnaire (SAQ, Spertus et al., 1995), Migraine Disability Assess ment (MIDAS, Stewart et al., 2001), Parkinson’s Disease Questionnaire (PDQ-39, Bushnell and Martin, 1999), and Fecal Incontinence Quality of Life Scale (FILC, Rockwood et al., 2000). The Oswestry Disability Index (ODI; Fairbank et al., 1980) and Roland Morris (Roland and Morris, 1983) are common measures of perceived function/disability The SF-36 assesses a variety of domains relating to physical and psycho logical well-being (Ware et al., 1993). This assessment
I. AN introduction to neuromodulation
Psychological test(s) and the evaluation process
tool has been widely used both pre and post treatment but may not be as sensitive or specific as first thought (Baron et al., 2006). It is important to remember that many of these scales are self-administered and rep resent the patient’s perception, which may or may not reflect reality. Indeed, Gronchi-Perrin et al. (2006) noted a discrepancy when PD patients were asked to rate their pre-DBS therapy functional status following treatment. Obtaining information on psychological and functional status prior to implantation can pro vide a baseline against which to evaluate outcomes. Patients manifesting manipulative or strongly mal adaptive personality disorders should be approached with caution. Personality disorders (PerD) make up a large part of the Axis II diagnoses in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) (1994) scheme and are marked by “behav ior that deviates markedly from the expectations of the individual’s culture” (p. 287) and leads to distress and impairment. (Diagnostic Criteria from DSM-IVTR; 2005). A personality “trait” represents a pattern of perceiving, or relating, to one’s environment and presents as less pathological compared to PerDs. The incidence of PerDs in chronic pain populations has been estimated to be as high as 50% (Fishbain et al., 1986; Polatin et al., 1993). The PerDs have been con veniently ordered into three clusters. Cluster A, i.e. Paranoid, Schizotypal, are characterized by individu als with odd or eccentric behavior. Cluster B include the more dramatic, emotional and manipulative per sonality disorders such as borderline, histrionic, nar cissistic and antisocial PerD. The anxious, fearful and depressive PerD, i.e. dependent, avoidant and obsessive–compulsive, make up cluster C. The cluster A patients (Paranoid, Schizotypal, char acterized by individuals with odd or eccentric behav ior) are prone to unusual somatic experiences. They may perceive the hardware or stimulation as produc ing psychological or somatic distortions. In extreme cases, there may be associated hallucinations or somatic delusions. Cluster B type patients (dramatic, emotional and manipulative personality disorders such as borderline, histrionic, narcissistic, and anti social PerD) often present as the greatest management problem. They tend to be noncompliant, challenging of authority, and demanding. They may have “hidden agendas.” Cluster C patients (the anxious, fearful and depressive PerD, i.e. dependent, avoidant and obsessive–compulsive) are likely to benefit from behavioral therapies to address their fears, anxieties, and depression; any of which can influence their per ception of pain and degree of disability. In our experi ence, they are more likely to have a better short-term
75
versus long-term result and pose a risk of a “falsepositive trial” – that is, they have good response to the trial but report decreased effect over time. A significant percentage of patients will report the negative impact of psychological stresses on the pain or primary symptom. While this technically defines a somatoform disorder, it does not necessarily exclude the patient as an appropriate candidate for neuromod ulation therapies. The greater concern is those patients who meet the DSM-IV-R (1994) criteria for somatiza tion disorder, indicating a life-long pattern likely to be unaltered by an intervention. Psychological tests and questionnaires should be administered and interpreted in the context of structured clinical interview. Whenever possible, the interview should include a significant-other as their interpretation of treatment effectiveness does not always match that of the patient (Willis and Doleys, 1999). The patient’s goal and expectations, current means of coping with their problem, level of readi ness for change and degree of acceptance of the reali ties of their situation can be measured informally via the interview. The evaluation should be conducted prior to the final determination being made regarding a temporary trial. Ideally, agreed-upon therapeutic goals can be addressed during the trial and used as a means to determine the desirability of proceeding to implantation. Logically, the more closely the trial cir cumstances mimic the final outcome the less chance there is of a “false-positive” trial. Allowing the patient to examine samples of the neuromodulation device to be utilized and viewing of audiovisual materials may help to elicit questions and allay patient anxiety. Patients should be instructed that there may be a “hierarchy” of symptom improve ment. For example, improved functioning and QoL does not always accompany a reduction in pain but may need to be addressed as separately targeted problems. Similarly, the author has recently encoun tered several patients with sacral stimulators wherein improvement in bladder functioning preceded sig nificant reduction in “pelvic pain.” The information presented to the patient, level of understanding and comprehension of the patient and significant-other, degree of discussion/agreement and the acknowl edgement of awareness of complications and adverse effects should be documented in the chart note. The ill-prepared or uncertain patient and significant-other may benefit from additional education/orientation therapy sessions. There are a variety of “pain” measures ranging from a single numerical pain rating (NPR) to a more comprehensive assessment of qualitative, quantitative,
I. AN introduction to neuromodulation
76
8. psychological issues and evaluation for patients undergoing implantable technology
suffering, affective, and pain unpleasantness. Appreciating “pain” as an experiential, multifac torial symptom whose components (sensory, affec tive, cognitive) interact in a dynamic fashion, at times rendering pain intensity and pain unpleasantness (affect) somewhat independent but related aspects, should influence the assessment. Instruments empha sizing this multidimensionality, i.e. McGill Pain Questionnaire (MPQ), approach should be favored. Upon reviewing the literature regarding psycho logical testing in SCS therapy, Doleys et al. (2001) were unable to identify any one or group of psychological tests or profiles that reliably predicted SCS outcomes. However, the grouping of patients based on diseaserelated variables such as pain, as opposed to psycho logical variables, may have obscured the influence of certain psychological factors/profiles (Doleys, 2003). The proposed “positive” and “negative” (Nelson et al., 1996; Doleys, 2003) psychological variables remain hypothetical, albeit theory-driven. There is some evidence that a “normal” psychological pro file may not predict a good outcome, at least as it relates to pain reduction (Doleys and Brown, 2001). It is important for the patient’s complaints, whether physical or psychological, to match the findings from examination and testing. Although there has been a tendency to derive some type of cutoff score for “predicting” outcomes, the development of a thera peutic algorithm considering the complexity of the targeted problem, psychosocial variables and pos sible need for adjunctive therapies during the trial and post implant would seem more in keeping with existing data. Consistent with the recommendations of Deyo et al. (1998) regarding the assessment of pain, the author has relied upon the MPQ, BDI, MMPI, ODI, and clinical interview for pain-related therapies as measures of pain, mood, personality and function, respectively. The total patient/family time required for the evaluation approximates 3–4 hours at a cost of about $500 dollars US or less depending upon insur ance coverage. One or more additional preparation/ educational sessions (Doleys, 2002) may be involved. Modification of this protocol would be required for disorders wherein the primary symptom is other than pain, i.e. bladder function, dystonia, etc. Each clinician is likely to have his/her favorite tests. For the field to move forward there needs to be some standardization of the process, if not the particu lars. The following are “process” suggestions: 1. Well known and validated tests should be used 2. Ideally, the test(s) should have validity scale(s), or some mechanism for detecting dissimilation
3. Tests should be used in the context of an overall evaluation including clinical interview 4. The assessment should be done by a knowledgeable and experienced, preferably doctoral level, provider 5. The evaluator should have contact with the patient, or at least the outcome data, from the preimplant trial and follow-up so as to determine the correlation between the evaluation and outcome 6. “Screening” tests should be re-administered on follow-up 7. Both disease-specific and generic measures should be obtained.
How to make what works work better There can be little doubt that neuromodulation is effective in the treatment of a number of disorders. The issue in part is how to maximize this effect of the therapy. “Relapse” rates are not always reported but there is a well-documented loss of benefit with time, especially in the area of chronic pain (Cameron, 2004; Mailis-Gagnon et al., 2004; May et al., 2005; Taylor et al., 2005). The addition of a psychological evalua tion and therapies may help to identify the presence of co-existing psychological disorders and reduce their negative impact on outcomes. For example, operant/ behavioral therapies have proven effective in a number of areas; cognitive behavior therapy with depression (Dodson, 1989), biofeedback with anal-rectal dysfunc tion (Byrne et al., 2007), relaxation techniques with headache (Holroyd et al., 2001), stress management with angina (van Dixhoom and White, 2005), and oper ant shaping of successive approximations and reinforce ment in function rehabilitation with neuromuscular, musculoskeletal, and “pain” disorders (Fordyce, 1976), to name a few. A recent study by Molloy et al. (2006) demonstrated that the combination of cognitive behav ioral/rehabilitation therapy before or after SCS or IT implantation resulted in increased improvement in affect distress, disability, self-efficacy and catastro phizing. Pain intensity, however, was not influenced. Indeed, Earl Bakken, the founder of Medtronic, Inc. (Minneapolis, Minnesota, USA) and holder of numer ous medical technology patents, advocates a holis tic approach in his “10 Points Related to Putting the Body Back Together” (personal communication). This approach includes “mind related medicine,” address ing relationships, stress, caring, compassion, attitude, belief(s) etc., and the role of “energy medicine,” e.g. guided imagery, massage, prayer.
I. AN introduction to neuromodulation
Summary
Summary The breadth and depth of neuromodulation as an acceptable medical treatment has expanded expo nentially. Advancements in medical treatments can take place in a least three areas: science, technology, and clinical application. Ideally, but not always, these areas should build on one another. Often, improved technology can enhance scientific discovery through clarification of processes and mechanisms. Initially, clinical application is hypothesis-driven based on sci entific principles, i.e. mechanism of nociceptive versus neuropathic pain, concordant paresthesiae, action of different pharmacological agents etc. However, with time and familiarity, clinical application can become a “trial-and-error” process. The availability of multi ple outlets for “scientific” reports can dilute scientific rigor in favor of information dissemination. Once pub lished, particularly if the p value is less than 0.05, the findings of scientific exploration are often heralded as evidentiary without critical comparison and scru tiny. This eventually begs the question of statistical versus clinical significance. In an effort to expand the treatment’s availability, other practitioners, some less technically skillful, are “trained” and incorporate the treatment into their clinical practice. The development of best practice guidelines is thus, unfortunately, built as much on clinical failures as successes and may or may not penetrate general practice, in part because of concerns over credentialing and/or limitation of access to the therapy. It is here that a preoccupation with the therapy and technology may betray sound sense in its application. A reliable change in the tar geted symptom may result in overlooking psychologi cal co-variants. Appreciating the social and economic context in which therapies are developed might be a justifiable argument for the establishment of a worldwide net work of “centers of excellence” from academic and private sectors for the purpose of collaborative, multi center, scientifically sound studies. These studies would then form the basis of treatment guidelines as well as encourage innovative exploration ensuring that ethical considerations (Ford and Henderson, 2006) are adhered to. The role of psychological factors in neuromodula tion is gaining increased attention. However, studies involving new technology/hardware, electrophysi ological properties and clinical applications still domi nate the literature. The reasons for this discrepancy are many and varied including: 1. Too few psychologists involved/ interested 2. The complexity of psycho/social issues
77
3. The lack of “standardized” outcomes including psycho/social factors 4. A general lack of understanding/acceptance of the bio-psycho-social model as it relates to neuromodulation 5. Cost of psychological evaluation/treatment 6. Little to be gained financially by technology/ pharmaceutical companies 7. Negative psychosocial profile may impact on the “bottom line” of the implanting physician. Hopefully, as the area of neuromodulation con tinues to unfold, additional attention will be given to the role of psychological variables. This will be best achieved by implanting physicians recognizing the potential impact of these variables, technologi cal manufactures providing support for clinical/out comes research, and psychologists increasing their involvement.
References Baron, R., Elashaal, A., Germon, T. and Hobart, J. (2006) Measuring outcomes in cervical spin surgery: think twice before using the SF-36. Spine 31: 2575–84. Beck, A.T., Steer, R.A. and Garbin, M.G. (1988) Psychometric proper ties of the Beck Depression Inventory and twenty five years of evaluation. Clin. Psychol. Rev. 8: 77–100. Bergamasco, B. and Lopiano, L. (2006) Chronic deep brain stimula tion of the subthalamic nucleus for Parkinson’s disease: effect on cognition, mood, anxiety and personality traits. Eur. Neurol. 55: 136–44. Block, A.R., Gatchel, R.J., Deardorff, W.W. and Guyer, R.D. (2003) The Psychology of Spine Surgery. Washington, DC: American Psychological Association Press. Blumetti, A.E. and Modesti, L.M. (1976) Psychological predictors of success or failure of surgical intervention for intractable back pain. In: J.J. Bonica and B. Albe-Fessard (eds), Advances in Pain Research and Therapy, Volume 1. New York: Raven Press, pp. 233–47. Brandwin, M.A. and Newman, G. (1982) MMPI indicators for treatment response to spinal cord stimulation in patients with chronic pain and patients with movement disorders. Psychol. Rep. 51: 1059–64. Burchiel, K.J., Anderson, V.C., Brown, F.D. et al. (1996) Prospective, multi-center study of spinal cord stimulation for relief of chronic back and extremity pain. Spine 21: 2786–94. Bushnell, D.M. and Martin, M.L. (1999) Quality of life and Parkinson’s disease: Translation and validation of the US Parkinson’s Disease Questionnaire (PDQ-39). Quality Life Research 8: 345–50. Byrne, C.M., Solomon, M.J., Young, J.M. et al. (2007) Biofeedback for fecal incontinence: short-term outcomes of 513 consecu tive patients and predictors of successful treatment. Dis. Colon Rectum 50 (4): 417–27. Cahana, A. (2002) Is optimal pain relief always optimal; bioethical considerations of interventional pain management at the end of life. Am. Pain Soc. Bull. 12: 1–4. Cameron, T. (2004) Safety and efficacy of spinal cord stimulation for the treatment of chronic pain: 20-year literature review. J. Neurosurg. 100 (Suppl. 3): 254–67.
I. AN introduction to neuromodulation
78
8. psychological issues and evaluation for patients undergoing implantable technology
Castelli, L., Perozzo, P., Zibetti, M., Crivelli, B. et al. (1999) Neuromodulation of the lower urinary tract. Exp. Physiol. 84: 149–60. Chapman, C.R. (2005) www.the-scientist.com/2005/03/28/S1/1/ (accessed July 2008). Covington, E.C., Gallagher, R.M. and Doleys, D.M. (2005) The asso ciation between chronic pain and mood and anxiety disorders. Pain Medicine News, Oct: 1–7. Craggs, M. and MacFarlane, J. (1999) Neuromodulation of the lower urinary tract. Exper. Physiol. 84: 149–60. Damian, A.M., McGrath, M.M., Willian, M.K. et al. (2000) Evaluation of a measurement strategy for Parkinson’s disease: Assessing patient health-related quality of life. Quality Life Research 9: 87–100. Daniel, M.S., Long, C., Hutcherson, M. and Hunter, S. (1985) Psychological factors and outcomes of electrode implantation for chronic pain. Neurosurgery 17: 773–7. De Vries, J., DeJongste, M.J.L., Versteegen, G.J. et al. (2006) Personality: predictors of neurostimulation outcomes in patients with chest pain and normal coronary arteries. Neuromodulation 9: 123–7. Derogatis, L. (1983) The SCL-90R Manual-II: Administration, Scoring, and Procedures. Towson, MD: Clinical Psychometric Research. Deuschi, G., Schade-Brittinger, C., Krack, P., Volkmann, J., Schafer, H., Botzel, K. et al. (2006) A randomized trial of deep-brain stim ulation for Parkinson’s disease. N. Engl. J. Med. 355: 896–908. Deyo, R.A., Battie, M., Beurkens, A.H. et al. (1998) Outcome meas ures for low back pain research: a proposal for standardized use. Spine 23: 2003–13. Diagnostic and Statistical Manual of Mental Disorders (4th edi tion: DSM-IV) (1994) Washington, DC: American Psychiatric Association Press. Diagnostic Criteria from DSM-IV-TR. (2005) Washington, DC: American Psychiatric Association Press. Dodson, K.S. (1989) A meta analysis of the efficacy of cognitive ther apy for depression. J. Consulting Clin. Psychol. 57: 414–19. Doleys, D.M. (2000a) Psychological assessment for implantable therapies. Pain Digest. 10: 16–23. Doleys, D.M. (2000b) Chronic pain. In: R.G. Frank and T.R. Elliott (eds), Handbook of Rehabilitation Psychology. Washington, DC: American Psychological Association Press, pp. 185–204. Doleys, D.M. (2002) Preparing patients for implantable technolo gies. In: D. Turk and R. Gatchel (eds), Psychological Aspects of Pain Management. New York: Guilford Press, pp. 334–47. Doleys, D.M. (2003) Psychologic evaluation for patients undergoing neuroaugmentative procedures. Neurosurg. Clin. North Am. 2003 14: 409–17. Doleys, D.M. (2006) Psychological factors in spinal cord stimulation therapy: brief review and discussion. Neurosurg Focus 21 (6), E1, 1–6. Doleys, D.M. and Brown, J. (2001) MMPI profile as an outcome “predictor” in the treatment of non-cancer pain patients utiliz ing intrathecal opioid therapy. Neuromodulation 4: 93–7. Doleys, D.M. and Doherty, D.C. (2000) Psychological and behav ioral assessment. In: P.P. Raj (ed.), Practical Management of Pain, 3rd edn. St Louis: Mosby Press, pp. 408–26. Doleys, D.M. and Kraus, T.J. (2007) Trialing for intrathecal therapy: comments and considerations. Practical Pain Manag. 7 (5): 48–9. Doleys, D.M., Brown, J.C. and Ness, T. (2006) Mutidimensional outcomes analysis of intrathecal, oral opioid, behavioral-func tional restoration therapy for failed back surgery syndrome: a retrospective study with 4 years’ follow-up. Neuromodulation 9: 270–83.
Doleys, D.M., Klapow, J.C. and Hammer, M. (1997) Psychological evaluation in spinal cord stimulation therapy. Pain Review 21: 234–8. Dworkin, S.F., VonKorff, M. and LeResche, L. (1990) Multiple pain and psychiatric disturbance: an epidemiological investigation. Arch. Gen. Psychiatry 47: 239–44. Fairbank, J.C., Davie, J.B., Couper, J. et al. (1980) The Oswestry Low Back Disability Questionnaire. Physiotherapy 66: 271–3. Ferrante, F.M., Rana, M.V. and Ferrante, M.A. (2004) Conversion dis order mimicking Dejerine–Roussy syndrome (thalamic stroke) after spinal cord stimulation. Reg. Anesth. Pain Med. 29: 164–7. Fishbain, D.A., Goldberg, M., Meagher, B.R. et al. (1986) Male and female chronic pain patients categorized by DSM III psychiatric diagnostic criteria. Pain 26: 181–97. Flor, H., Breitenstein, C., Birbumer, N. and Furst, M. (1995) A psy chophysiological analysis of spouse solicitousness towards pain behaviors, spouse interaction, and pain perception. Behavior Therapy 216: 255–72. Flor, H., Knost, B. and Birbaumer, N. (2002) The role of operant con ditioning in chronic pain: an experimental investigation. Pain 95: 111–18. Flum, D.R. (2006) Interpreting surgical trials with subjective out comes: avoiding UnSPORTsmanlike conduct. JAMA 296: 2483–5. Follett, K.A. and Doleys, D.M. (2002) Selection of Candidates for Intrathecal Drug Administration System to Treat Chronic Pain: Considerations in Pre-Implant Trials. Minneapolis, MN: Medtronic. Ford, P.J. and Henderson, J.M. (2006) The clinical and research eth ics of neuromodulation. Neuromodulation 9: 250–2. Fordyce, W.E. (1976) Behavioral Methods for Chronic Pain and Illness. St Louis: Mosby, p. 236. Graz, B., Wietisbach, V., Porchet, F. and Vader, J.P. (2005) Prognosis or “curabo effect?” Physician prediction and patients outcome of surgery for low back pain and sciatica. Spine 30: 1448–52. Gronchi-Perrin, A., Viollier, S., Ghika, J., Combremont, P., Villemure, J.G., Bogousslavsky, J. et al. (2006) Does subthalamic nucleus deep brain stimulation really improve quality of life? Mov. Disord. 21: 1465–8. Holroyd, K.A., O’Donnell, F.J., Stensland, M. et al. (2001) Management of chronic tension-type headache with tri-cyclic antidepressant medication, stress-management therapy, and their combination. A randomized controlled trial. JAMA 285: 2208–15. Houeto, J.L., Mallet, L., Mesnage, V., Tezenas du Montcel, S., Behar, C., Gargiulo, M. et al. (2006) Subthalamic stimulation in Parkinson disease: behavior and social adaptation. Arch. Neurol. 63: 1090–5. Keller, L.S. and Butcher, J.N. (1991) Assessment of Chronic Pain Patients with the MMPI-2. Minneapolis, MN: University of Minnesota Press, p. 362. Kerns, R.D. and Habib, S. (2004) A critical review of the pain readi ness to change model. J. Pain 5: 357–67. Kupsch, A., Benecke, R., Muller, J. et al. (2006) Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N. Engl. J. Med. 355: 1978–90. Leone, M. (2006) Deep brain stimulation in headache. Lancet (Neurol.) 5: 873–5. Long, D., Erickson, D., Campbell, J. and North, R. (1981) Electrical stimulation of the spinal cord and peripheral nerves for pain control. Appl. Neurophysiol. 44: 207–17. Long, D. (1980) Psychological factors and outcomes of electrode implantation for chronic pain. Neurosurgery 7: 225–9. Long, D.M., BenDebba, M. and Tirgerson, W.S. (1996) Persistent back pain and sciatica in the United States: Patient characteris tics. J. Spinal Disorders 9: 40–58.
I. AN introduction to neuromodulation
references
Loughrey, J.P. and Nedeljkovic, S.S. (2002) Dissociative mental state in a patient with an intrathecal drug administration system. Anesth. Analg. 95: 1009–11. Mailis-Gagnon, A., Furlan, A.D., Sandoval, J.A. and Taylor, R. (2004) Spinal cord stimulation for chronic pain. Cochrane Database Syst. Rev., CD003783. May, M.S., Banks, C. and Thompson, S.J. (2005) A retrospective, long-term third-party follow-up of patients considered for spi nal cord stimulation. Neuromodulation 8: 88–99. McCracken, L.M., Vowles, K.E. and Eccleston, C. (2004) Acceptance of chronic pain. Component analysis and revised assessment method. Pain 107: 159–66. McMahon, M.J., Gatchel, R.J., Polatin, P.B. and Mayer, T.J. (1997) Early childhood abuse in chronic spinal disorder patients: A major barrier to treatment success. Spine 22: 2408–24. Meilman, P.W., Leibrock, L.G. and Leong, F.T. (1989) Outcome of implanted spinal cord stimulation in the treatment of chronic pain: arachnoiditis versus single nerve root injury and mono neuropathy. Clin. J. Pain 5: 189–93. Melzack, R. and Casey, K. (1968) Sensory, motivational and central determinants of pain of pain. In: D.J. Kenshalo (ed.), The Shin Senses. Springfield, IL: Charles C Thomas, pp. 423–38. Melzack, R. and Wall, P.D. (1965) Pain mechanisms: a new theory. Science 150: 971–9. Melzack, R. (1975) The McGill Pain Questionnaire: major properties and the scoring methods. Pain 1: 277–99. Molloy, A.R., Nichloas, M., Asghari, A. et al. (2006) Does a combi nation of intensive cognitive-behavioral pain management and a spinal implantable devise confer and advantages? A prelimi nary examination. Pain Practice 6 (2): 96–103. Nelson, D.V., Kennigton, M., Novy, D.M. and Squitieri, P. (1996) Psychological selection criteria for implantable spinal cord stim ulators. Pain Forum 5: 93–103. North, R., Kidd, D.H., Wimberly, R.L. and Edwin, D. (1996) Prognostic value of psychological testing in spinal stimulation patients: a prospective study. Neurosurgery 39: 301–11. North, R.B., Ewend, M.G., Lawton, M.T. et al. (1991) Failed back surgery syndrome: five year follow-up after spinal cord stimu lation implant. Neurosurgery 28: 692–9. Olson, K.A., Bedder, M.D., Anderson, V.C. et al. (1998) Psychological variables associated with outcome of spinal cord stimulation trials. Neuromodulation 1: 6–13. Paluzzi, A., Belli, A., Bain, P., Liu, X. and Aziz, T.M. (2006) Operative and hardware complications of deep brain stimulation for movement disorders. Br. J. Neurosurg. 20: 290–5. Polatin, P.B., Kinney, R.K., Gatchel, R.J. et al. (1993) Psychiatric ill ness and low back pain. Spine 18: 66–71. Prehn, A.W., Vawter, D.E., Gervais, K.G. et al. (2006) Studying neu rosurgical implants for Parkinson disease: a question of design. Neurology 24: 1503–5. Price, D.D. (1999) Psychological Mechanisms of Pain and Analgesia. Seattle, WA: International Association for the Study of Pain Press. Raffaeli, W., Andruccioli, J., Righetti, D. et al. (2006) Intraspinal ther apy for the treatment of chronic pain: a review of the literature between 1990 and 2005 and suggested protocol for its rational safe use. Neuromodulation 9: 290–308. Rockwood, T.H., Church, J.M., Fleshman, J.W. et al. (2000) Fecal incontinence quality of life scale: quality of life instrument for patients with fecal incontinence. Dis. Colon Rectum 43: 9–16. Roland, M. and Morris, R. (1983) A study of the natural history of back pain: Part 1. Development of a reliable and sensitive meas ure of disability and low back pain. Spine 8: 141–4. Rome, H.P. and Rome, J.D. (2000) Limbically augmented pain syn drome (LAPS): Kindling, cortical limbic sensitization, and the
79
convergence of affective and sensory symptoms in chronic pain disorders. Pain Med. 1: 1–23. Sator-Katzenschlager, S.M., Schiesser, A.W., Kozek-Langenecker, S.A. et al. (2003) Does pain relief improve pain behavior and mood in chronic pain patients? Anesth. Analg. 97: 791–7. Schocket, K.G., Gatchel, R.J., Stowell, A.W. et al. (in press) Behavioral medicine evaluation for categorizing patients for potential treat ment efficacy for spinal cord stimulation and intrathecal drug delivery: a preliminary study. Neuromodulation. Schofferman, J., Anderson, D., Hines, R. et al. (1992) Childhood psy chological trauma correlates with unsuccessful lumbar spine surgery. Spine 17 (Suppl. 6): S1380–S1384. Schupbach, M., Gargiulo, M., Welter, M.L. et al. (2006) Neurosurgery in Parkinson disease: a distressed mind in a repaired body? Neurology 66: 1811–16. Shealy, C.N. (1975) Dorsal column stimulation: optimization of application. Surg. Neurol. 4: 142–5. Shealy, C.N., Mortimer, J.T. and Reswick, J.B. (1967) Electrical inhi bition of pain by stimulation of the dorsal columns: preliminary report. Anesth. Analg. 46: 4489–91. Skidmore, F.M., Rodriguez, R.L., Fernandez, H.H. et al. (2006) Lessons learned in deep brain stimulation for movement and neuropsychiatric disorders. CNS Spectr. 11: 521–36. Spertus, J.A., Winder, J.A., Dewhurst, T.A. et al. (1995) Development and evaluation of the Seattle Angina Questionnaire: a new func tional status measure for coronary artery disease. J. Am. Coll. Cardiol. 25: 333–41. Spielberger, C.D., Groschuh, R.L. and Lusheve, R.F. (1997) Manual for the State-Trait Anxiety Scale. Palo Alto, CA: Consulting Psychology Press. Stewart, W.F., Lipton, R.B., Dowson, M.B. and Sawyer, J. (2001) Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology 56 (Suppl. 1): S20–S28. Taylor, R.S., Van Buyten, J.P. and Buchser, E. (2005) Spinal cord stim ulation for chronic back and leg pain and failed back surgery syndrome: a systematic review and analysis of prognostic fac tors. Spine 30: 152–60. Turk, D.C., Dworkin, R.R., Allen, N. et al. (2003) Core outcome domains for chronic pain clinical trials: IMMPACT recommen dations. Pain 106: 337–54. Turk, D.C. and Rudy, T.E. (1991) Neglected topics in the treatment of chronic pain patients – relapse, noncompliance, and adher ence enhancement. Pain 44: 5–28. van Dixhoom, J. and White, A. (2005) Relaxation theory for rehab ilitation and prevention of ischemic heart disease. Eur. J. Cardiovasc. Prev. Rehabil. 12 (3): 193–202. Verdolin, M.H., Stedje-Larsaen, E.T. and Hickey, A.H. (2007) Ten consecutive cases of complex regional pain syndrome of less than 12 months duration in active duty United States military personnel treated with spinal cord stimulation. Anesth. Analg. 104 (6): 1557–62. Wallis, B.J., Lord, S.M. and Bogduk, N. (1997) Resolution of psy chological distress of whiplash patients following treatment by radiofrequency neurotomy: a randomized, double-blind, placebo-controlled trial. Pain 73: 15–22. Ware, J.E., Snow, K.K., Kosinski, M. and Gandek, B. (1993) SF-36 Health Survey: Manual and Interpretation Guide. Boston, MA: Nimrod Press. Wichman, T. and Delong, M.R. (2006) Deep brain stimulation for neurologic and neuropsychiatric disorders. Neuron 52: 197–204. Willis, K.D. and Doleys, D.M. (1999) The effect of long-term intra spinal infusion therapy with noncancer pain patients: evaluation
I. AN introduction to neuromodulation
80
8. psychological issues and evaluation for patients undergoing implantable technology
of patient, significant-other, and clinic staff appraisals. Neuro modulation 2: 241–53. Winkelmuller, M. and Winkelmuller, F. (1996) Long-term effects of continuous intrathecal opiate therapy in chronic pain of nonmalignant etiology. J. Neurosurg. 85: 458–67. Wojtecki, L., Timmerman, L., Jorgens, S. et al. (2006) Frequencydependent reciprocal modulation of verbal fluency and motor functions. Arch. Neurol. 63: 1273–6. Yamada, K., Goto, S., Matsuaki, K. et al. (2006) Psychiatric symptoms and subthalamic nucleus in Parkinson’s disease: a retrospective study in our Japanese patients. Neuromodulation 9: 107–14.
Yamashita, K., Ohzono, K. and Hiroshima, K. (2006) Patient satisfac tion as an outcome measure after surgical treatment for lumbar spinal stenosis: Testing the validity and discriminative ability in terms of symptom and functional status. Spine 31 (22): 2602–8. Zdanowicz, N., Janne, P., Reynaert, C. and Wunsch, A. (1999) Induction of schizophreniform disorder by a spinal cord stimu lator. Psychosomatics 40: 76–8.
I. AN introduction to neuromodulation
C H A P T E R
9
Deep Brain Stimulation: Ethical Issues in Clinical Practice and Neurosurgical Research Joseph J. Fins
o u t line Regulation: From Research to Therapy
81
Informed Consent: Theoretical and Operational Issues In the Setting of Decisional Capacity In the Setting of Decisional Incapacity Neuroethics, Consent, and Exceptionalism
83 83 84 86
As an emerging therapy that also is the subject of active clinical investigation, deep brain stimulation (DBS) can be easily misunderstood. It can be lion ized because of powers it does not possess or feared because of speculative applications that remain in the realm of science fiction (Fins, 2002). Such dichotomous views of neuromodulation can distort ethical analysis, either by accelerating inappropriate dissemination or impeding necessary research. In this chapter we will consider the ethics of both clinical application and research in order to more carefully articulate a norma tive framework for neuromodulation (Fins, 2004a).
86
Historical Determinants Neurosurgical Antecedents Psychosurgery
87 87 88
References
89
first must determine whether a procedure constitutes established therapy or remains investigational. Deter mining this distinction is critical lest the investigator or clinician inadvertently mislead a potential research participant or patient about the safety and efficacy of an intervention. The most extreme example of such misrepresenta tions has been called the “therapeutic misconception,” where research is misunderstood as being therapeutic (Applebaum et al., 2004). A therapeutic misconception can have its origins in the hopes and desperation of a patient eager for cure or in the manner within which consent is obtained for enrollment in a clinical trial. Usually, these misperceptions stem from both a com bination of hope and hype, which may or may not be intended on the part of the investigator. The therapeu tic misconception is more than a theoretical concern; empirical studies have demonstrated a high degree of its prevalence in clinical research, although it has yet to be studied in deep brain stimulation (Glannon, 2006).
Regulation: from research to therapy To apply the proper ethical frame against which to evaluate the risks and benefits of neuromodulation we
Neuromodulation
Conflicts of Interest: Disclosure and Justification
81
© 2008, 2009 Elsevier Ltd.
82
9. Deep Brain Stimulation: Ethical Issues in Clinical Practice and Neurosurgical Research
To ensure that consent is representative of the actual state of affairs it is absolutely critical that those engaged in neuromodulation have a precise stereotaxy about where their work is located in time and space, its stage and location on the research to clinical con tinuum. A failure to be clear about these coordinates will confuse the articulation (and understanding) of risks and benefits. Whereas established therapies have demonstrated a requisite degree of safety and efficacy, both questions remain open for investigative interventions. Moreover, questions about safety and efficacy change as a trial evolves from initial stages into maturation. At the out set, when a device like DBS is being piloted, the oper ative question is one of safety. Although investigators may have a therapeutic hypothesis that lead to an ini tial trial, phase I trials are not primarily about demon strating effect. Instead they are about demonstrating safety or an acceptable degree of toxicity. In such phase I clinical trials, the goal is to deter mine safety parameters and ascertain the incidence and prevalence of adverse effects (AEs) ascribed to the device or intervention. AEs are categorized as minor or major depending upon criteria established in the clinical trial. Although the details of what con stitutes a minor or major AE will differ depending upon the circumstances, the distinction generally hinges on reversibility and severity. Because it is dif ficult to always know whether adverse occurrences may be causally related to the device or the trial, sens itivity in reporting events is more appropriate than specificity. This is especially true when trials are blinded and investigators are unaware of all the cir cumstances of a particular subject’s response or when there are multi-institutional data and patterns can only be discerned by pooling information from multiple sources. AEs or toxicity data must be reported to regulatory bodies such as the local Institutional Review Board (IRB), which is responsible for approval of protocols within the investigator’s institution, and to the Food and Drug Administration (FDA), which allows such research to proceed with an Investigational Device Exemption (IDE). The IDE process regulates devices that pose significant risk such as the deep brain stim ulator and supplement the statutory oversight of the IRB (Pritchard et al., 1999). To assess data in such circumstances and to assess the overall success of the trial as it progresses, the FDA and/or IRB may require the additional estab lishment of a disinterested Data Safety Monitoring Board (DSMB). A DSMB is composed of experts who can make such assessments and who do not have a
conflict of interest that might distort their analyses of the data. A DSMB can halt a trial if it is unsafe, or con versely if the results demonstrate a degree of success that makes additional recruitment of subjects unnec essary from a statistical standpoint. FDA procedures are required by law and seek to establish safety and efficacy for new devices as well as when devices approved for one indication are used for another purpose such as targeting a new ana tomic locale. An example of this would be the use of an approved deep brain stimulator for Parkinson’s disease and utilizing it for another disorder or the tar geting of it to different nuclei. These circumstances would not be therapeutic but rather investigational and would require a new IDE as well as review by an Institutional Review Board. Although this point may seem obvious to the reader, it bears emphasis. Some investigators may try to assert that the use of an established device is therapeutic in order to avoid the additional regula tory oversight of a new IDE process. Alternately, they may view borderline uses as therapeutic (Miller et al., 1998). In either case, clinical-investigators should seek IRB guidance to avoid the appearance of impropriety and potential conflicts of interest. Returning to the evolution of a clinical protocol, a successful phase I trial will show an acceptable degree of safety and a promising degree of efficacy. If we analogize to drug trials, a 5% response is considered enough to warrant the progression into subsequent stages geared at determining whether an intervention is efficacious. Phase II trials seek to demonstrate effi cacy and phase III, at least in the context of pharma cological studies, are meant to compare efficacy of the new intervention against established therapeutic ones. This later comparison can compare the overall benefit of the proposed therapy along dual axes of both intended and unintended (side) effects. A device is deemed therapeutic when its safety and efficacy have been demonstrated in prospec tive trials. The evidence for approval needs to be methodologically rigorous and ideally involve dou ble-blinded and randomized trials. Studies can be done following implantation of electrodes with sub jects and evaluators being blinded to whether or not stimulation is taking place. Such blinded studies have been conducted in the evaluation of DBS and are important because there is documented poten tial for a placebo effect, which can confound evi dence regarding efficacy. For example, it has been shown in Parkinson’s disease that motor performance improved when subjects believed they were being stim ulated, when in fact they were not (Pollo et al., 2002).
I. AN INTRODUCTION TO NEUROMODULATION
Informed consent: theoretical and operational issues
It has also been shown that patient expectation plays a role in functional neurosurgery (Mercado et al., 2006). The demarcation line between research and ther apy changes from year to year given the dynamism of neuromodulation, and this, in part, explains why there is some confusion about discerning established therapy from the investigational. At time of writing DBS is recognized as therapeutic for the management of chronic pain (Gildenberg, 2006), the evaluation and management of epilepsy (Kopell and Rezai, 2000), and the treatment of Parkinson’s disease and other move ment disorders. The Food and Drug Administration approved use of the deep brain stimulator for refrac tory Parkinson’s disease and essential tremor in 1997 (Blank, 1999). Subsequent to approval DBS has been found effective in prospective, double-blind studies (Kumar et al., 1998; Deep-Brain Stimulation for Parkinson’s Disease Study Group, 2001). DBS also has an established diagnostic niche in intraoperative corti cal mapping prior to tumor resection and ablations for movement disorders, like the pallidotomy for move ment disorders. This technique was pioneered by the great neurosurgeon Wilder Penfield in the localiza tion of seizure foci in epilepsy prior to surgical resec tion of the causative areas (Penfield, 1977; Feindel, 1982, 1998). Investigative work in neuromodulation of the brain is on-going in a wide range of neuropsychiatric con ditions (Roth et al., 2001). Clinical investigators are conducting trials for use in obsessive–compulsive disorders which awaits FDA approval (Rapoport and Inoff-Germain, 1997; Greenberg et al., 2006), depres sion (Doughert and Rauch, 2007), and traumatic brain injury (Schiff et al., 2007). Ultimately, the boundary between experimental work and therapeutic deploy ment rests on FDA approval of the device and the consensus of the medical community that the putative treatment is effective and safe and that the intended beneficial outcome will appear without adverse longor short-term effects. Because late effects may occur after an intervention has been approved as therapy, regulatory bodies like the FDA also engage in post-marketing surveillance of adverse events or the tracking of unexpected com plications. Post-marketing surveillance is especially important when considering the safety of prosthetic devices, whose engineering might fail after success ful insertion and a clinically fruitful deployment. Moreover, in the context of the device, there may be in vivo material failures or complications related to the capacitance of batteries which may need to replaced at a shorter than expected interval.
83
Informed consent: theoretical and operational issues In the Setting of Decisional Capacity It is a tenet of modern medical ethics that com petent patients and subjects have a right to selfdetermination (Schloendorff v Society of New York Hospital, 1914), that is, autonomous dominion over themselves and their bodies (Fins, 2001). Legally competent patients or subjects are those who possess decision-making capacity and who have reached the age of majority (or depending upon local jurisdic tion are emancipated minors). Individuals with deci sion-making capacity have the ability to understand risks and benefits and utilize a “rational standard” when considering their options (Zaubler et al., 1996). Assessment of this capacity, and its implications for consent, should involve an interdisciplinary team including psychiatrists, psychologists and ethicists (Nuttin et al., 2002, 2003; Fins, Rezai et al., 2006; Ford and Kubu, 2006; Kubu and Ford, 2007). The ability to make such choices depends, in great part, upon the quality of information that is shared with the patient or subject through the process of informed consent. This process can be undermined if there is a fundamental misconstrual of whether the process pertains to therapy or research. It could well be asserted that distinguishing research from therapy is most critical in the context of informed consent (Applebaum and Lidz, 2006). An unproven interven tion, by definition, is ethically more disproportionate than an established therapy. By that, I mean that the ratio of real and potential risks relative to the bene fits is greater. If an investigative intervention is mis understood as being therapeutic it influences how these relative risks and benefits are understood, both dimensions of the informed consent process. The ethical concept of equipoise is another way of understanding this relationship of risks and benefits as they relate to the question of research versus ther apy. Equipoise, or standing between two positions, is generally defined as the investigator’s uncertainty about a scientific hypothesis regarding the efficacy of a proposed therapy (Freedman, 1987). It is that uncertainty, in the face of a credible hypothesis, that defines the work as investigational. Once data resolve the uncertainty, equipoise is lost and the on-going viability of the therapeutic speculation is either con firmed or denied. If the former occurs, the trial tends towards the therapeutic, e.g. advances towards mat uration. If the latter occurs, it may be halted at an early stage.
I. AN INTRODUCTION TO NEUROMODULATION
84
9. Deep Brain Stimulation: Ethical Issues in Clinical Practice and Neurosurgical Research
Investigators and clinicians should use these heur istics to determine whether a proposed intervention constitutes established therapy or research and explic itly clarify this issue with the patient or research par ticipant. If the consent addresses research, then the investigator must be clear that direct medical benefit cannot be promised in early phase I trials. In that case, the expectation for a “successful” trial will be that others will benefit from knowledge gleaned from the subject’s participation. Later stages may offer a proba bilistically greater chance of benefit, although not one equivalent to a vetted therapy. Following this contextualization, specific risks and benefits need to be addressed. Success rates for estab lished therapies should be shared with patients. It is important to unambiguously communicate bene fits (when they are known) (Kim, 2006) and provide appropriate reassurance, in the case of DBS, about the capability of stereotactic techniques, coupled with neuroimaging, to precisely target specific brain sites or nuclei. This means that the insertion of electrodes can be done without damage to adjacent tissue. In order to foster transparency, and keep patients fully informed, data should also be supplied about how local outcomes compare with national ones. This point bears special emphasis because there may be more significant regional variation in functional and stereotactic neurosurgery than other areas of neuro surgical practice because it is a new area of surgical expertise and without its own sub-specialty board. This makes it especially critical to define outcomes and establish criteria about what constitutes a DBS failure (Hariz, 2005). Beyond questions of relative operative compe tence, complication rates should also be shared related to hemorrhage; infection; seizures and hardwarerelated malfunctions that might necessitate revision or removal of the device. Informed consent discussions should also address psychiatric and neuropsychiatric adverse events that may be associated with DBS. Metaanalyses of published data suggest very low rates of adverse effects such as affective changes (depression (2–4%), mania (0.9–1.7%), emotional changes (0.1– 0.2%), and suicidal ideation or attempt (0.3–0.7%) with a completion rate of 0.16–0.32% (Appleby et al., 2007). Some of these complications may be mitigated by the putative reversibility of DBS via the removal of electrodes or the deactivation of devices. This point also needs to be part of the informed consent discussion. Unlike ablative surgery that results in irreversible dam age of brain tissue from the intentional destruction of targeted areas, it is important to note that the effects of DBS are generally felt to be reversible. Most believe that stimulators can be turned off and electrodes removed
without sequelae in most circumstances, although some emerging data suggest that DBS may induce changes in gene expression (Shirvalkar et al., 2006). Alternative therapies should also be discussed in order to assure that patients are aware of other options that might exist to address their problem. Provision of this additional information, for example, discussion of remaining pharmacologic agents for Parkinson’s dis ease, helps to maintain the patient’s ability to make an informed choice about DBS. Trust is instilled in the doctor–patient relationship by sharing information about a less invasive modality that might yet be suc cessful with less morbidity. Perhaps, most critically, the sharing of such infor mation demonstrates a willingness to allow the patient to freely choose their course of therapy. If a patient felt that the only alternative was agreeing to the insertion of a deep brain stimulator he or she would feel con strained in the choices available to them. Desperation may lead a patient to consent to any treatment that offers the possibility of symptomatic relief. Providing information about alternatives helps to foster volun tary choice, in line with the important ethical concept of voluntariness. Voluntariness comes out of the Nuremberg Trial and the subsequent Nuremberg Code of 1947 which addressed human subjects research in the wake of the abuses by Nazi doctors during the Holocaust (Trials of War Criminals, 1949). Respect for voluntariness requires that the informed consent process provides the requisite knowledge of risks and benefits while protecting the right to refuse participation. It has long been my view that the doctrine of informed consent is only tested when a patient or subject decides counter to the recommendation of a doctor or investigator. It is only in such circumstances that the power structure is challenged, true voluntariness is expressed, and patient self-determination sustained. Such refusals may also occur after consent has been given; a competent patient retains the right to with draw him- or herself from treatment. The standard for such withdrawals should be high when there are con comitant risks, such as the interruption of an operative procedure or the premature removal of a device. One commentator has suggested a standard of “informed revocation of consent” under which the individual fully understands the risks and benefits associated with a change of heart (Ford, 2007).
In the Setting of Decisional Incapacity Individuals with severe psychiatric illness or head trauma, who may be treated with DBS or enrolled in
I. AN INTRODUCTION TO NEUROMODULATION
Informed consent: theoretical and operational issues
related research, may be at risk for decisional incapac ity. When these individuals are unable to engage in the informed consent process, they are considered a vul nerable population and in need of special protections because they are unable to autonomously defend their interests. Authorization for treatment or research in the setting of decisional incapacity poses special chal lenges because surrogate decision-makers are called upon to make choices for patients or subjects who are no longer able to represent their own interests. Surrogates are generally asked to make decisions based on hierarchical standards of decision-making (Sachs and Siegler, 1991). If they are known, surro gates should be directed by the expressed wishes of the now-incapacitated individual. Absent that, surro gates should invoke substituted judgment, what they believe the patient would decide if they were able to communicate. If prior wishes, or inferential know ledge are not available, then surrogates are meant to invoke what is called a best interests standard, what a “generic” person would decide if confronted with the question requiring a decision. As precise as these cat egories appear, surrogates never can know the prefer ences of the incapacitated individual with certainty, and thus inevitably bring an element of discretion and judgment when authorizing treatment or enrolling a subject in research (Fins et al., 2005). These surrogate judgment calls are ethically less complex when the question at hand involves a deci sion to pursue an established therapy. As we have seen, therapeutic interventions, by definition, have a favorable risk–benefit profile. Because of this, surro gates may legally authorize treatment given the ethical proportionality of therapy. It is a normative decision; when given a choice, most capacitated patients would choose to receive an established therapy to ameliorate illness. It is quite another matter when the question is whether to enroll a decisionally incapacitated indi vidual in a clinical trial. While surrogates are gener ally allowed to consent to therapeutic procedures, their authority is more constrained when permission is sought for enrollment for research, unless they have been authorized prospectively with an advance directive for research. Beyond that unlikely occur rence (only a minority of Americans have an advance directive that would direct medical care in the event of incapacity), there remains debate within ethical and legal circles about how much authority can be vested in surrogate decision-makers when research involves the decisionally incapacitated. At the federal level, the National Bioethics Advisory Commission (NBAC), in its report “Research involv ing persons with Mental Disorders that may affect
85
Decisionmaking Capacity,” proposed guidelines to regulate the conduct of research on individuals who are unable to provide consent (National Bioethics Advisory Commission, 1998). Although these recom mendations were never enacted into statutes or prom ulgated as regulations, they are worth considering in some detail because they delineate this problem space. NBAC recommended three regulatory categories: research presenting minimal risk; research present ing greater than minimal risk that offers the prospect of direct medical benefit to subjects; and research pre senting greater than minimal risk without offering the prospect of direct medical benefit. For research involv ing minimal risk, a legally authorized representative could consent to enrollment in research of a decision ally incapacitated subject with or without the sub ject’s “prospective authorization” for research. Legally authorized representatives could also authorize enroll ment in research with or without prospective authori zation when there was the prospect of direct medical benefit. Prospective authorization would be required for legally authorized representatives to provide authorization for protocols that involved greater than minimal risk without the prospect of direct medical benefit. When prospective authorization is not avail able such research could only go forward with the permission of the legally authorized representative and the additional regulatory approval of a Special Standing Panel (SSP) convened by the Secretary of Health and Human Services or possibly the local IRB pursuant operating under guidance from HHS. Although the NBAC recommendations were criti cized for their potential adverse impact on worthy research (Michels, 1999; Miller and Fins, 1999; Fins and Miller, 2000), they do point to the ethical com plexity of neuromodulation research when (i) subjects lack decision-making capacity, (ii) the research has yet to demonstrate the prospect of direct medical benefit, and (iii) it poses more than minimal risk, all charac teristics of phase I trials. To address the challenge of research with this population, I proposed a consensus model of authorization with my colleague Franklin G. Miller (Fins and Miller, 2000). For IRB approved trials, we suggested the need for agreement amongst the subject’s legally authorized representative (LAR), physician, clinical investigator and a lay volunteer subject advocate with pertinent experience. We argued that the achievement of consensus from such a quartet would lead to ethically sound deci sions for potentially vulnerable subjects who could be harmed by either inappropriate inclusion or exclusion from the research enterprise. Although all involved in research have a duty to protect the incapacitated
I. AN INTRODUCTION TO NEUROMODULATION
86
9. Deep Brain Stimulation: Ethical Issues in Clinical Practice and Neurosurgical Research
subject from harm, the principles of respect for per sons, beneficence and justice can also be invoked to assert a fiduciary obligation to design and execute well-considered, scientifically sound clinical trials for this historically marginalized population (Fins and Miller, 2000; Fins and Schiff, 2000; Fins, Giacino et al., 2006). This perspective, in support of surrogate con sent-based research, has been shown to be consistent with the views of some subjects at risk for decisional incapacity (Kim et al., 2005).
Neuroethics, Consent, and Exceptionalism A final issue that has bearing on informed consent is whether DBS is ethically different because the object of its effect is the brain. And, if a salient difference is demonstrated, its application or study should be mor ally proscribed. No other organ is so closely involved with concepts of mind and self than the brain. Earlier commentators have written of the folk belief that to interfere with the brain “surgically carries a peculiar penumbra of sacrilege” (Editorial, 1972). While it is true that DBS may alter cognition, mem ory or affect and thus alter one’s personality, this capa bility is not unique to neuromodulation of the brain. Conventional neurosurgery, psychoactive drugs, gen eral anesthesia and cognitive rehabilitation all have this capability, as does naturally occurring injury, dis ease or spontaneous recovery. This shared capability suggests that there should be no prima facie prohibi tion for DBS. Having made this argument, it would be a mistake to assume that DBS does not pose special challenges about discerning risks and benefits because the brain is the target organ. The work of my colleagues and I in a clinical trial seeking to use DBS as a potential agent of cognitive rehabilitation following traumatic brain injury (TBI) raised the question of whether fostering additional self-awareness is always an ethical good (Cohadon et al., 1985; Fins, 2000; Schiff et al., 2007). Partial cognitive recovery could theoretically lead to greater awareness of one’s impairment and lead to suf fering. Again, this theoretical possibility is not unique to the application of DBS to TBI. A similar phenom ena is seen in the incidence of substance abuse several years after the incident injury, suggesting that recov ery is sometimes accompanied by a degree of mourn ing and melancholia associated with the realization of what has been lost and what challenges remain (Jorge et al., 2005). This realization is shared by patients who progress spontaneously or who are helped in con ventional rehabilitation. Whatever the etiology, the proper ethical response is the timely identification
of distress and its proper treatment with appropriate counseling and psychopharmacologic agents, when indicated. Finally, should an intervention be ego-dystonic, the patient or surrogate may ask for device deactiva tion. Moreover, consistent with the design of our trial of thalamic stimulation in the minimally conscious state, protocol design should include the provision for longitudinal assessment of decision-making capacity to ensure that subjects who regain this capability can participate in decisions about the on-going risks and benefits of continued study enrollment (Schiff and Fins, 2007; Schiff et al., 2007; Schiff et al., in press).
Conflicts of interest: disclosure and justification Because neuromodulation of the brain is such a young discipline and still undergoing rapid techno logical change and innovation, there is a good chance that the use of this technology may involve some degree of conflict of interest between clinicians, clinicalinvestigators and industrial suppliers and/or sponsors. Conflicts of interest are not inherently wrong. In fact sometimes they are essential to complete research that otherwise may not be funded under current modes of governmental support and statutory means to engage in technology transfer, namely the Bayh–Dole Patent and Trademark Laws Amendment (Fins and Schachter, 2001) (35 U.S.C. §§ 200–12, 1994). Conflicts become problematic when they are not adequately disclosed during the informed consent process or in published papers. They also become problematic when economic motivations impede access to care or the responsible promotion of clinical research. It is my view that prac titioners and investigators have an affirmative obliga tion to work to promote improved access to care and responsibly manage any necessary conflicts of inter est in order to maintain patient and public trust. If a novel device can only be developed through an indus trial partnership it seems justified and investigators who work with industry should not be viewed preju dicially by their colleagues, journal editors, regulators or society at large. They should be lauded for their frank disclosure of a potential conflict. In contrast, it is a deviation from professional norms and expectations when personal gain is the primary motivation. The American Association of Academic Medical Centers (AAMC) has promulgated stringent guidelines to direct behavior when there are conflicts of interests in research. They suggest the need for investigators to
I. AN INTRODUCTION TO NEUROMODULATION
Historical determinants
overcome what they describe as a “rebuttable presump tion” – investigators with financial conflicts of interest should not be allowed to conduct clinical trials until they overcome the presumption that they should not be involved in the research (AAMC Task Force, 2003). Although I am sympathetic to the AAMC’s intent, I would prefer to support a prospective doctrine of “disclose and justify” which does not presume an investiga tor’s ineligibility but rather assumes that researchers will act in good faith guided by the dual ethical princi ples of beneficence and justice (Fins, 2007). This is a more constructive stance that can allow neurosurgeons, engineers and scientists to leverage their expertise, on the patient’s behalf, when work ing with corporate sponsors. They can help ensure that the exclusivity granted by patents does not make products so prohibitively expensive and support efforts to direct a percentage of royalties to the care of the underserved who may need a neuroprosthetic device or the support of translational research. Such altruism will help maintain public trust and safeguard ethical propriety of innovators and of their corporate sponsors.
Historical determinants No discussion of the ethics of DBS would be com plete without addressing historical determinants that so shape public perception about this work. In this next section we will trace the history of electrical stim ulation of the brain from the latter part of the nine teenth century through to the twentieth and consider the contentious issues surrounding the psychosurgery debate. This history is complex and only a part of it can be told here. But it is a dimension of the work that needs to be understood in order to proceed responsi bly and responsively.
Neurosurgical Antecedents Despite the frequent focus of contemporary head lines, neuromodulation of the brain has its roots in the work of neurophysiologists and neuroanatomists in the latter half of the nineteenth century when, as in our own time, there was a fascination with the interac tion of electricity and the brain. During that time Broca localized speech in the left hemisphere and Hughlings Jackson formulated his hypothesis that generalized seizures, which now bear his name, resulted from aberrant electrical activity in the cortex (Penfield, 1972). Early neurophysiolo gists also engaged in animal experimentation using
87
electrical stimulation of the brain (Zimmerman, 1982). In 1870, Eduard Hitzig and Gustav Fritsch demon strated motor activity in a dog following stimula tion and David Ferrier, in 1873, induced seizures in a dog following contralateral stimulation (Thomas and Young, 1993). The first reported case of electrical stimulation of the brain in a human being was performed in 1874 by Roberts Bartholow, a Cincinnati physician (Thomas and Young, 1993). In what today could only be described as an ethical breach in a highly vulnerable patient, Bartholow stimulated the brain of a patient laid bare by invasive basal cell carcinoma that had locally exposed brain. An historical account reported that the patient was dying and grateful for the care she had received from Dr Bartholow and agreed to be studied. Bartholow demonstrated the insensate nature of dura mater and reproduced the findings of Ferrier that motor activity could be elicited by stimulation of the contralateral hemisphere.1 But in demonstrat ing that he could induce seizures from electrical stimulation and unconsciousness, Bartholow caused the patient’s death from refractory seizure activity, an outcome that led to contemporary ethical critique from his colleagues who questioned the authenticity of her willingness to be studied and the distress that had been induced (Morgan, 1982). Bartholow’s study, disproportionate in its degree of danger and its lack of any intended patient benefit, was in stark contrast with the work of later practitioners who utilized elec trical stimulation of the brain to map cortical function under local anesthesia. The pioneering neurosurgeon Harvey Cushing used electrical stimulation to optimize tumor resec tions and minimize postoperative functional loss (Cushing, 1909). His student, Wilder Penfield, extended this approach to study epilepsy and plan resections of scar tissue causing seizure activity (Fins, 2008). A by-product of his therapeutic efforts was the description of the human homunculus (Penfield, 1977; Feindel, 1982). The development of stereotactic surgery in 1947 was a major advance that would be critical to the precise three-dimensional localization of nuclei in the brain and the insertion of electrodes without full craniotomy (Gildenberg, 1990; al-Rodhan and Kelly, 1992). 1
Ever since the ethical breaches of the Holocaust (see above), schol ars have debated whether it is appropriate to cite studies that have serious ethical flaws and disregarded human subjects’ protections (see S.G. Post, The echo of Nuremberg: Nazi data and ethics. J. Med. Ethics 1991; 17 (1): 42–4). I believe this report of Bartholow’s work and observations – as reported by Thomas and Young (1993) – is justified because it is recounted so as to foster ethical practice and research.
I. AN INTRODUCTION TO NEUROMODULATION
88
9. Deep Brain Stimulation: Ethical Issues in Clinical Practice and Neurosurgical Research
Electrical stimulation of the brain has also been employed in the service of analgesia and anesthe sia. The first use of electrical stimulation of the brain for the control of chronic pain was demonstrated by Robert G. Heath in 1954, and in 1969 David Reynolds described the production of analgesia produced by stimulation of midbrain gray matter. Deep stimulation of other selected targets was demonstrated to relieve pain in the 1970s (Young, 1990). As has been recounted, the most important cur rent application of DBS has been in the treatment of movement disorders. The history of this work is more recent. Siegfried noted in 1985 that thalamic stimu lation for pain control could improve tremor in a patient with Parkinson’s disease (Gildenberg, 1998), although the modern era of neuromodulation began in 1987 when the French neurosurgeon Alim Benabid noted improvements of Parkinsonian tremor follow ing stimulation of the thalamus during brain mapping prior to ablative surgery (Speelman and Bosch, 1998). Benabid’s singular contribution was in translating basic science work and clinical observations into the development of the field of which this text is such an exemplar (Fins and Schachter, 2001).
Psychosurgery While these developments in localization, pain management and treatment of motor disorders were generally accepted without controversy, electrical stimulation of the brain was also being investigated for the treatment of psychiatric disorders.2 This was a far more contentious part of the story because the pro cedure was contextualized within the broader societal debate over psychosurgery in the 1960s and 1970s (Gaylin et al., 1975; Fins, 2003). This discordance is evident in the definition used by The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, which studied the question of psychosurgery and issued a report in 1977 (The National Commission, 1977). The Commission, established by an Act of Congress (The National Research Act, 1974), adopted a Cartesian view of both the brain and the ways it might 2
For the purposes of this chapter, my discussion of psychosurgery is limited to electrical stimulation of the brain and work done in the 1960s and 1970s. I am not considering the ethics of ablative proce dures, which for the most part characterized the era of psychosur gery before the advent of neuroleptic drugs in the early 1950s. For a discussion of that period and the relevant ethical issues, the reader is advised to consult J.D. Pressman, Last Resort, Psychosurgery and the Limits of Medicine. New York: Cambridge University Press, 1998.
be electrically stimulated (Fins, 2004b). Although, the Commission opined that “psychosurgery includes the implantation of electrodes, destruction or direct stimulation of the brain by any means,” not all electri cal stimulation constituted psychosurgery. It was only included when its primary purpose was to “control, change, or affect any behavioral or emotional distur bance.” It excluded brain surgery for the treatment of somatic disorders such as Parkinson’s disease, epilepsy or pain management from the definition of psychosurgery. Commentators from that era worried about the psychiatric use of electrical stimulation, especially as they might be employed to assert social control and remediate turbulent times marked by crime and civic unrest. These concerns were prompted, in part, by the controversial work of the Spanish physiologist Jose M.R. Delgado who worked at Yale during that era. He advanced the idea of psychocivilizing society using an implantable brain implant that could be oper ated by remote control (Delgado and Anshen, 1969). Delgado gained international fame when he allegedly stopped a charging bull in a Cordoba bullring using a radio controlled electrode called a “stimoceiver” (Osmundsen, 1965). The possibility of controlling aggression was picked up in popular culture and exemplified by Michael Crichton’s Terminal Man, whose main character under went electrical stimulation of the brain to treat violent behavior (Crichton, 1977), and the notion of mind control remains a lingering leitmotif (Anon., 2002; Horgan, 2004). Lay reports describing a remotely controlled “cyborg” rat with a brain implant (Talwar et al., 2002) alluded to Delgado’s work (Boyce, 2002; Onion, 2002). This error of omission leads to the misrepresenta tion of the past and fosters a misuse of historical anal ogy which has the potential to distort current policy regarding the regulation of this novel technology (Fins, 2002). Such media accounts fail to paint a full picture of the modern psychosurgery era and rarely, if ever, mention the deliberations of the National Commission or other contemporaneous deliberative bodies. Although the Commission was predicted to con demn psychosurgery writ large and find evidence of social control, this was not the case. In a remark able rebuke to popular expectations, the Commission chose not to recommend an outright ban on psycho surgery. Instead, it concluded that there was enough demonstrated potential for some procedures in spe cifically selected subjects. This led the Commission to recommend continued experimentation so long
I. AN INTRODUCTION TO NEUROMODULATION
references
as it was limited in scope, clearly distinguished from “accepted practice”, and accompanied by strict regu latory guidelines. Moreover, none of the National Commission, the American Psychiatric Association Task Force on Psychosurgery (Donnelly, 1978) or the Behavioral Control Research Group of the Hastings Institute (Blatte, 1974) (a bioethics think-tank study ing the issue) has concluded that psychosurgery had been used for social control, an instrument of political or racial repression. The importance of psychosurgery to public percep tion of neuromodulation cannot be overstated. The actions of our era will be understood against the real and mythic excesses of the psychosurgery period. For this reason, investigators and practitioners need to familiarize themselves with this history. A failure to do this will lead to avoidable errors of judgment while engagement of the past will promote responsible and responsive inquiry (Fins, Rezai et al., 2006).
Acknowledgments Dr Fins is the recipient of an Investigator Award in Health Policy Research (Minds Apart: Severe Brain Injury and Health Policy) from The Robert Wood Johnson Foundation. He also gratefully acknowledges grant support from the Charles A. Dana Foundation (Mending the Brain, Minding our Ethics II), the Buster Foundation (Neuroethics and Disorders of Consciousness), and the editorial assistance of Jennifer Hersh, MBE.
References AAMC Task Force on Financial Conflicts of Interest in Clinical Research (2003) Protecting subjects, preserving trust, promoting progress I: policy and guidelines for the oversight of individual financial interests in human subjects research. Acad. Med. 78 (2): 225–36. al-Rodhan, N.R. and Kelly, P.J. (1992) Pioneers of stereotactic neuro surgery. Stereotact. Funct. Neurosurg. 58 (1–4): 60–6. Anon. (2002) The future of mind control. The Economist, May 25. Applebaum, P.S. and Lidz, C.W. (2006) Re-evaluating the therapeu tic misconception: response to Miller and Jaffe. Kennedy Inst. Ethics J. 16 (4): 353–66. Applebaum, P.S., Lidz, C.W. and Grisso, T. (2004) Therapeutic mis conception in clinical research: frequency and risk factors. IRB 26 (2): 1–8. Appleby, B.S., Duggan, P.S., Regenberg, A. and Rabins, P.V. (2007) Psychiatric and neuropsychiatric adverse events associated with deep brain stimulation: a meta-analysis of ten years’ experience. Mov. Disord. 22 (12): 1722–8. Blank, R.H. (1999) Brain Policy. Washington, DC: Georgetown University Press. Blatte, H. (1974) State prisons and the use of behavior control. The Hastings Center Report 4 (4): 11.
89
Boyce, N. (2002) Enter the cyborgs: promise and peril in a marriage of brains and silicon. US News & World Report 13 May, pp. 56–8. Cohadon, F., Richer, E., Bougiera, A., Deliack, P. and Loiseau, H. (1985) Deep brain stimulation in cases of prolonged post-traumatic unconsciousness. In: Y. Lazrthesy and A.R.M. Upton (eds), Neurostimulation: An Overview. Mount Kisco: Futura Publishing Co. Crichton, M. (1977) Terminal Man. New York: Knopf. Cushing, H. (1909) A note upon the faradic stimulation of the post central gyrus in conscious patients. Brain 32: 44–53. Deep-Brain Stimulation for Parkinson’s Disease Study Group (2001) Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. N. Engl. J. Med. 345 (13): 956–63. Delgado, J.M. and Anshen, R.N. (eds) (1969) Physical Control of the Mind: Toward a Psychocivilized Society. New York: Harper and Row. Donnelly, J. (1978) The incidence of psychosurgery in the United States, 1971–1973. Am. J. Psychiatry 135 (12): 1476–80. Doughert, D.D. and Rauch, S.L. (2007) Somatic therapies for treat ment-resistant depression: new neurotherapeutic interventions. Psychiatr. Clin. North Am. 30 (1): 31–7. Editorial (1972) Psychosurgery. Lancet 7767 (2): 69–70. Feindel, W. (1982) The contributions of Wilder Penfield to the func tional anatomy of the human brain. Human Neurobiol. 1 (4): 231–4. Feindel, W. (1998) Brain stimulation combined with electrocor tiography in the surgery of epilepsy: historical highlights. Electroencephalography Clin. Neurophysiol. 48: 1–8. Fins, J.J. (2000) A proposed ethical framework for interventional cognitive neuroscience: a consideration of deep brain stimula tion in impaired consciousness. Neurol. Res. 22: 273–8. Fins, J.J. (2001) Truth telling and reciprocity in the doctor–patient relationship: a North American perspective. In: E. Bruera and R.K. Portenoy (eds), Topics in Palliative Care, Volume 5. New York: Oxford University Press, pp. 81–94. Fins, J.J. (2002) The ethical limits of neuroscience. Lancet Neurol. 1: 213. Fins, J.J. (2003) From psychosurgery to neuromodulation and pal liation: history’s lessons for the ethical conduct and regulation of neuropsychiatric research. Neurosurg. Clin. North Am. 14 (2): 303–19. Fins, J.J. (2004a) Deep brain stimulation. In: S.G. Post (Editor-inChief), Encyclopedia of Bioethics, 3rd edn. New York: MacMillan Reference, Volume 2, pp. 629–34. Fins, J.J. (2004b) Neuromodulation, free will and determinism: lessons from the psychosurgery debate. Clin. Neurosci. Res. (1–2): 113–8. Fins, J.J. (2007) Disclose and justify: intellectual property, conflicts of interest, and neurosurgery. Congress Quarterly (The Official Newsmagazine of the Congress of Neurological Surgeons) 8 (3): 34–6. Fins, J.J. (2008) A leg to stand on: Sir William Osler and Wilder Penfield’s “Neuroethics.” Am. J. Bioethics-Neuroethics 8(1): 37–46. Fins, J.J. and Miller, F.G. (2000) Enrolling decisionally incapacitated subjects in neuropsychiatric research. CNS Spectrums 5 (10): 32–42. Fins, J.J. and Schachter, M. (2001) Investigators, industry and the heuristic device. Ethics, patent law and clinical innovation. Accountability in Research 8 (3): 219–33. Fins, J.J. and Schiff, N.D. (2000) Diagnosis and treatment of trau matic brain injury. JAMA 283: 2392. Fins, J.J., Giacino, J., Rezai, A. and Schiff, N. (2006) Ethical insights from a neuromodulation trial to restore function in the mini mally conscious state. Society for Neuroscience 36th Annual Meeting, Abstract.
I. AN INTRODUCTION TO NEUROMODULATION
90
9. Deep Brain Stimulation: Ethical Issues in Clinical Practice and Neurosurgical Research
Fins, J.J., Maltby, B.S., Friedmann, E., Green, M., Norris, K., Adelman, R. and Byock, I. (2005) Contracts, covenants and advance care planning: an empirical study of the moral obli gations of patient and proxy. J. Pain Symptom Manage. 29 (1): 55–68. Fins, J.J., Rezai, A.R. and Greenberg, B.D. (2006) Psychosurgery: avoiding an ethical redux while advancing a therapeutic future. Neurosurgery 59 (4): 713–16. Ford, P.J. (2007) Neurosurgical implants: clinical protocol considera tions. Cambridge Q. Healthc. Ethics 16: 308–11. Ford, P.J. and Kubu, C.S. (2006) Stimulating debate: ethics in a multidisciplinary functional neurosurgery committee. J. Med. Ethics 32: 106–9. Freedman, B. (1987) Equipoise and the ethics of clinical research. N. Engl. J. Med. 317 (3): 141–5. Gaylin, W.M., Meister, J.S. and Neville, R.C. (eds) (1975) Operating on the Mind: The Psychosurgery Conflict. New York: Basic Books. Gildenberg, P.L. (1990) The history of stereotactic surgery. Neurosurg. Clin. North Am. 1 (4): 765–80. Gildenberg, P.L. (1998) The history of surgery for movement disor ders. Neurosurg. Clin. North Am. 9 (2): 283–93. Gildenberg, P.L. (2006) History of neuromodulation for Chronic Pain Medicine. Pain Med. 7 (s1): S7–S13. Glannon, W. (2006) Phase I oncology trials: why the therapeutic misconception will not go away. J. Med. Ethics 32 (5): 252–5. Greenberg, B.D., Malone, D.A., Friehs, G.M., Rezai, A.R., Kubu, C.S., Malloy, P.F., Salloway, S.P., Okun, M.S., Goodman, W.K. and Rasmussen, S.A. (2006) Three-year outcomes in deep brain stimulation for highly resistant obsessive–compulsive disorder. Neuropsychopharmacology 31 (11): 2384–93. Hariz, M.I. (2005) What is a deep brain stimulation “failure” and how do we manage our own failures? Arch. Neurol. 62: 1938. Heath, R.G. (1954) Studies in Schizophrenia. Cambridge, MA: Harvard University Press. Horgan, J. (2004) The myth of mind control: will anyone ever decode the human brain? Discover, http://discovermagazine. com/2004/oct/cover/article_print. Jorge, R.E., Starkstein, S.E., Arndt, S., Moser, D., Crespo-Facorro, B. and Robinson, R.G. (2005) Alcohol misuse and mood disorders follow ing traumatic brain injury. Arch. Gen. Psychiatry 62 (7): 742–9. Kim, S.Y. (2006) Asessing and communicating the risks and benefits of gene transfer clinical trials. Curr. Opin. Mol. Ther. 8 (5): 384–9. Kim, S.Y., Kim, H.M., McCallum, C. and Tariot, P.N. (2005) What do people at risk for Alzheimer’s disease think about surrogate consent for research? Neurology 65 (9): 1395–401. Kopell, B.H. and Rezai, A. (2000) The continuing evolution of psy chiatric neurosurgery. CNS Spectrums 5 (10): 20–31. Kubu, C.S. and Ford, P.J. (2007) Ethics in the clinical application of neural implants. Cambridge Q. Healthc. Ethics 16: 317–21. Kumar, R., Lozano, A.M., Kim, Y.J., Hutchinson, W.D., Sime, E., Halket, E. and Lang, A.E. (1998) Double-blind evaluation of sub thalamic nucles deep brain stimulation in advanced Parkinson’s disease. Neurology 51 (3): 850–5. Mercado, R., Constantoyannis, C., Mandat, T., Kumar, A., Schulzer, M., Stoessl, A.J. et al. (2006) Expectation and the placebo effect in Parkinson’s disease with patients with subthalamic nucleus deep brain stimulation. Mov. Disord. 21 (9): 1457–61. Michels, R. (1999) Are research ethics bad for our mental health? N. Engl. J. Med. 340 (18): 1427–30. Miller, F.G. and Fins, J.J. (1999) Protecting vulnerable research sub jects without unduly constraining neuropsychiatric research. Arch. Gen. Psychiatry 56: 701–2. Miller, F.G., Rosenstein, D.L. and DeRenzo, E.G. (1998) Professional integrity in clinical research. JAMA 280: 1449–54.
Morgan, J.P. (1982) The first reported case of electrical stimulation of the human brain. J. Hist. Med. 37 (1): 51–64. National Bioethics Advisory Commission (1998) Research Involving Persons With Mental Disorders That May Affect Decisionmaking Capacity. Rockville, MD. Nuttin, B., Gybels, J., Cosyns, P., Gabriels, L., Meyerson, B., Andreewitch, S. et al. (2002, 2003) Deep brain stimulation for psychiatric disorders. Neurosurgery 51 (2): 519, Reprinted in: Neurosurg. Clin. North Am. 14 (2): xv–xvi. Onion, A. (2002) Rat robots, scientists develop remote-controlled rats. ABCnews.com, May 1. www.abcnews.go.com/sections/scitech/ DailyNews/rats020501.html (accessed 28 November 2007). Osmundsen, J.A. (1965) “Matador” with a radio stops wired bull: modified behavior in animals subject of brain study. New York Times, May 17. Penfield, W. (1972) The electrode, the brain and the mind. Z. Neurol. 201 (4): 297–309. Penfield, W. (1977) No Man Alone: A Neurosurgeon’s Life. Boston, MA: Little Brown. Pollo, A., Torre, E., Lopiano, L., Rizzone, M., Lanotte, M., Cavanna, A. et al. (2002) Expectation modulates the response to subthalamic nucleus stimulation in Parkinsonian patients. Neuroreport 13 (11): 1383–6. Pritchard, W.F., Abel, D.B. and Karanian, J.W. (1999) The US food and drug administration, investigational device exemptions and clinical investigation of cardiovascular devices: information for the investigator. J. Vasc. Interv. Radiol. 10 (2 Pt.1): 115–22. Rapoport, J.L. and Inoff-Germain, G. (1997) Medical and surgical treatment of obsessive–compulsive disorder. Neurol. Clin. 15 (2): 421–8. Reynolds, D.V. (1969) Surgery in the rat during electrical analgesia induced by focal brain stimulation. Science 164 (878): 444–5. Roth, R.M., Flashman, L.A., Saykin, A.J. and Roberts, D.W. (2001) Deep brain stimulation in neuropsychiatric disorders. Curr. Psychiatry Rep. 3: 366–72. Sachs, G.A. and Siegler, M. (1991) Guidelines for decision making when the patient is incompetent. J. Crit. Illness 6: 348–59. Schiff, N.D. and Fins, J.J. (2007) Deep brain stimulation and cogni tion: moving from animal to patient. Curr. Opin. Neurol. 20 (6): 638–42. Schiff, N.D., Giacino, J.T., Fins, J.J. (in press) Deep brain stimulation, neuroethics and the minimally conscious state: moving beyond proof of principle. Arch. Neurol. Schiff, N.D., Giacino, J.T., Kalmar, K., Victor, J.D., Baker, K., Gerber, M. et al. (2007) Behavioral improvements with thalamic stimulation after severe traumatic brain injury. Nature 448 (7153): 600–3. Shirvalkar, P., Seth, M., Schiff, N.D. and Herrera, D.G. (2006) Cognitive enhancement with central thalamic electrical stimula tion. Proc. Natl Acad. Sci. U S A 103 (45): 17007–12. Speelman, J.D. and Bosch, D.A. (1998) Resurgence of functional neurosurgery for Parkinson’s disease: a historical perspective. Mov. Disord. 13 (3): 582–8. Talwar, S.K., Xu, S., Hawley, E.S., Weiss, S.A., Moxon, K.A. and Chapin, J.K. (2002) Rat navigation guided by mind control. Nature 417 (6884): 37–8. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research (1977) Use of psycho surgery in practice and research: report and recommendations of National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. Federal Register 42 (99 (May 23): 26318–32. Thomas, R.K. and Young, C.D. (1993) A note on the early history of electrical stimulation of the human brain. J. Gen Psychol. 120 (1): 73–81.
I. AN INTRODUCTION TO NEUROMODULATION
references
Trials of War Criminals before the Nuremburg Military Tribunals under Control Council Law No. 10 (1949) Vol. 2. Washington, DC: US Government Printing Office, pp. 181–2. Young, R.F. (1990) Brain stimulation. Neurosurg. Clin. North Am. 1 (4): 865–79. Zaubler, T.S., Viederman, M. and Fins, J.J. (1996) Ethical, legal, and psychiatric issues in capacity, competence, and informed consent: an annotated bibliography. Gen. Hosp. Psychiatry 18: 155–72.
91
Zimmerman, M. (1982) Electrical stimulation of the human brain. Human Neurobiol. 1 (4): 27–229.
Cases and Statutes Schloendorff v Society of New York Hospital, 211 N.Y. 125 (1914). The National Research Act (July 12, 1974). Pub. L. 93–348. 35 U.S.C. §§ 200-12 (1994) (granting intellectual property rights to research findings to institutions that received federal grants).
I. AN INTRODUCTION TO NEUROMODULATION
S E C T I O N II
Fundamentals of neuromodulation Introduction Narendra Bhadra, J. Thomas Mortimer, P. Hunter Peckham, and Elliot S. Krames Neuromodulation and neurostimulation therapies and interventions are built upon a foundation of an understanding of neural structures and the behavior of the neural circuits of the nervous system. As this understanding has increased, so have our capabilities to intervene with increasing efficiency and efficacy with neuromodulatory interventions. These interventions may be electronic, as many of the devices deployed today are, but they may also be pharmacologic or cellular in nature. The first four chapters in this section discuss the fundamental features of the nervous system that underlie our ability to deploy successful technologies: “Anatomy of the Nervous System”, by Joshua Rosenow, MD, of the Department of Neurosurgey, Northwestern University Feinberg School of Medicine; “Fundamentals of Electrical Stimulation” by J. Thomas Mortimer, PhD and Narendra Bhadra, MD, PhD, from the Neural Engineering Center, Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio; “Neuromodulation and Neuronal Plasticity” by Alon Y. Mogilner, MD, PhD, Section of Functional and Restorative Neurosurgery,
Neuromodulation
North Shore-LIJ Health System, Manhasset, New York; and “Gene-Based Neuromodulation” by Thais Federici, PhD, Jonathan Riley, BSE, and Nicholas Boulis, MD, of the Cleveland Clinic Department of Neurosciences and Center for Neurological Restoration, Cleveland, Ohio. These chapters are followed by a subsection on mechanisms (Section A). The term “mechanism” has many meanings. In biology a mechanism explains how a feature is created. In chemistry it explains a reaction pathway. In the context of this section on mechanisms we intend to mean its “mechanism of action” or the means by which a drug or device exerts its biologic effects. Although mechanisms will be discussed in other sections of this work, Section IIA is intended to give an overview of some of the problems when focusing on the effects of stimulation at the neural interface. In this section, Dr Warren Grill, PhD, Associate Professor of the Department of Biomedical Engineering at Duke University, Durham, North Carolina, will discuss “Electrical Field Generation for Excitation and Inhibition,” Kendal Lee, MD, of the Department
93
© 2008, 2009 Elsevier Ltd.
94
II. Fundamentals of neuromodulation
of Neurosurgery at the Mayo Clinic of Rochester, Minnesota, Charles Blaha, PhD, of the Department of Psychology at the University of Memphis, Memphis, Tennessee, and Jonathan Bledsoe, MD, of the Depart ment of Neurosurgery at the Mayo Clinic, Rochester, Minnesota, will review what is known regarding the mechanisms of action of deep brain stimulation (DBS), and Dr Cameron McIntyre, of the Cleveland Clinic, Cleveland, Ohio, will discuss the “Use of Computational Models in Neurostimulation.” Dr Grill in his chapter summarizes the quantitative principles describing the generation of potentials in the central nervous system by delivery of electrical stimulation and finds that potentials generated are dependent on the electrical properties of the tissue, which in the CNS are both inhomogeneous and anisotropic, and electrode geometry. In their chapter on mechanisms of DBS, Drs Lee, Blaha, and Bledsoe describe the evidence from the literature for five possible mechanisms of action/actions for DBS which include: (1) inactivation of action potential generation in efferent outputs (depolarization block), (2) activation of neuronal terminals that inhibit and/or excite efferent outputs (synaptic modulation), (3) depletion of neurotransmitter in
terminals of efferent outputs (synaptic depression), (4) anti-oscillatory action on basal ganglion circuitry (network jamming or modulation), and (5) sustained enhancement of neurotransmitter release (synaptic facilitation). Dr McIntyre discusses computational models for the action of stimulation in brain nuclei. Dr McIntyre states that “DBS is an effective clinical treatment for several medically refractory neurological disorders, however, the clinical successes of DBS are tempered by the limited understanding of the response of neurons to applied electric fields, and scientific definition of the therapeutic mechanisms of DBS remains elusive … In addition, it is presently unclear which electrode designs and stimulation parameters are optimal for maximum therapeutic benefit and minimal side effects. Detailed computer modeling of DBS has recently emerged as a powerful technique to enhance our understanding of the effects of DBS and to create a virtual testing ground for new stimulation paradigms.” Dr McIntyre’s chapter summarizes the fundamentals of neurostimulation modeling, presents some scientific contributions of computer models to the field of DBS, and demonstrates the application of DBS modeling tools to augment the clinical utility of DBS.
II. Fundamentals of neuromodulation
C H A P T E R
10
Anatomy of the Nervous System Joshua M. Rosenow
o u t l i ne Gross Structures Brain Spinal Cord Autonomic Nervous System
95 95 98 98
Sensory System Pyramidal Motor System References
Gross structures
106
The parietal lobe serves both primary and complex sensory functions (graphesthesia) as well as corti cal regions for speech comprehension (Wernicke’s area) and association. The occipital lobes are prim arily involved in vision, containing both the primary and secondary visual regions. The hemispheres are connected by the fibers of the corpus callosum (see Figure 10.1). The primary motor and sensory cortices are organized in a homuncular pattern with the foot located in the interhemispheric fissure, the hip area medially, with the medial-to-lateral organization of arm–hand–face–mouth (see Figure 10.2). The basal ganglia are located deep within the hemi spheres and are comprised of the c-shaped caudate nucleus, the putamen, and the globus pallidus (see Figure 10.3). Some also include the amygdala in the temporal lobe in this group of structures. The caudate and puta men are connected by thin gray matter bridges and together are termed the lentiform nucleus. The anterior limb of the internal capsule passes between these bridges. The connection between these structures is more robust ventromedially. The caudate follows the curve of the ventricular system, with the tail ending
Brain The nervous system is divided into central and peripheral divisions, along with the separate autonomic system. The central nervous system consists of the brain and spinal cord while the peripheral nervous sys tem consists of the nerves to the trunk and extremities. The brain is composed of the hemispheres, the brain stem and the cerebellum. The hemispheres are divided into the frontal, temporal, parietal, and occip ital lobes. The frontal lobe houses higher personality and executive functions. The central sulcus marks the dividing line between the frontal and parietal lobes, with the primary motor cortex on the anterior aspect of this sulcus and the primary sensory cortex on the posterior border. The opercular cortex on the frontal side of the sylvian fissure in the dominant hemisphere houses the motor speech area (Broca’s area). The tem poral lobe contains areas subserving memory (hip pocampus), emotion and primitive urges (amygdala), hearing (primary auditory cortex, Heschel’s gyrus) and speech (dominant posterior temporal region).
Neuromodulation
99 106
95
2009 Elsevier Ltd. © 2008,
96
10. Anatomy of the nervous system
in the anterior temporal lobe near the amygdala. The globus pallidus is divided into internal and external segments, the globus pallidus interna and externa, respectively. The posterior limb of the internal cap sule lies at the medial border of the globus pallidus. The basal ganglia are involved in the control of both cognitive and motor function. They form a network of deep nuclei connected with both one another and the cortex via both direct and indirect pathways through the thalamus. The nuclei of the basal ganglia form the basis of the extrapyramidal motor control system that modulates motor function.
Cleft for internal capsule
Caudate Body nucleus Head
Thalamus
Pulvinar Medial geniculate body Lateral geniculate body Tail of caudate nucleus
Lentiform nucleus (globus pallidus medial to putamen) Amygdaloid body
Fornix
Frontal lobe
Lateral ventricle
Parietal lobe
Caudate nucleus Internal capsui Putamen Claustrum Globus pallidus
Occipital lobe
Thalamus Amygdala Optic tract
Temporal lobe
Uncus
ganglia
Ne
Toes Hip
ck
ng Fi
e Ankle
Th
p
Hi
Kne
X
er s um b
of the major cerebral lobes
Trunk
Figure 10.3 Schema of the anatomic organization of the basal
Shoulder Elb ow W ris t
Figure 10.1 A schematic diagram of the general organization
ow id Br yel s E are N s Lip Tongue
Trunk Hand Face
Larynx
Lateral sulcus X�
Figure 10.2 The primary motor and sensory cortices are arranged somatotopi cally with fibers serving the lower body more medially located and those serving the face more laterally located
II. FUNDAMENTALS OF NEUROMODULATION
97
Gross structures
The brain stem is further divided into the dien cephalon (thalamic complex), the mesencephalon (mid brain), metencephalon (pons), and myelencephalon (medulla). The diencephalon includes the thalamus, which functions as a relay center for most motor and sensory tracts, the epithalamus (pineal, habenular nuclei, stria medullaris), which functions to control the diurnal cycle, the hypothalamus, which regulates mul tiple pituitary hormones via releasing factors as well as producing its own hormones (ADH, vasopressin),
and the subthalamic nucleus, which participates in the extrapyramidal motor system along with the basal ganglia. The thalamus is bounded laterally by the pos terior limb of the internal capsule and caudally by the midbrain. The midbrain contains the nuclei for cranial nerves III and IV as well as the corticobulbar and corticospi nal tracts carrying motor fibers from the cortex to the brain stem and spinal cord, respectively. (See Figure 10.4 in the cerebral peduncles.)
Cerebral aqueduct Trochlear nucleus (iv) Periaqueductal gray Nucleus of the inferior colliculus Medial longitudinal fasciculus Lateral lemniscus Ventral and lateral spinothalamic tracts and spinotectal tract Reticular formation Central tegmental tract Decussation of the superior cerebellar peduncle Substantia nigra Trigeminothalamic tract Parieto-temporo-occipito-pontine fibers of crus cerebri Medial lemniscus Corticospinal and corticobulbar fibers of crus cerebri Rubrospinal tract Frontopontine fibers of crus cerebri
Edinger-westphal nucleus Periaqueductal gray Stratum opticum of superior colliculus Superior colliculus
Cerebral aqueduct
Spinotectal tract Brachium of inferior colliculus Ventral and lateral spinothalamic tracts Medial geniculate nucleus Reticular formation Trigeminothalamic tract Medial lemniscus Parieto-temporo-occipito-pontine fibers of crus cerebri Corticospinal and corticobulbar fibers of crus cerebri Substantia nigra Red nucleus Medial longitudinal fasciculus Frontopontine fibers of crus cerebri Oculomotor nucleus Dorsal and ventral tegmental decussations Oculomotor nerve (iii)
Figure 10.4 The major nuclei and tracts of the midbrain at the levels of the inferior colliculus (top) and superior colliculus (bottom)
II. FUNDAMENTALS OF NEUROMODULATION
98
10. Anatomy of the nervous system Cerebellar vermis Forth ventricle Superior cerebellar peduncle Medial longitudinal fasciculus Tectospinal tract Abducens nucleus (vi) Medial vestibular nucleus Superior vestibular nucleus Lateral vestibular nucleus Facial nerve root (vii) Middle cerebellar peduncle Spinal tract and nucleus of trigeminal nerve Facial nucleus (vii) Central tegmental tract Lateral lemniscus Lateral and ventral spinothalamic tracts and spinotectal tract Superior olivary nucleus Pontine fibers Abducens nerve root (vi) Corticospinal and corticobulbar fibers Pontine nuclei Medial lemniscus
Figure 10.5 The major nuclei and tracts of the pons at the level of the middle cerebellar peduncle
The fibers of the dentatorubrothalamic tract decus sate in the midbrain after emerging from the superior cerebellar peduncle on their way to the red nucleus in the midbrain tegmentum and then on to the thalamus. The dorsal aspect (tectum) of the midbrain consists of the paired superior and inferior colliculi subserving coordination of vision and hearing, respectively. The pedunculopontine nucleus is also located here. This nucleus functions as part of the extrapyramidal motor system as part of the “locomotor center.” It has con nections to the pallidum, cortex, and substantia nigra. The pons is dominated by the crossing fibers of the middle cerebellar peduncles (see Figure 10.5). The pons contains the nuclei of cranial nerves V, VI, VII, and VIII. The facial colliculus is the bulge in the roof of the midbrain formed by the fibers of cranial nerve VII looping over the nucleus of cranial nerve VI. The brain stem anatomy of cranial nerve V is described in more detail below. The IVth ventricle lies between the roof of the pons and the ventral cerebellum. Cranial nerves III, IV, and VI control extraocular movement. Cranial nerve V controls facial sensation as well as mas seter muscle function. Cranial nerve VII controls the muscles of facial expression as well as carrying some of the parasympathetic fibers for salivation and tearing. The medulla houses the nuclei of cranial nerves IX, X, XI, and XII. The pyramidal tracts decussate here. The nuclei cuneatus and gracilis for the spinal sen sory tracts are located here as well. The caudal end of the medulla is continuous with the spinal cord (see Figure 10.6).
Spinal Cord The spinal cord extends from the caudal medulla to the conus medullaris, which usually lies approxi mately at the level of L1–L2 in adults. There are 31 pairs of spinal roots: 8 cervical, 12 thoracic, 5 lumbar, 5 sacral and 1 coccygeal (see Figure 10.7). The spinal gray matter is located more centrally within the cord. The cord may be divided into right and left halves, as well as dorsal and ventral halves. The dorsal paramedian region is occupied by the dorsal sen sory tracts, the fasciculus gracilis (for the lower extremi ties) and fasciculus cuneatus (for the upper extremities). Further laterally the dorsal horn of gray matter sepa rates these pathways from the lateral corticospinal tract, which are the fibers from the primary motor cortex. Just ventral to the dentate ligament are the rubrospinal and spinothalamic tracts, which transmit secondary motor and sensory information, respectively. The ventrome dial aspect contains the vestibulospinal and anterior corticospinal tracts, which function to transmit vestibu lar and position information. Figure 10.8 shows the gen eral arrangement of ascending and descending tracts in the spinal cord. The gray matter organization will be discussed in more detail below.
Autonomic Nervous System The autonomic nervous system innervates the glands, viscera, heart, and smooth muscle. This sys tem is divided into parasympathetic and sympathetic
II. FUNDAMENTALS OF NEUROMODULATION
99
Gross structures Dorsal motor nucleus of vagus (x) Tectospinal tract
Fourth ventricle
Hypoglossal nucleus Medial longitudinal fasciculus
Medial vestibular nucleus Nucleus of fasciculus solitarius Inferior vestibular nucleus Tractus solitarius Reticular formation Inferior cerebellar peduncle Spinal tract and nucleus of trigminal nerve Rubrospinal tract Ventral spinocerebellar tract Nucleus ambiguus
Fascicle of vagus nerve (x) Lateral and ventral spinothalamic tracts and spinotectal tract Principal nucleus of the inferior olivary complex Medial and dorsal accessory olivary nuclei Hypoglossal nerve (xii) Corticospinal and corticobulbar fibers in the pyramid
Medial lemniscus
Figure 10.6 The major nuclei and tracts of the medulla at the level of the lower aspect of the IVth ventricle
divisions. Each division consists of a set of ganglia with both pre- and postganglionic branches (see Figure 10.9). The sympathetic ganglia are located in either the paraspinal chain or the prevertebral plexuses. The sympathetic system originates in the posterior hypothalamus and medulla. Efferents (fibers leaving a nucleus and traveling to a target) travel into the spi nal cord where they synapse in the intermediolateral cell column, located between T2 and L1. From here, the preganglionic myelinated fibers travel as white rami communicantes to the paravertebral chain and either synapse and send postganglionic gray (unmy elinated) rami communicantes to the spinal nerves or pass through to the prevertebral ganglia that supply autonomic innervation to the viscera (see Figure 10.10). The sympathetic fibers to the head extend from the superior cervical ganglion to follow the branches of the external carotid artery. The preganglionic parasympathetic fibers emerge with cranial nerves III, VII, IX, and X, as well as from the intermediolateral cell column at the S2–S4 levels. These synapse in ganglia much closer to (or actually in) the target organs, such as the heart, gastrointestinal tract, and genitourinary system.
Sensory System First order afferents for fine touch and position sense have their nuclei in the dorsal root ganglia
and travel centrally in the dorsal columns of the spi nal cord, synapsing in the medullary dorsal column nuclei. They then cross and ascend as the medial lem niscus to the ventrocaudal nucleus of the thalamus. From there, third order fibers travel to the sensory cortex. The thalamic homunculus is arranged such that the face is medial, the lower body is lateral, and the upper extremity lies between (see Figure 10.11). Central processes of afferents for pain and tempera ture extend from the dorsal root ganglia to synapse in Lissauer’s tract (as described below) and then cross in the cord just ventral to the central canal to form the contralateral ventral spinothalamic tract, with fibers organized with the lower body more laterally and upper body more medially. These ascend to the thala mus as well, synapsing primarily in the contralateral sensory thalamic nuclei. Third order neurons from the thalamus then project to the somatosensory cortex. Rexed first described the laminar organization of the spinal gray matter in the 1950s (Rexed, 1952, 1954) (see Figure 10.12). Afferent fibers enter the dorsal horn via the dorso lateral fasciculus of Lissauer. Afferent spinothalamic axons may travel vertically several spinal segments in this superficial layer before eventually synapsing with neurons in lamina I, the posteromarginal nucleus. This layer contains nociceptive-specific neurons that respond almost exclusively to noxious stimuli (Carpenter, 1991c; Byers and Bonica, 2001; Terman
II. FUNDAMENTALS OF NEUROMODULATION
100
10. Anatomy of the nervous system
C1
C1 C2 C3 C4
Base of skull Cervical enlargement
C2 C3 C4 C5 C6 C7 C8
C5 C6 C7 T1
T1
T2
T2
T3
T3 T4 T5 T5 T6 T6 T7 T7 T8 T8 T9 T9 T10 T10 T4
Lumbar enlargement
T11
T11
T12
T12
L1
Conus medullaris (termination of spinal cord)
L1 L2
L2
L3 Internal filum terminale of pia mater
L3
L4
Cauda equina
L4 L5 L5 Sacrum
External filum terminale of dura mater
S2
S1
S3 Termination of S4 dural sac S5 Coccygeal nerve Coccyx
Figure 10.7 The organization and anatomy of the spinal cord and spinal roots
and Bonica, 2001). They contain multiple neuropep tides, including substance P, calcitonin gene-related peptide (CGRP), enkephalin, and serotonin. Substance P and CGRP in particular play an important role in dorsal horn nociception (Donnerer and Amann, 1992; Donnerer and Stein, 1992; Donnerer et al., 1992a, 1992b). Lamina I cells send axons contralaterally across the ventral aspect of the central canal to form the lateral spinothalamic tract (STT). Lamina I also contains a class of cells that respond to a large vari ety of both noxious and non-noxious stimuli. These wide dynamic range (WDR) cells are able to alter their discharge frequency substantially to reflect the type of input stimulus. Noxious stimuli evoke higher frequency discharges from WDR cells. As described below, these cells play an important role in the devel opment of chronic neuropathic pain.
Lamina II, the substantia gelatinosa, modulates input from sensory receptors. Nociceptive and thermo receptive input is concentrated in the superficial layer of this lamina (IIo) while mechanoreceptor input is targeted to the deeper aspect (IIi) (Carpenter, 1991c; Terman and Bonica, 2001). Projections from substan tia gelatinosa neurons terminate in lamina I and in lamina II at other spinal levels. Opiate receptors are plentiful in both laminae I and II. Importantly, each sublayer of lamina II appears to contain distinct sub populations of C-fibers. Those C-fibers terminating in lamina IIo are similar to those that terminate in lamina I in that they express substance P and CGRP and con tain the trkA receptor for nerve growth factor (NGF). In contrast, the C-fibers terminating in lamina IIi do not express either CGRP or substance P and express the binding site for lectin IB4, an indicator of sensitiv ity to glial-derived neurotrophic factor (GDNF). This lamina also contains numerous local circuit neurons whose dendritic arbors may extend into both deeper and more superficial laminae. The A-fibers terminate primarily in lamina III, as do some of the A mechanoreceptive fibers. Lamina IV also serves as a target zone for A-fibers. Some of the cells in this layer project back to layer I, aiding in inte gration of sensory information. Lamina V contains a large number of STT projection cells that receive input from A- and C-fibers. A substantial proportion of the cells here are WDR neurons. These have large receptive fields whose center is responsive to both noxious and non-noxious stimuli and a surrounding area respon sive primarily to noxious stimuli only. Stimulation of the region surrounding this field causes inhibition of the WDR neuron (Terman and Bonica, 2001). Lamina X encompasses the gray matter surrounding the central canal of the spinal cord. The exact function of the cells here is not clear, but they are thought to play a role in visceral sensation as well as the holo spinal integration of nociceptive information. Some A-fibers directly terminate here, possibly carrying both visceral and cutaneous inputs. The trigeminal system has an analogous anatomic arrangement. Cell bodies for facial nociceptors are located in the Gasserian ganglion. The peripheral processes project via the three divisions of the trigem inal nerve and the central processes enter the brain stem via the trigeminal sensory root. Trigeminal sen sory input is then segregated depending on the type of information. Those cells carrying proprioception have their cell bodies in the trigeminal mesencephalic nucleus. The main sensory nucleus is located in the pons and receives large myelinated A afferents. Caudal to this nucleus is the spinal nucleus, which extends caudally through pons and medulla and is
II. FUNDAMENTALS OF NEUROMODULATION
101
Gross structures 3a 3b
S
S
L
Th
C 4a
L 1a Th C 2b
2a
C
Th L S 5a 4b
2b 1b
5b
2d
6
2c
Motor and decending (efferent) pathways (left, red)
Sensory and ascending (afferent) pathways (right, blue)
1. Pyramidal Tracts
3. Dorsal Column Medial Lemniscus System
1a. Lateral corticospinal tract
3a. Gracile fasciculus
1b. Anterior corticospinal tract
3b. Cuneate fasciculus
2. Extrapyramidal Tracts
4. Spinocerebellar Tracts
2a. Rubrospinal tract
4a. Posterior spinocerebellar tract
2b. Reticulospinal tract
4b. Anterior spinocerebellar tract
2c. Vestibulospinal tract
5. Anterolateral System
2d. Olivospinal tract
5a. Lateral spinothalamic tract 5b. Anterior spinothalamic tract
Somatotopy Abbreviations: S: Sacral, L: Lumbar Th: Thoracic, C: Cervical
6. Spino-olivary fibers
(a) Principal fiber tracts of spinal cord Fasciculus gracilis
Ascending pathways Descending pathways Fibers passing in both directions Septomarginal fasciculus (oval bundle) Interfascicular fasciculus (comma tract)
Fasciculus cuneatus
Lateral corticospinal (pyramidial) tract (crossed)
Dorsolateral tract (fasciculus) (of Lissauer)
Rubrospinal tract
Dorsal (posterior) spinocerebellar tract
Lateral (medullary) reticulospinal tract
Lateral spinothalamic tract and spinoreticular tract
Ventral (anterior) or medial (pontine) reticulospinal tract
Ventral (anterior) spinocerebellar tract
Vestibulospinal tract
Spino-olivary tract
Ventral (anterior) corticospinal tract (direct)
Spinotectal tract Ventral (anterior) spinothalamic tract Fasciculus proprius
Tectospinal tract Medial longitudinal (sulcomarginal) fasciculi
(b)
Figure 10.8 The major ascending and descending tracts of the spinal cord
II. FUNDAMENTALS OF NEUROMODULATION
102
10. Anatomy of the nervous system Ciliary
III
Midbrain
Eye Sphenopalaline
VII VII IX
Medulla I C.
Submaxillary X
Olic
Sup. cerv. g.
Lacrimal gland Mucous mem. nose and palate Submaxillary gland Sublingual gland Mucous mem. mouth Parotid gland Heart
I T.
Larynx Trachea
chnic lan
Sma ll s
p
Oreal splanch nic Celiac
Bronchi Esophagus Stomach Blood ves. of abd. Liver and ducts
Superior mesenteric gang. I L. Inferior mesenteric gang.
Pancreas Adrenal Small intestine
Large intestine
I S.
Rectum
Pelvic ne
rve
Kidney Bladder Sexual organs External genitalia
Figure 10.9 The schematic organization of the autonomic nervous system
essentially the extension of lamina I into the brain stem (see Figure 10.13). This structure is further subdivided into several subnuclei. The subnucleus oralis is located most ros trally, followed by the subnucleus interpolaris, and the large subnucleus caudalis. The subnuclei oralis and interpolaris share common tactile and pressure input with the main sensory nucleus. Nociceptive
input is directed towards the subnucleus caudalis and the junction between interpolaris and caudalis. Subnucleus caudalis has several levels of somato topic organization. The classic model, described by Déjérine, is the onion peel analogy. Fibers from the central portions of the face terminate in the more ros tral portions of the subnucleus caudalis, while those in progressively more peripheral rings terminate at
II. FUNDAMENTALS OF NEUROMODULATION
103
Gross structures
Sympathetic ganglion
Cell of Dogiel 2 6 7
Spinal ganglion
Posterior nerve root Spinal nerve
Sympathetic cord
2 1
Anterior nerve root
6 3
1 3 4 5
Wh
ite r
Gr ay
ram
us c om m
amu
unica n
s co
mm
unic
ans Sympathetic ganglion
s
Figure 10.10 The schematic organization of the gray and white rami communicantes of the autonomic nervous system
CN LD VLc Deep structures
MD VPLc
Cutaneous
CM VPM VPI
IC
Figure 10.11 Like the primary motor and sensory cortices, the motor and sensory thalamic nuclei have a homuncular arrangement with the face more medially located and lower body more laterally located. The distal extremities are located more caudally than the proximal extremities
II. FUNDAMENTALS OF NEUROMODULATION
104
10. Anatomy of the nervous system
Sulcii s1) Dorsal-Median Sulcus s2) Dorsal-Intermediate S. s3) Dorsolateral S. s4) Ventral-Median S. s5) Ventrolateral S.
s1 s2
d g
c
s3 a b e
h
h
s4
f
Rexed Lamina a) Lissauer’s Tract b) Marginal Zone c) Substantia Gelatinosa d) Body of Dorsal Horn e) Intermediate Horn f) Ventral Horn g) Central Canal h) Lower Motor Neurons
s5
Figure 10.12 Rexed’s laminae within the dorsal horn of the spinal cord (http://en.wikipedia.org/wiki/Spinal_cord) MIDBRAIN Mesencephalic nucleus Trigeminal ganglion
Trigeminal nerve
PONS Main sensory nucleus
Spinal nucleus of V
MEDULLA
Figure 10.13 A schematic diagram of the organization of the trigeminal sensory nuclei in the brain stem
more caudal levels. Nociceptive fibers from other cranial nerves (VII, IX, X) synapse in the more medial aspects of the subnucleus. Kunc was able to demon strate that a cut along the medial aspect of the spinal trigeminal nucleus produces analgesia in the distri bution of these other cranial nerves, sparing most of the trigeminal system. However, his incision also interrupted nociceptive fibers from the mandibular branch of the trigeminal nerve, thus demonstrating another layer or organization. Trigeminal fibers enter the subnucleus caudalis from its dorsal and lateral aspects. Mandibular division fibers are positioned dor sally with maxillary and ophthalmic division axons
clustered dorsolaterally and laterally, respectively. Cells in the subnucleus caudalis then form the trigemino thalamic tract (TTT). The STT and the TTT project primarily to the con tralateral sensory thalamus. This is the ventrocaudal nucleus (Vc) of Hassler’s nomenclature or the ventro posterior nucleus (VP) of the Anglo-American system. Once again, a definite somatotopic organization is present. Fibers from the legs and lower body project to the more lateral thalamus (VPL) while the trigeminal system sends axons to synapse in the more medial regions of the nucleus (VPM). Distal parts of the limbs are represented more ventrally within the nuclei while inputs from the trunk and other central regions termi nate more dorsally (Carpenter, 1991b). The thalamus then sends wide projections to the cerebral cortex. Most of the STT projection cells originate in lami nae I and V of the dorsal horn. Smaller contributions come from laminae VII and IX. Their axons then cross ventral to the central canal on their way to the con tralateral ventrolateral region (Carpenter, 1991d). The decussation may occur either at the corresponding spi nal level or one or two segments higher. This helps to account for the discrepancy between sensory level and injury level observed in spinal cord injury patients. Somatotopy is maintained within the spinothalamic tract. The first fibers to form the tract, those from the lumbosacral region, lie dorsolaterally. Fibers from suc cessively more cranial levels then lie progressively more ventral and medial (Carpenter, 1991c). Some of the axons from lamina I, as well as those from laminae VII and IX, project to sites outside of the ventrocaudal thalamus (Carpenter, 1991b; Chudler
II. FUNDAMENTALS OF NEUROMODULATION
105
Gross structures
To thalamus
From nociceptive endings (A� and C fibers)
Inhibitory interneuron in substantia gelatinosa
�
�
�
� �
Tract cell
Figure 10.14 A schematic diagram of the gate con trol theory of pain. Non-nociceptive sensory fibers stim ulate the inhibitory interneurons, whereas nociceptive afferents inhibit them. An increase in non-nociceptive input will reduce the rate of firing of the spinothalamic tract neurons
From non-nociceptive endings (A� and A� fibers)
and Bonica, 2001). Known as the paleospinothalamic tract, these axons synapse in the brain stem reticular formation, hypothalamus, or other thalamic nuclei. Many of the axons originating outside of lamina I come from WDR cells, which tend to have a higher conduction velocity than the axons from lamina I noci ceptive cells. These cells not only respond to a wide range of stimuli, but also have larger receptive fields than nociceptive cells. It is believed that the smaller fields of the nociceptive cells aid in pain localization and discrimination. The WDR cells may play the inte grative role of the “T” cells in Melzack and Wall’s (1965) original description of the gate control theory. In their model, the “T,” or transmission, cells are the convergence point of signals from multiple peripheral afferents. These cells were depicted as being able to handle numerous types of sensory input. The signal transmitted depended on the status of the pain gate (see Figure 10.14). The broader characteristics of the WDR cells are felt to be involved in the affective com ponent of pain, hence their projection to the reticular formation, periaqueductal gray, and medial thalamic nuclei sites that have been implicated in modulating this (Willis and Westlund, 1997). Other thalamic nuclei are involved in pain process ing. The intralaminar nuclei, such as the nuclei para fascicularis (Pf), centrum medianum (CM), centralis medialis, and centralis lateralis, as well as the nucleus medius dorsalis (MD), all receive higher order noci ceptive inputs, either directly from the STT or (more commonly) by way of other thalamic nuclei or the brain stem nuclei (Bowsher et al., 1968; Reyes-Vazquez, Prieto-Gomez et al., 1989; Mao et al., 1992; Chudler and Bonica, 2001; Krout et al., 2002). These sites have served as targets for neurosurgeons treating intractable
pain (Richardson and Akil, 1977). Antinociception may be evoked by stimulation (Richardson and Akil, 1977) or infusion of opioids (Reyes-Vazquez, Qiao et al., 1989; Mao et al., 1992; Harte et al., 2000) into these areas. There are many other targets for nociceptive projec tion axons (Chudler and Bonica, 2001). These include the midbrain reticular formation, the colliculi, hypo thalamus, basal ganglia, amygdala and limbic sys tem. Functional imaging has disclosed activation of an extensive list of supraspinal structures in response to pain, including the medullary reticular formation, locus coeruleus, lateral parabrachial region, anterior pretectal nucleus, the medial, lateral and posterior tha lamic regions, basal ganglia, and the parietal, cingulate, frontal, insular and orbital cortices (Porro et al., 1999). The thalamus projects to the somatosensory cortex. The primary somatosensory cortex (SI, Brodmann’s areas 3a/b,2,1) corresponds to the postcentral gyrus and the neighboring sulci (Carpenter, 1991a). The secondary somatosensory cortex (SII) is located just posterior to SI on the medial hemisphere. Resection of the SI cortex has been attempted for control of pain without long-term success (Chudler and Bonica, 2001). Most nociceptive afferents terminate in corti cal layers III and IV (Chudler et al., 1990). The ventro basal thalamus projects cutaneous sensation primarily to areas 3b and 1. It has been demonstrated that the anticipation of painful stimuli can lead to activation of the sensory cortex (Porro et al., 2002). Both SI and SII cortices receive nociceptive input from the thalamus. The SI cortex is basically arranged in Penfield’s classic homuncular pattern, although variations in fine organ ization exist. The lower extremities are represented on the medial aspect of the gyrus and even into the
II. FUNDAMENTALS OF NEUROMODULATION
106
10. Anatomy of the nervous system
interhemispheric fissure. Regions such as the hand and face (especially the lips) have an especially generous cortical representation. The SII cortex also is arranged somatotopically and receives some amount of bilateral input. However, the homunculus is reversed, with the face areas for SI and SII aligned (Carpenter, 1991a). Pain appears to be processed sequentially by the SI and SII cortices (Tran et al., 2002). The insula has also been found to play a role in the higher order processing of pain. Painful stimula tion can activate the insula, as seen on fMRI (Niddam et al., 2002). Moreover, this effect may be noted bilat erally (Hsieh et al., 1995; Frot and Mauguiere, 2003). Interestingly, these pathways seem to require that a certain level of consciousness be present for them to be utilized. Laureys et al. (2002) reported that areas such as the insula, SII, and cingulate cortices showed no activity when patients in a vegetative state were given a painful stimulus. The strength of insular activation is related to the magnitude of the stimulus (Bornhovd et al., 2002). While some have localized insular activation to the pos terior insula (Ostrowsky et al., 2002), it is clear that the anterior insula plays an important role as well (Hsieh et al., 1995; Peyron et al., 2000; Treede et al., 2000). In fact, Maihofner et al. (2002) demonstrated that the sensation of cold pain may completely bypass the SI cortex and be primarily processed in the posterior insula. The cingulate cortex is also activated by painful sensations (Peyron et al., 2000; Schnitzler and Ploner, 2000; Rolls et al., 2003). This region receives input from the intralaminar and medial thalamus. It is most likely responsible for the affective and motivational aspects of pain. This is partly indicated by studies (Ploner et al., 2002) showing that “second pain” leads to ante rior cingulate activation whereas “first pain” only activates the SI cortex. Moreover, distracting a subject during the application of a painful stimulus attenu ates the anterior cingulate activation (Frankenstein et al., 2001). Hofbauer et al. (2001) used hypnosis in an attempt to dissociate the affective and nociceptive components of pain while investigating the cortical representation of each. While their effort was only partially successful, they did demonstrate decreases in anterior cingulate activity when the affective com ponent was modulated. Hsieh et al. (1995) noted that the right anterior cingulate appeared to be dominant in that it was activated by both ipsilateral and contral ateral stimulation.
Pyramidal Motor System The corticospinal tracts originate from the pri mary motor cortex with significant contributions
(about 35%) from the postcentral gyrus and a smaller contribution (10%) from the frontal lobe. These fibers pass through the corona radiata and posterior limb of the internal capsule to the brain stem. Modulating collaterals exist to the red nucleus, vestibular nucleus, thalamus, reticular formation, and other structures. After decussating in the medulla, the fibers descend in the lateral aspect of the spinal cord before synapsing in Rexed’s layers VIII and IX of the spinal gray matter. Postsynaptic fibers then form the ventral root contri bution to the peripheral nerves. The extrapyramidal motor system will be discussed in more detail in other chapters in this text.
References Bornhovd, K., Quante, M., Glauche, V., Bromm, B., Weiller, C. and Buchel, C. (2002) Painful stimuli evoke different stimulusresponse functions in the amygdala, prefrontal, insula and som atosensory cortex: a single-trial fMRI study. Brain 125: 1326–36. Bowsher, D., Mallart, A., Petit, D. and Albe-Fessard, D. (1968) A bul bar relay to the centre median. J. Neurophysiol. 31: 288–300. Byers, M.R. and Bonica, J.J. (2001) Peripheral pain mechanisms and nociceptor plasticity. In: J.D. Loeser (ed.), Bonica’s Management of Pain, Vol. 1. Philadelphia, PA: Lippincott Williams & Wilkins, pp. 26–72. Carpenter, M.B. (1991a) The cerebral cortex. In: M.B. Carpenter (ed.), Core Text of Neuroanatomy, Vol. 1. Baltimore, MD: Williams & Wilkins, pp. 390–433. Carpenter, M.B. (1991b) The diencephalon. In: M.B. Carpenter (ed.), Core Text of Neuroanatomy, Vol. 1. Baltimore, MD: Williams & Wilkins, pp. 250–97. Carpenter, M.B. (1991c) Spinal cord: gross anatomy and internal structure. In: M.B. Carpenter (ed.), Core Text of Neuroanatomy, Vol. 1. Baltimore, MD: Williams & Wilkins, pp. 57–82. Carpenter, M.B. (1991d) Tracts of the spinal cord. In: M.B. Carpenter (ed.), Core Text of Neuroanatomy, Vol. 1. Baltimore, MD: Williams & Wilkins, pp. 83–114. Chudler, E.H. and Bonica, J.J. (2001) Supraspinal mechanisms of pain and nociception. In: J.D. Loeser (ed.), Bonica’s Management of Pain, Vol. 1. Philadelphia, PA: Lippincott Williams & Wilkins, pp. 153–79. Chudler, E.H., Anton, F., Dubner, R. and Kenshalo, D.R., Jr (1990) Responses of nociceptive SI neurons in monkeys and pain sen sation in humans elicited by noxious thermal stimulation: effect of interstimulus interval. J. Neurophysiol. 63: 559–69. Donnerer, J. and Amann, R. (1992) Time course of capsaicin-evoked release of CGRP from rat spinal cord in vitro. Effect of concen tration and modulations by ruthenium red. Ann. N Y Acad. Sci. 657: 491–2. Donnerer, J., Schuligoi, R. and Amann, R. (1992a) Time-course of capsaicin-evoked release of calcitonin gene-related peptide from rat spinal cord in vitro. Effect of concentration and modulation by Ruthenium Red. Regul. Pept. 37: 27–37. Donnerer, J., Schuligoi, R. and Stein, C. (1992b) Increased content and transport of substance P and calcitonin gene-related peptide in sensory nerves innervating inflamed tissue: evidence for a regulatory function of nerve growth factor in vivo. Neuroscience 49: 693–8. Donnerer, J. and Stein, C. (1992) Evidence for an increase in the release of CGRP from sensory nerves during inflammation. Ann. N Y Acad. Sci. 657: 505–6.
II. FUNDAMENTALS OF NEUROMODULATION
references
Frankenstein, U.N., Richter, W., McIntyre, M.C. and Remy, F. (2001) Distraction modulates anterior cingulate gyrus activations dur ing the cold pressor test. Neuroimage 14: 827–36. Frot, M. and Mauguiere, F. (2003) Dual representation of pain in the operculo-insular cortex in humans. Brain 126: 438–50. Harte, S.E., Lagman, A.L. and Borszcz, G.S. (2000) Antinociceptive effects of morphine injected into the nucleus parafascicularis thalami of the rat. Brain Res. 874: 78–86. Hofbauer, R.K., Rainville, P., Duncan, G.H. and Bushnell, M.C. (2001) Cortical representation of the sensory dimension of pain. J. Neurophysiol. 86: 402–11. Hsieh, J.C., Belfrage, M., Stone-Elander, S., Hansson, P. and Ingvar, M. (1995) Central representation of chronic ongoing neuropathic pain studied by positron emission tomography. Pain 63: 225–36. Krout, K.E., Belzer, R.E. and Loewy, A.D. (2002) Brainstem projec tions to midline and int